var title_f34_24_35200="Position of function hand";
var content_f34_24_35200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60552&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Position of function of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 427px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The safe position shows the wrist extended 20&deg;, MCP joints flexed at 90&deg;, and the PIP and DIP joints fully extended.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harrison, BP, Hilliard, MW. Emergency department evaluation and treatment of hand injuries. Emerg Med Clin North Am 1999; 17:793. Copyright &copy; 1999 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35200=[""].join("\n");
var outline_f34_24_35200=null;
var title_f34_24_35201="Calculator: International Prognostic Index for non-Hodgkin lymphoma";
var content_f34_24_35201=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"IPINHL_form\" name=\"IPINHL_form\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: International Prognostic Index for non-Hodgkin lymphoma",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <div id=\"calc_input\">",
"      <center>",
"       <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc1\" onclick=\"IPINHL_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Age &gt;60 years old (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc2\" onclick=\"IPINHL_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Serum lactate dehydrogenase concentartion above normal (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc3\" onclick=\"IPINHL_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Ann Arbor stage III or IV (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc4\" onclick=\"IPINHL_fx();\" type=\"checkbox\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           More than one extranodal disease site (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td align=\"left\" colspan=\"3\">",
"          <span class=\"medCalcFontCCTabBold\">",
"           ECOG performance scale",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"IPINHL_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Performance status 0: Fully active; no performance restrictions (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"IPINHL_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Performance status 1: Strenuous physical activity restricted; fully ambulatory and able to carry out light work (0 points)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"IPINHL_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Performance status 2: Capable of all self-care but unable to carry out any work activities. Up and about &gt;50 percent of waking hours (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"IPINHL_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Performance status 3: Capable of only limited self-care; confined to bed or chair &gt;50 percent of waking hours (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"        <tr>",
"         <td width=\"20\">",
"          <br/>",
"         </td>",
"         <td align=\"right\">",
"          <input name=\"cc5\" onclick=\"IPINHL_fx();\" type=\"radio\"/>",
"         </td>",
"         <td align=\"left\">",
"          <span class=\"medCalcFontCCTab\">",
"           Performance status 4: Completely disabled; cannot carry out any self-care; totally confined to bed or chair (1 point)",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <div id=\"calc_result\">",
"      <span class=\"medCalcFontCCTabBold\">",
"       Total Criteria Point Count:",
"      </span>",
"      <input name=\"cctotal\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <input name=\"reset\" type=\"reset\" value=\"Reset Form\"/>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          When applied to a group of 2031 patients with aggressive non-Hodgkin lymphoma treated with anthracycline-based regimens  that did NOT include rituximab, 5 year overall survival (OS) and complete response (CR) rates were as follows:",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr1_1\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0 to 1 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Low risk with 73% 5 year OS and 87% CR",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_2\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           2 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           Low-intermediate risk with 51% 5 year OS and 67% CR",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_3\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           High-intermediate risk with 43% 5 year OS and 55% CR",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr1_4\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           4 to 5 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           High risk with 26% 5 year OS and 44% CR",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"       <tr>",
"        <td bgcolor=\"#eeeeee\" width=\"1%\">",
"         <br/>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <span class=\"medCalcFontTitleBox\">",
"          When applied to 1063 patients treated with rituximab plus CHOP/CHOP-like chemotherapy, 3 year event-free survival (EFS),  progression free survival (PFS) and overall survival (OS) were as follows:",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <center>",
"       <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"        <tr id=\"rr2_5\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           0 to 1 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           EFS 81%, PFS 87% and OS 91%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr2_6\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           2 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           EFS 69%, PFS 75% and OS 81%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr2_7\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           3 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           EFS 53%, PFS 59% and OS 65%",
"          </span>",
"         </td>",
"        </tr>",
"        <tr id=\"rr2_8\">",
"         <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px;\">",
"          <span class=\"medCalcFontOneBold\">",
"           4 to 5 points:",
"          </span>",
"         </td>",
"         <td align=\"left\" style=\"border-left: 0px;\">",
"          <span class=\"medCalcFontOne\">",
"           EFS 50%, PFS 50% and OS 59%",
"          </span>",
"         </td>",
"        </tr>",
"       </table>",
"      </center>",
"     </div>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"     </span>",
"    </div>",
"    <div id=\"calc_notes\">",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       <b>",
"        ECOG",
"       </b>",
"       : Eastern Cooperative Oncology Group",
"      </li>",
"      <li>",
"       <b>",
"        NHL",
"       </b>",
"       : Non-Hodgkin lymphoma",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive  non-Hodgkin's lymphoma.",
"        <i>",
"         N Engl J Med",
"        </i>",
"        . 1993; 329:987.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International prognostic index remains a valid  predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era.",
"        <i>",
"         J Clin Oncol",
"        </i>",
"        . 2010; 28:2373. Epub 2010 Apr 12. Erratum in: J Clin Oncol 2011; 29:779.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Oken MM, Creech RH, Tormey DC, et al, Eastern Cooperative Oncology Group, Robert Comis M.D., Group Chair.  Toxicity and response criteria of the Eastern Cooperative Oncology Group.",
"        <i>",
"         Am J Clin Oncol",
"        </i>",
"        . 1982; 5:649.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"   <script language=\"JavaScript1.1\" type=\"text/javascript\">",
"    &lt;!--",
"",
";",
"IPINHL_fx();",
"//--&gt;",
"   </script>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35201=[" ",
"",
"var calctxt = '';",
"var xmltxt = '';",
"var htmtxt = '';",
"",
"",
"function IPINHL_fx() {",
"with(document.IPINHL_form){",
"",
"Score = 0.0;",
"doCalc = true;",
"",
"if (cc1.checked){",
"Score = Score + 1;",
"}",
"if (cc2.checked){",
"Score = Score + 1;",
"}",
"if (cc3.checked){",
"Score = Score + 1;",
"}",
"if (cc4.checked){",
"Score = Score + 1;",
"}",
"if (cc5[0].checked){",
"Score = Score + 0;",
"}",
"if (cc5[1].checked){",
"Score = Score + 0;",
"}",
"if (cc5[2].checked){",
"Score = Score + 1;",
"}",
"if (cc5[3].checked){",
"Score = Score + 1;",
"}",
"if (cc5[4].checked){",
"Score = Score + 1;",
"}",
"cctotal.value = Score;",
"",
"if (doCalc){",
"rrclr();",
"if (( Score >= 0) && ( Score <= 1)){ document.getElementById('rr1_1').bgColor = '#cccccc';",
"}",
"if (( Score >= 2) && ( Score <= 2)){ document.getElementById('rr1_2').bgColor = '#cccccc';",
"}",
"if (( Score >= 3) && ( Score <= 3)){ document.getElementById('rr1_3').bgColor = '#cccccc';",
"}",
"if (( Score >= 4) && ( Score <= 5)){ document.getElementById('rr1_4').bgColor = '#cccccc';",
"}",
"if ((Score >= 0) && (Score <= 1)){ document.getElementById('rr2_5').bgColor = '#cccccc';",
"}",
"if ((Score >= 2) && (Score <= 2)){ document.getElementById('rr2_6').bgColor = '#cccccc';",
"}",
"if ((Score >= 3) && (Score <= 3)){ document.getElementById('rr2_7').bgColor = '#cccccc';",
"}",
"if ((Score >= 4) && (Score <= 5)){ document.getElementById('rr2_8').bgColor = '#cccccc';",
"}",
"",
"}",
"}",
"}",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr1_4').bgColor = \"\";",
"document.getElementById('rr2_5').bgColor = \"\";",
"document.getElementById('rr2_6').bgColor = \"\";",
"document.getElementById('rr2_7').bgColor = \"\";",
"document.getElementById('rr2_8').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f34_24_35201=null;
var title_f34_24_35202="Cromolyn sodium (nasal): Pediatric drug information";
var content_f34_24_35202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cromolyn sodium (nasal): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?23/27/23987?source=see_link\">",
"    see \"Cromolyn sodium (nasal): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/12/197?source=see_link\">",
"    see \"Cromolyn sodium (nasal): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13319698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NasalCrom&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8011994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cromolyn Nasal Spray&reg; [OTC];",
"     </li>",
"     <li>",
"      Rhinaris-CS Anti-Allergic Nasal Mist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10576454\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Inhalation, Miscellaneous",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10576461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/27/23987?source=see_link\">",
"      see \"Cromolyn sodium (nasal): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intranasal: Children &ge;2 years and Adults: 1 spray in each nostril 3-4 times/day; maximum dose: 1 spray in each nostril 6 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8012205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, intranasal, as sodium [spray]: 40 mg/mL (26 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NasalCrom&reg;: 40 mg/mL (13 mL) [contains benzalkonium chloride; 5.2 mg/inhalation]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8011996\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10576462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Clear nasal passages by blowing nose prior to use.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10576459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10576455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of seasonal or perennial allergic rhinitis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8011992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       NasalCrom&reg; may be confused with Nasacort&reg;, Nasalide&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8012098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Unpleasant taste",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Coughing; hoarseness; increase in burning, irritation, sneezing, or stinging inside of nose; postnasal drip",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Epistaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10576456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cromolyn or any component",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299100\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8012122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13763439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted; however, studies in pregnant women have not shown signs of adverse effects  or increased teratogenicity with use during pregnancy (Gilbert, 2005; Mazzotta, 1999).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10576460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevents the mast cell release of histamine, leukotrienes, and slow-reacting substance of anaphylaxis by inhibiting degranulation after contact with antigens",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10576463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/12/197?source=see_link\">",
"      see \"Cromolyn sodium (nasal): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cromolyn nasal spray is not effective for the immediate relief of nasal allergies; must be used at regular intervals for 1-2 weeks for optimal control of nasal allergies; to prevent nasal allergy symptoms, start using product 1-2 weeks before contact with the cause of allergies.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15958 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-9070587B58-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35202=[""].join("\n");
var outline_f34_24_35202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13319698\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011994\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576454\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576461\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012205\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011996\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576462\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576459\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576455\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011992\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012098\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576456\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299100\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012122\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13763439\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576460\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10576463\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15958\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15958|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?23/27/23987?source=related_link\">",
"      Cromolyn sodium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/12/197?source=related_link\">",
"      Cromolyn sodium (nasal): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/3/28723?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?16/46/17124?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?18/45/19154?source=related_link\">",
"      Cromolyn sodium (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?17/12/17605?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?28/53/29524?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?27/63/28660?source=related_link\">",
"      Cromolyn sodium (systemic therapy and oral inhalation): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_24_35203="Bi-directional Doppler";
var content_f34_24_35203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F76440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F76440&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Bi-directional Doppler",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Summit Doppler Systems, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35203=[""].join("\n");
var outline_f34_24_35203=null;
var title_f34_24_35204="Computed tomography after endovascular repair";
var content_f34_24_35204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79584&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Computed tomography after endovascular repair",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Contrast enhanced computed tomography following endovascular repair of abdominal aortic aneurysm shows contrast outside of endograft and within the aneurysm sac, confirming the presence of an endoleak (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35204=[""].join("\n");
var outline_f34_24_35204=null;
var title_f34_24_35205="Nephrology pattern 8 answer";
var content_f34_24_35205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82728&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 8 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mesangial proliferative glomerulonephritis. Light micrograph of a mesangial glomerulonephritis showing segmental areas of increased mesangial matrix and cellularity (arrows). This finding alone can be seen in many diseases, including IgA nephropathy and lupus nephritis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35205=[""].join("\n");
var outline_f34_24_35205=null;
var title_f34_24_35206="Golimumab: Drug information";
var content_f34_24_35206=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Golimumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/13/1238?source=see_link\">",
"    see \"Golimumab: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F7764598\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7710508\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Simponi&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10165746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Simponi&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F7714309\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antipsoriatic Agent;",
"     </li>",
"     <li>",
"      Antirheumatic, Disease Modifying;",
"     </li>",
"     <li>",
"      Monoclonal Antibody;",
"     </li>",
"     <li>",
"      Tumor Necrosis Factor (TNF) Blocking Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F7764854\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Should be administered in conjunction with methotrexate in rheumatoid arthritis; may administer with or without methotrexate or other nonbiologic disease-modifying antirheumatic drugs (DMARDs) in psoriatic arthritis or ankylosing spondylitis. Golimumab should not be used in combination with biologic DMARDs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis:",
"     </b>",
"     SubQ: 50 mg once per month",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F7764855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F7764860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simponi&reg;: 50 mg/0.5 mL (0.5 mL) [contains natural rubber/natural latex in packaging, polysorbate 80; autoinjector]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simponi&reg;: 50 mg/0.5 mL (0.5 mL) [contains natural rubber/natural latex in packaging, polysorbate 80; prefilled syringe]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F7764600\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874784\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152822.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM152822.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F7764856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Subcutaneous injection: Prior to administration, allow syringe to sit at room temperature for 30 minutes. Solution should be clear to slightly opalescent and colorless to light yellow. Discard if solution is cloudy, discolored, or has foreign particles. Hold autoinjector firmly against skin and inject subcutaneously into thigh, lower abdomen (below navel), or upper arm.  A loud click is heard when injection has begun. Continue to hold autoinjector against skin until second click is heard (may take 3-15 seconds). Following second click, lift autoinjector from injection site. Discard any unused portion. Rotate injection sites and avoid injecting into tender, red, hard, or bruised skin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F7714311\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of active rheumatoid arthritis (moderate-to-severe), active psoriatic arthritis, and active ankylosing spondylitis",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F7764751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory tract infection (16%; includes laryngitis, nasopharyngitis, pharyngitis, and rhinitis)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Infection (28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypertension (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (2%), fever (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Constipation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Hepatic: ALT increased (4%), AST increased (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site reactions (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchitis (2%), sinusitis (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Viral infection (5%; includes herpes and influenza), antibody formation (4%), fungal infection (superficial; 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Abscess, anaphylaxis, aspergillosis, atypical mycobacterial infection, bacterial arthritis, candidiasis, cellulitis, coccidioidomycosis, HBV reactivation, histoplasmosis, hypersensitivity reactions, infective bursitis, leukemia, leukopenia, listeriosis, lupus-like syndrome, lymphomas, malignancy (other than nonmelanoma skin cancer), multiple sclerosis, neutropenia, optic neuritis, pancytopenia, peripheral demyelinating polyneuropathy, pneumocystosis, pneumonia, psoriasis (including new onset, palmoplantar, pustular, or exacerbation), pyelonephritis, sarcoidosis, sepsis, septic shock, skin exfoliation, thrombocytopenia, tuberculosis (including reactivation of latent and new infection), vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F7764747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the FDA-approved manufacturer&rsquo;s labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Hypersensitivity to golimumab, latex, or any other component of formulation or packaging; patients with severe infections (eg, sepsis, tuberculosis, opportunistic infections); moderate or severe heart failure (NYHA class III/IV)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F7764748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Autoimmune disorder: Autoantibody formation and onset of lupus-like syndrome (rarely) has been associated with use of TNF-blockers. Monitor and discontinue if symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatitis B: Rare reactivation of hepatitis B virus (HBV) has occurred in chronic virus carriers, usually in patients receiving concomitant immunosuppressants; evaluate for HBV prior to initiation in all patients. Patients who test positive for HBV surface antigen should be referred for hepatitis B evaluation/treatment prior to golimumab initiation. Monitor during and for several months following discontinuation of treatment in HBV carriers; interrupt therapy if reactivation occurs and treat appropriately with antiviral therapy; if resumption of therapy is deemed necessary, exercise caution and monitor patient closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Infections:",
"     <b>",
"      [U.S. Boxed Warning]: Patients receiving golimumab  are at increased risk for serious infections which may result in hospitalization and/or fatality; infections usually developed in patients receiving concomitant immunosuppressive agents (eg, methotrexate or corticosteroids) and may present as disseminated (rather than local) disease. Active tuberculosis (or reactivation of latent tuberculosis), invasive fungal (including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, and pneumocystosis) and bacterial, viral or other opportunistic infections (including legionellosis and listeriosis) have been reported in patients receiving TNF-blocking agents, including golimumab. Monitor closely for signs/symptoms of infection. Discontinue for serious infection or sepsis. Consider risks versus benefits prior to use in patients with a history of chronic or recurrent infection. Consider empiric antifungal therapy in patients who are at risk for invasive fungal infection and develop severe systemic illness.",
"     </b>",
"     Caution should be exercised when considering use in the elderly, patients taking concomitant immunosuppressants, patients with comorbid conditions that predispose them to infections (eg, diabetes), or residence/travel from areas of endemic mycoses (blastomycosis, coccidioidomycosis, histoplasmosis). Do not initiate golimumab therapy in patients with active infection, including localized infection which is clinically important. Patients who develop a new infection while undergoing treatment should be monitored closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Severe systemic hypersensitivity reactions (including anaphylaxis), have been reported (some have occurred with the first dose); discontinue therapy immediately if signs develop and initiate appropriate treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Malignancy:",
"     <b>",
"      [U.S. Boxed Warning]: Lymphoma and other malignancies have been reported in children and adolescent patients receiving TNF-blocking agents.",
"     </b>",
"     Half of the malignancies reported in children were lymphomas (Hodgkin and non-Hodgkin) while other cases varied and included malignancies not typically observed in this population. The impact of golimumab on the development and course of malignancy is not fully defined. Compared to the general population, an increased risk of lymphoma has been noted in clinical trials; however, rheumatoid arthritis alone has been previously associated with an increased rate of lymphoma. Lymphomas and other malignancies were also observed (at rates higher than expected for the general population) in adult patients receiving TNF-blocking agents. Hepatosplenic T-cell lymphoma (HSTCL), a rare T-cell lymphoma, has also been associated with TNF-blocking agents, primarily reported in adolescent and young adult males with Crohn&rsquo;s disease or ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tuberculosis:",
"     <b>",
"      [U.S. Boxed Warning]: Tuberculosis (disseminated or extrapulmonary) has been reported in patients receiving golimumab; both reactivation of latent infection and new infections have been reported. Patients should be evaluated for tuberculosis risk factors and latent tuberculosis infection (with a tuberculin skin test) prior to therapy. Treatment of latent tuberculosis should be initiated before use. Patients with initial negative tuberculin skin tests should receive continued monitoring for tuberculosis throughout treatment;",
"     </b>",
"     active tuberculosis has developed in this population during treatment with TNF-blocking agents. Use with caution in patients who have resided in regions where tuberculosis is endemic. Consider antituberculosis therapy if an adequate course of treatment cannot be confirmed in patients with a history of latent or active tuberculosis or for patients with risk factors  despite negative skin test.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Demyelinating disease: Use with caution in patients with pre-existing or recent onset central or peripheral nervous system demyelinating disorders; rare cases of new-onset or exacerbation of demyelinating disorders (eg, multiple sclerosis, optic neuritis, Guillain-Barr&eacute; syndrome, polyneuropathy) have been reported. Consider discontinuing use in patients who develop peripheral or central nervous system demyelinating disorders during treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use with caution in patients with heart failure or decreased left ventricular function; worsening and new-onset heart failure has been reported with TNF-blockers, including golimumab; discontinue with onset or worsening of symptoms.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Rare cases of pancytopenia and other significant cytopenias, including aplastic anemia, have been reported with TNF-blocking agents. Pancytopenia, leukopenia, neutropenia, and thrombocytopenia have occurred with golimumab. Consider discontinuing therapy with significant hematologic abnormalities. Use with caution in patients with underlying hematologic disorders.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abatacept: Due to a higher incidence of serious infections, concomitant use with abatacept is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anakinra: Due to a higher incidence of neutropenia and serious infections, concomitant use with anakinra is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Disease-modifying antirheumatic drugs (DMARDs): Use caution when switching between biological disease modifying antirheumatic drugs (DMARDs); overlapping of biological activity may increase the risk for infection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use with caution in elderly patients; general incidence of infection is higher in elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage form specific issues:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Some dosage forms may contain dry natural rubber (latex).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Polysorbate 80: Some dosage forms may contain polysorbate 80.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunizations: Patients should be brought up to date with all immunizations before initiating therapy. Live vaccines should not be given concurrently; there is no data available concerning secondary transmission of live vaccines in patients receiving therapy. In clinical trials, humoral response to pneumococcal vaccine was not suppressed in psoriatic arthritis patients receiving golimumab.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7734106\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abatacept: Anti-TNF Agents may enhance the adverse/toxic effect of Abatacept. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anakinra: Anti-TNF Agents may enhance the adverse/toxic effect of Anakinra. An increased risk of serious infection during concomitant use has been reported.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canakinumab: Anti-TNF Agents may enhance the adverse/toxic effect of Canakinumab. Specifically, the risk for serious infections and/or neutropenia may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Certolizumab Pegol: Anti-TNF Agents may enhance the immunosuppressive effect of Certolizumab Pegol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilonacept: Anti-TNF Agents may enhance the adverse/toxic effect of Rilonacept.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May enhance the immunosuppressive effect of Anti-TNF Agents.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Anti-TNF Agents may enhance the adverse/toxic effect of Tofacitinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F7764602\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7764743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Golimumab crosses the placenta. Based on data from other TNF-blockers, antibodies may be present in the newborn serum for up to 6 months and infants exposed to golimumab",
"     <i>",
"      in utero",
"     </i>",
"     may be at risk of increased infection. Administration of live vaccines to newborns is not recommended until 6 months after the last maternal dose. Canadian labeling recommends that women of childbearing potential use reliable contraception during and for at least 6 months after discontinuation of golimumab therapy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F7764745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F7764746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether golimumab is secreted in human milk. Because many immunoglobulins are secreted in milk and the potential for serious adverse reactions exists, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321953\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Simponi Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/0.5 mL (0.5 mL): $2846.33",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F7764858\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential; latent TB screening (prior to initiating and periodically during therapy); HBV screening (prior to initiating [all patients]; during and for several months following therapy [HBV carriers]); monitor improvement of symptoms and physical function assessments; signs/symptoms of infection (prior to, during, and following therapy); signs/symptoms/worsening of heart failure signs and symptoms of hypersensitivity reaction; symptoms of lupus-like syndrome; signs/symptoms of malignancy (eg, splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Simponi (AT, AU, BE, CH, CZ, DE, DK, EE, FR, GB, HK, HN, IE, IL, NL, NO, NZ, PL, PT, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F7764845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Human monoclonal antibody that binds to human tumor necrosis factor alpha (TNF&alpha;), thereby interfering with endogenous TNF&alpha; activity. Biological activities of TNF&alpha; include the induction of proinflammatory cytokines (interleukin [IL]-6, IL-8, Granulocyte-colony stimulating factor, granulocyte-macrophage colony stimulating factor), expression of adhesion molecules (E-selectin, vascular cell adhesion molecule [VCAM]-1, intercellular adhesion molecule [ICAM]-1) necessary for leukocyte infiltration, activation of neutrophils and eosinophils.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F7764847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : I.V.: 0.058-0.126 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: SubQ: ~53%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: SubQ: 2-6 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Braun J, Baraliakos X, Hermann KG, et al, &ldquo;Golimumab Reduces Spinal Inflammation in Ankylosing Spondylitis: MRI Results of the Randomised, Placebo- Controlled GO-RAISE Study,&rdquo;",
"      <i>",
"       Ann Rheum Dis",
"      </i>",
"      , 2012, 71(6):878-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35206/abstract-text/22128083/pubmed\" id=\"22128083\" target=\"_blank\">",
"        22128083",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Genovese MC, Han C, Keystone EC, et al, &ldquo;Effect of Golimumab on Patient-Reported Outcomes in Rheumatoid Arthritis: Results From the GO-FORWARD Study,&rdquo;",
"      <i>",
"       J Rheumatol",
"      </i>",
"      , 2012, 39(6):1185-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35206/abstract-text/22505702/pubmed\" id=\"22505702\" target=\"_blank\">",
"        22505702",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Inman RD, Davis JC Jr, van der Heijde D, et al, &ldquo;Efficacy and Safety of Golimumab in Patients With Ankylosing Spondylitis, Results of a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2008, 58(11):3402-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35206/abstract-text/18975305/pubmed\" id=\"18975305\" target=\"_blank\">",
"        18975305",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kavanaugh A, Mcinnes I, Mease P, et al, &ldquo;Golimumab, a New Human Tumor Necrosis Factor &alpha; Antibody, Administered Every Four Weeks as a Subcutaneous Injection in Psoriatic Arthritis, Twenty-Four-Week Efficacy and Safety Results of a Randomized, Placebo-Controlled Study,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2009, 60(4):976-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35206/abstract-text/19333944/pubmed\" id=\"19333944\" target=\"_blank\">",
"        19333944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kay J, Matteson EL, Dasgupta B, et al, &ldquo;Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate, A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study,&rdquo;",
"      <i>",
"       Arthritis Rheum",
"      </i>",
"      , 2008, 58(4):964-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35206/abstract-text/18383539/pubmed\" id=\"18383539\" target=\"_blank\">",
"        18383539",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Keystone EC, Genovese MC, Klareskog L, et al, &ldquo;Golimumab, a Human Antibody to TNF- &alpha; Given by Monthly Subcutaneous Injections, in Active Rheumatoid Arthritis Despite Methotrexate: The GO-FORWARD Study,&rdquo;",
"      <i>",
"       Ann Rheum Dis,",
"      </i>",
"      , 2009, 68(6):789-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35206/abstract-text/19066176/pubmed\" id=\"19066176\" target=\"_blank\">",
"        19066176",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lopez-Oilvo MA, Tayar JH, Martinez-Lopez JA, et al, &ldquo;Risk of Malignancies in Patients With Rheumatoid Arthritis Treated With Biologic Therapy: A Meta-Analysis,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2012, 308(9): 898-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35206/abstract-text/22948700/pubmed\" id=\"22948700\" target=\"_blank\">",
"        22948700",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh JA, Furst DE, Bharat A, et al, &ldquo;2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis,&rdquo;",
"      <i>",
"       Arthritis Care Res (Hoboken)",
"      </i>",
"      , 2012, 64(5):625-39.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35206/abstract-text/22473917/pubmed\" id=\"22473917\" target=\"_blank\">",
"        22473917",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9086 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35206=[""].join("\n");
var outline_f34_24_35206=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764598\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7710508\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10165746\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7714309\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764854\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764855\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896398\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896399\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764860\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764600\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874784\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764856\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7714311\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764751\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764747\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764748\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299418\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7734106\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764602\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764743\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764745\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764746\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321953\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764858\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961950\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764845\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7764847\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9086\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9086|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?1/13/1238?source=related_link\">",
"      Golimumab: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_24_35207="Naloxone: Drug information";
var content_f34_24_35207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Naloxone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/10/31907?source=see_link\">",
"    see \"Naloxone: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/4/20551?source=see_link\">",
"    see \"Naloxone: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2980444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Naloxone Hydrochloride Injection&reg;;",
"     </li>",
"     <li>",
"      Naloxone Hydrochloride Injection&reg; USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F199499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidote;",
"     </li>",
"     <li>",
"      Opioid Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F199464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Available routes of administration include I.V. (preferred), I.M., and SubQ; other available routes (unlabeled) include  inhalation via nebulization (adults only), intranasal (adults only), and intraosseous (I.O.). Endotracheal administration is the least desirable and is supported by only anecdotal evidence (case report) (Neumar, 2010); nebulized naloxone has been shown to be an effective alternative to parenteral administration when needleless administration is desired (Weber, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Opioid overdose (with standard ACLS protocols):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V., I.M., SubQ: Initial: 0.4-2 mg; may need to repeat doses every 2-3 minutes; after reversal, may need to readminister dose(s) at a later interval (ie, 20-60 minutes) depending on type/duration of opioid. If no response is observed after 10 mg total, consider other causes of respiratory depression.",
"     <b>",
"      Note:",
"     </b>",
"     May be given endotracheally (unlabeled route) as 2-2.5 times the initial I.V. dose (ie, 0.8-5 mg) (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <i>",
"      Continuous infusion (unlabeled dosing):",
"     </i>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     For use with exposures to long-acting opioids (eg, methadone), sustained release product, and symptomatic body packers after initial naloxone response. Calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen  (Tenenbein, 1984)",
"     <b>",
"      or",
"     </b>",
"     use two-thirds (",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     ) of the initial effective naloxone bolus on an hourly basis (typically 0.25-6.25 mg/hour); one-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) of the initial bolus dose should be readministered 15 minutes after initiation of the continuous infusion to prevent a drop in naloxone levels; adjust infusion rate as needed to assure adequate ventilation and prevent withdrawal symptoms (Goldfrank, 1986).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inhalation via nebulization (unlabeled route): 2 mg; may repeat. Switch to I.V. or I.M. administration when possible (Weber, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intranasal administration (unlabeled route): 2 mg (1 mg per nostril); may repeat in 5 minutes if respiratory depression persists.",
"     <b>",
"      Note:",
"     </b>",
"     Onset of action is slightly delayed compared to I.M. or I.V. routes (Kelly, 2005; Robertson, 2009; Vanden Hoek, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reversal of respiratory depression with therapeutic opioid doses:",
"     </b>",
"     I.V., I.M., SubQ.: Initial: 0.04-0.4 mg; may repeat until desired response achieved. If desired response is not observed after 0.8 mg total, consider other causes of respiratory depression.",
"     <b>",
"      Note:",
"     </b>",
"     May be given endotracheally (unlabeled route) as 2-2.5 times the initial I.V. dose (ie, 0.08-1 mg) (Neumar, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion (unlabeled dosing):",
"     </i>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     For use with exposures to long-acting opioids (eg, methadone) or sustained release products. Calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen (Tenenbein, 1984)",
"     <b>",
"      or",
"     </b>",
"     use two-thirds (",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     ) of the initial effective naloxone bolus on an hourly basis (typically 0.2-0.6 mg/hour);  one-half (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) of the initial bolus dose should be readministered 15 minutes after initiation of the continuous infusion to prevent a drop in naloxone levels; adjust infusion rate as needed to assure adequate ventilation and prevent withdrawal symptoms (Goldfrank, 1986).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Opioid-dependent patients being treated for cancer pain (NCCN guidelines, v.2.2011):",
"     </i>",
"     I.V.: 0.04-0.08 mg (40-80",
"     <b>",
"      mcg",
"     </b>",
"     ) slow I.V. push; administer every 30-60 seconds until improvement in symptoms; if no response is observed after total naloxone dose 1 mg, consider other causes of respiratory depression.",
"     <b>",
"      Note:",
"     </b>",
"     May dilute 0.4 mg/mL (1 mL) ampul into 9 mL of normal saline for a total volume of 10 mL to achieve a 0.04 mg/mL (40",
"     <b>",
"      mcg",
"     </b>",
"     /mL) concentration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Postoperative reversal:",
"     </i>",
"     I.V.: 0.1-0.2 mg every 2-3 minutes until desired response (adequate ventilation and alertness without significant pain).",
"     <b>",
"      Note:",
"     </b>",
"     Repeat doses may be needed within 1-2 hour intervals depending on type, dose, and timing of the last dose of opioid administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Opioid-induced pruritus (unlabeled use):",
"     </b>",
"     I.V. infusion: 0.25",
"     <b>",
"      mcg/kg/hour",
"     </b>",
"     ;",
"     <b>",
"      Note:",
"     </b>",
"     Monitor pain control; verify that the naloxone is not reversing analgesia (Gan, 1997)",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F199481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/4/20551?source=see_link\">",
"      see \"Naloxone: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     I.V. (preferred), I.M., SubQ, intraosseous (I.O.) (unlabeled), and endotracheal (unlabeled) routes may be used. Endotracheal administration is the least desirable and is supported by only anecdotal evidence (case report) (Neumar, 2010):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Opioid overdose (with standard PALS protocols):",
"     </b>",
"     Infants, Children, and Adolescents: I.V., intraosseous (I.O.) (unlabeled route), endotracheal (unlabeled route):",
"     <b>",
"      Note:",
"     </b>",
"     I.V. administration is preferred; I.O. and endotracheal routes are alternative routes recommended by the PALS guidelines (Kleinman, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &lt;5 years or &le;20 kg (unlabeled dose): 0.1 mg/kg/dose (maximum dose: 2 mg); repeat every 2-3 minutes if needed (Hegenbarth, 2008; Kleinman, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;5 years or &gt;20 kg: 2 mg; if no response, repeat every 2-3 minutes. If no response is observed after 10 mg total, consider other causes of respiratory depression (Hegenbarth, 2008; Kleinman, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Continuous infusion (unlabeled dosing):",
"     </i>",
"     I.V.: If continuous infusion is required, calculate dosage/hour based on effective intermittent dose used and duration of adequate response seen (Tenenbein, 1984)",
"     <b>",
"      or",
"     </b>",
"     use  two-thirds  (",
"     <sup>",
"      2",
"     </sup>",
"     /",
"     <sub>",
"      3",
"     </sub>",
"     ) of the initial effective naloxone bolus on an hourly basis; titrate dose (typically 0.04-0.16 mg/kg/hour for 2-5 days in children);  one-half  (",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     ) of the initial bolus dose should be readministered 15 minutes after initiation of the continuous infusion to prevent a drop in naloxone levels; increase infusion rate as needed to assure adequate ventilation and prevent withdrawal symptoms (Goldfrank, 1986).",
"     <b>",
"      Note:",
"     </b>",
"     The infusion should be discontinued by reducing the infusion in decrements of 25%; closely monitor the patient (eg, pulse oximetry) after each adjustment and after discontinuation of the infusion for recurrence of opioid-induced respiratory depression (Perry, 1996).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Reversal of respiratory depression with therapeutic opioid dosing:",
"     </b>",
"     Infants, Children, and Adolescents: I.V.: 0.001-0.015 mg/kg/dose; dose may be repeated as needed (Hegenbarth, 2008; Kleinman, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Postoperative reversal:",
"     </i>",
"     I.V.:  0.005-0.01 mg/kg (Fischer, 1974); may repeat every 2-3 minutes as needed based on response (adequate ventilation without significant pain)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F199465\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F199436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 0.4 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 0.4 mg/mL (1 mL); 1 mg/mL (2 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F199421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F199440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. push: Administer over 30 seconds as undiluted preparation",
"     <b>",
"      or",
"     </b>",
"     administer as diluted preparation slow I.V. push by diluting 0.4 mg (1 mL) ampul with 9 mL of normal saline for a total volume of 10 mL to achieve a concentration of 0.04 mg/mL (APS, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V. continuous infusion: Dilute to 4",
"     <b>",
"      mcg",
"     </b>",
"     /mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or normal saline",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., SubQ: May administer I.M. or SubQ if unable to obtain I.V. access",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endotracheal (unlabeled route): There is only anecdotal support for this route of administration. May require a slightly higher dose than used in other routes. Dilute to 1-2 mL with normal saline; flush with 5 mL of saline and then administer 5 ventilations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation via nebulization (unlabeled route): Dilute 2 mg of naloxone with 3 mL of normal saline and administer via nebulizer face mask (Mycyk, 2003; Weber, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intranasal (unlabeled route): Administer total dose equally divided into each nostril using a mucosal atomizer device (MAD) (Kelly, 2005; Robertson, 2009; Vanden Hoek, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F199505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS; do not mix with alkaline solutions or solutions containing bisulfite or metabisulfite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Fenoldopam, linezolid, propofol.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, pantoprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, heparin, ondansetron.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F199439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Complete or partial reversal of opioid drug effects, including respiratory depression; management of known or suspected opioid overdose; diagnosis of suspected opioid dependence or acute opioid overdose",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F199496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Opioid-induced pruritus",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F199507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Naloxone may be confused with Lanoxin&reg;, naltrexone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Narcan may be confused with Marcaine&reg;, Norcuron&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Narcan [multiple international markets] may be confused with Marcen brand name for ketazolam [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F199497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse reactions are related to reversing dependency and precipitating withdrawal. Withdrawal symptoms are the result of sympathetic excess. Adverse events occur secondarily to reversal (withdrawal) of narcotic analgesia and sedation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiac arrest, fever, flushing, hypertension, hypotension, tachycardia, ventricular fibrillation ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, coma, crying (excessive [neonates]), encephalopathy, hallucination, irritability,  nervousness, restlessness, seizure (neonates), tremulousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reaction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Ache, hyperreflexia (neonates), paresthesia, piloerection, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea, hypoxia, pulmonary edema, respiratory depression, rhinorrhea, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, hot flashes, shivering, yawning",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F199443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to naloxone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F199425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute opioid withdrawal: Administration of naloxone causes the release of catecholamines; may precipitate acute withdrawal or unmask pain in those who regularly take opioids. Symptoms of acute withdrawal in opioid-dependent patients may include pain, hypertension, sweating, agitation, irritability; in neonates, symptoms may include shrill cry, failure to feed. Carefully titrate the dose to reverse hypoventilation; do not fully awaken patient or reverse analgesic effect (postoperative patient).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease or in patients receiving medications with potential adverse cardiovascular effects (eg, hypotension, pulmonary edema or arrhythmias); pulmonary edema and cardiovascular instability, including ventricular fibrillation, have been reported in association with abrupt reversal when using narcotic antagonists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Use caution in patients with history of seizures; avoid use in the treatment of meperidine-induced seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opioid overdose: Recurrence of respiratory depression is possible if the opioid involved is long-acting; observe patients until there is no reasonable risk of recurrent respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Out-of-hospital administration: Opioid overdose: To prevent overdose deaths, there are initiatives to dispense naloxone for self- or buddy-administration to patients at risk of opioid overdose (eg, recipients of high-dose opioids, suspected or confirmed history of illicit opioid use) and individuals likely to be present in an overdose situation (eg, family members of illicit drug users) (Albert, 2011; Bennett, 2011).  Needleless administration via nebulization and the intranasal route by first responders and bystanders has also been described (Doe-Simkins, 2009; Weber, 2012).  Needleless administration provides an alternative route of administration in patients with venous scarring due to illicit drug use (eg, heroin).  There is a low incidence of death following naloxone reversal of opioid toxicity in patients who refuse transport to a healthcare facility (Wampler, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Postoperative reversal: Appropriate use: Excessive dosages should be avoided after use of opiates in surgery. Abrupt postoperative reversal may result in nausea, vomiting, sweating, tachycardia, hypertension, seizures, and other cardiovascular events (including pulmonary edema and arrhythmias).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299739\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F199430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F199432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F199446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Naloxone crosses the placenta. Consider the benefit to the mother and the risk to the fetus before administering to a pregnant woman who is known or suspected to be opioid dependent; may precipitate withdrawal in both the mother and fetus. In general, medications used as antidotes should take into consideration the health and prognosis of the mother (Bailey, 2003). Use caution in pregnant women with mild-to-moderate hypertension during labor; severe hypertension may occur.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F199468\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F199447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if naloxone is excreted into breast milk, however, systemic absorption following oral administration is low (Smith, 2012) and any exposure of naloxone to a nursing infant would therefore be limited. Since naloxone is used for opioid reversal, the opioid concentrations in the milk of a breast-feeding mother and potential transfer of the opioid to the infant should be considered.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323451\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Naloxone HCl Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.4 mg/mL (1 mL): $8.82",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (2 mL): $20.34",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F199434\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Respiratory rate, heart rate, blood pressure, temperature, level of consciousness, ABGs or pulse oximetry",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F199448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Feng Du (CL);",
"     </li>",
"     <li>",
"      Intrenon (CZ);",
"     </li>",
"     <li>",
"      Jin Er Lun (CL);",
"     </li>",
"     <li>",
"      Mapin (HK, MY);",
"     </li>",
"     <li>",
"      Min-I-Jet Naloxone (GB);",
"     </li>",
"     <li>",
"      Nalone (FR);",
"     </li>",
"     <li>",
"      Naloxon (BG, CH, DE);",
"     </li>",
"     <li>",
"      Naloxone Abello (ES);",
"     </li>",
"     <li>",
"      Naloxone Hydrochlorid (GB);",
"     </li>",
"     <li>",
"      Naloxonum Hydrochloricum (PL);",
"     </li>",
"     <li>",
"      Naloxonum Prolongatum (PL);",
"     </li>",
"     <li>",
"      Narcan (AE, AU, BE, BF, BH, BJ, BR, CI, CY, EG, ET, FR, GB, GH, GM, GN, GR, IL, IQ, IR, IT, JO, KE, KP, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NZ, OM, PK, PL, QA, SA, SC, SD, SG, SL, SN, SY, TN, TW, TZ, UG, VE, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Narcanti (AT, DK, HN, HU, MX, NO, PL, UY);",
"     </li>",
"     <li>",
"      Narcotan (IN);",
"     </li>",
"     <li>",
"      Narlox (PH);",
"     </li>",
"     <li>",
"      Narxona (AR);",
"     </li>",
"     <li>",
"      Naxone (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nexodal (FI, IE, NL, PT, SE);",
"     </li>",
"     <li>",
"      Zynox (ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F199424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pure opioid antagonist that competes and displaces narcotics at opioid receptor sites",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F199442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Endotracheal, I.M., SubQ: 2-5 minutes; Inhalation via nebulization: ~5 minutes (Mycyk, 2003); Intranasal: ~8-13 minutes (Kelley, 2005; Robertson, 2009); I.V.: ~2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: ~30-120 minutes depending on route of administration; I.V. has a shorter duration of action than I.M. administration; since naloxone's action is shorter than that of most opioids, repeated doses are usually needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic via glucuronidation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Neonates: 3-4 hours; Adults: 0.5-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Albert S, Brason FW, Sanford CK, et al, \"Project Lazarus: Community-Based Overdose Prevention in Rural North Carolina,\"",
"      <i>",
"       Pain Med",
"      </i>",
"      , 2011, 12(Suppl 2):77-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/21668761/pubmed\" id=\"21668761\" target=\"_blank\">",
"        21668761",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bailey B, \"Are There Teratogenic Risks Associated With Antidotes Used in the Acute Management of Poisoned Pregnant Women?\"",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(2):133-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/12769509/pubmed\" id=\"12769509\" target=\"_blank\">",
"        12769509",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bennett AS, Bell A, Tomedi EG, et al, \"Characteristics of an Overdose Prevention, Response, and Naloxone Distribution Program in Pittsburgh and Allegheny County, Pennsylvania,\"",
"      <i>",
"       J Urban Health",
"      </i>",
"      , 2011, 88(6):1020-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/21773877/pubmed\" id=\"21773877\" target=\"_blank\">",
"        21773877",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bergasa NY, Alling DW, Talbot TL, et al, &ldquo;Effects of Naloxone Infusions in Patients With the Pruritus of Cholestasis. A Double-Blind, Randomized, Controlled Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 1995, 123(3):161-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/7598296/pubmed\" id=\"7598296\" target=\"_blank\">",
"        7598296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boeuf B, Gauvin F, Guerguerian AM, et al, &ldquo;Therapy of Shock With Naloxone: A Meta-Analysis,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26(11):1910-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/9824088/pubmed\" id=\"9824088\" target=\"_blank\">",
"        9824088",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyer EW, &ldquo;Management of Opioid Analgesic Overdose,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2012, 367(2):146-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/22784117/pubmed\" id=\"22784117\" target=\"_blank\">",
"        22784117",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chamberlain JM and Klein BL, &ldquo;A Comprehensive Review of Naloxone for the Emergency Physician,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1994, 12(6):650-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/7945608/pubmed\" id=\"7945608\" target=\"_blank\">",
"        7945608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doe-Simkins M, Walley AY, Epstein A, et al, &ldquo;Saved by the Nose: Bystander-Administered Intranasal Naloxone Hydrochloride for Opioid Overdose,&rdquo;",
"      <i>",
"       Am J Public Health",
"      </i>",
"      , 2009, 99(5):788-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/19363214/pubmed\" id=\"19363214\" target=\"_blank\">",
"        19363214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Drugs for Pediatric Emergencies,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 101(1):E13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/9734990/pubmed\" id=\"9734990\" target=\"_blank\">",
"        9734990",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fischer CG and Cook DR, &ldquo;The Respiratory and Narcotic Antagonistic Effects of Naloxone in Infants,&rdquo;",
"      <i>",
"       Anesth Anal",
"      </i>",
"      , 1974, 53(6):849-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/4473926/pubmed\" id=\"4473926\" target=\"_blank\">",
"        4473926",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gan TJ, Ginsberg B, Glass PS, et al, &ldquo;Opioid-Sparing Effects of a Low-Dose Infusion of Naloxone in Patient-Administered Morphine Sulfate,&rdquo;",
"      <i>",
"       Anesthesiology",
"      </i>",
"      , 1997, 87(5):1075-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/9366459/pubmed\" id=\"9366459\" target=\"_blank\">",
"        9366459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldfrank L, Weisman RS, Errick JK, et al, &ldquo;A Dosing Nomogram for Continuous Infusion Intravenous Naloxone,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1986, 15(5):566-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/3963538/pubmed\" id=\"3963538\" target=\"_blank\">",
"        3963538",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hantson P, Evenepoel E, Ziade D, et al, &ldquo;Adverse Cardiac Manifestations Following Dextropropoxyphene Overdose: Can Naloxone Be Helpful?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 25(2):263-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/7832361/pubmed\" id=\"7832361\" target=\"_blank\">",
"        7832361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hegenbarth MA, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008, 121(2):433-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/18245435/pubmed\" id=\"18245435\" target=\"_blank\">",
"        18245435",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hoffman RS and Goldfrank LR, &ldquo;The Poisoned Patient With Altered Consciousness. Controversies in the Use of a 'Coma Cocktail',&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1995, 274(7):562-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/7629986/pubmed\" id=\"7629986\" target=\"_blank\">",
"        7629986",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson C, Mayer P, and Grosz D, &ldquo;Pulmonary Edema Following Naloxone Administration in a Healthy Orthopedic Patient,&rdquo;",
"      <i>",
"       J Clin Anesth",
"      </i>",
"      , 1995, 7(4):356-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/7546765/pubmed\" id=\"7546765\" target=\"_blank\">",
"        7546765",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan JL, Marx JA, Calabro JJ, et al, &ldquo;Double-Blind, Randomized Study of Nalmefene and Naloxone in Emergency Department Patients With Suspected Narcotic Overdose,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1999, 34(1):42-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/10381993/pubmed\" id=\"10381993\" target=\"_blank\">",
"        10381993",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kelly A, Kerr D, Dietze P, et al, &ldquo;Randomised Trial of Intranasal Versus Intramuscular Naloxone in Prehospital Treatment for Suspected Opioid Overdose,&rdquo;",
"      <i>",
"       Med J Aust",
"      </i>",
"      , 2005, 182(1):24-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/15651944/pubmed\" id=\"15651944\" target=\"_blank\">",
"        15651944",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kendrick WD, Woods AM, Daly MY, et al, &ldquo;Naloxone Versus Nalbuphine Infusion for Prophylaxis of Epidural Morphine-Induced Pruritus,&rdquo;",
"      <i>",
"       Anesth Analg",
"      </i>",
"      , 1996, 82(3):641-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/8623975/pubmed\" id=\"8623975\" target=\"_blank\">",
"        8623975",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kjellberg F and Tramer MR, &ldquo;Pharmacological Control of Opioid-Induced Pruritus: A Quantitative Systematic Review of Randomized Trials,&rdquo;",
"      <i>",
"       Eur J Anaesthesiol",
"      </i>",
"      , 2001, 18(6):346-57.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/11412287/pubmed\" id=\"11412287\" target=\"_blank\">",
"        11412287",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):876-908.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/20956230/pubmed\" id=\"20956230\" target=\"_blank\">",
"        20956230",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Merigian KS, &ldquo;Cocaine-Induced Ventricular Arrhythmias and Rapid Atrial Fibrillation Temporally Related to Naloxone Administration,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1993, 11(1):96-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/8447884/pubmed\" id=\"8447884\" target=\"_blank\">",
"        8447884",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mycyk MB, Szyszko AL, and Aks SE, &ldquo;Nebulized Naloxone Gently and Effectively Reverses Methadone Intoxication,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 2003, 24(2):185-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/12609650/pubmed\" id=\"12609650\" target=\"_blank\">",
"        12609650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Comprehensive Cancer Network&reg; (NCCN), &ldquo;Clinical Practice Guidelines in Oncology&trade;: Adult Cancer Pain,&rdquo; Version 2.2011. Available at  file://www.nccn.org/professionals/physician_gls/PDF/pain.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Connor PG and Kosten TR, &ldquo;Rapid and Ultrarapid Opioid Detoxification Techniques,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1998, 279(3):229-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/9438745/pubmed\" id=\"9438745\" target=\"_blank\">",
"        9438745",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olsen KS, &ldquo;Naloxone Administration and Laryngospasm Followed by Pulmonary Edema,&rdquo;",
"      <i>",
"       Intensive Care Med",
"      </i>",
"      , 1990, 16(5):340-1.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/2212264/pubmed\" id=\"2212264\" target=\"_blank\">",
"        2212264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Malley-Dafner L, Davies P, &ldquo;Naloxone-Induced Pulmonary Edema,&rdquo;",
"      <i>",
"       Am J Nurs",
"      </i>",
"      , 2000, 100(11):24AA-JJ.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pasero C and McCaffery M, &ldquo;Reversing Respiratory Depression With Naloxone,&rdquo;",
"      <i>",
"       Am J Nurs",
"      </i>",
"      , 2000, 100(2):26.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/10683639/pubmed\" id=\"10683639\" target=\"_blank\">",
"        10683639",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry HE and Shannon MW, &ldquo;Diagnosis and Management of Opioid- and Benzodiazepine-Induced Comatose Overdose in Children,&rdquo;",
"      <i>",
"       Curr Opin Pediatr",
"      </i>",
"      , 1996, 8(3):243-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/8814402/pubmed\" id=\"8814402\" target=\"_blank\">",
"        8814402",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain,&rdquo; 6th ed, Glenview, IL: American Pain Society (APS), 2008.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robertson TM, Hendey GW, Stroh G, et al, &ldquo;Intranasal Naloxone is a Viable Alternative to Intravenous Naloxone for Prehospital Narcotic Overdose,&rdquo;",
"      <i>",
"       Prehosp Emerg Care",
"      </i>",
"      , 2009, 13(4):512-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/19731165/pubmed\" id=\"19731165\" target=\"_blank\">",
"        19731165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salvucci AA Jr, Eckstein M, and Iscovich AL, &ldquo;Submental Injection of Naloxone,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1995, 25(5):719-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/7741359/pubmed\" id=\"7741359\" target=\"_blank\">",
"        7741359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith K, Hopp M, Mundin G, et al, \"Low Absolute Bioavailability of Oral Naloxone in Healthy Subjects,\"",
"      <i>",
"       Int J Clin Pharmacol Ther",
"      </i>",
"      , 2012, 50(5):360-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/22541841/pubmed\" id=\"22541841\" target=\"_blank\">",
"        22541841",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Storrow AB, Wians FH Jr, Mikkelsen SL, et al, &ldquo;Does Naloxone Cause a Positive Urine Opiate Screen?&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1994, 24(6):1151-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/7978599/pubmed\" id=\"7978599\" target=\"_blank\">",
"        7978599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tandberg D and Abercrombie D, &ldquo;Treatment of Heroin Overdose With Endotracheal Naloxone,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1982, 11(8):443-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/7103164/pubmed\" id=\"7103164\" target=\"_blank\">",
"        7103164",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tenenbein M, &ldquo;Continuous Naloxone Infusion for Opiate Poisoning in Infancy,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1984, 105(4):645-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/6481543/pubmed\" id=\"6481543\" target=\"_blank\">",
"        6481543",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Trujillo MH, Guerrero J, Fragachan C, et al, &ldquo;Pharmacologic Antidotes in Critical Care Medicine: A Practical Guide for Drug Administration,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1998, 26(2):377-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/9468179/pubmed\" id=\"9468179\" target=\"_blank\">",
"        9468179",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vanden Hoek TL, Morrison LJ, Shuster M, et al, &ldquo;Part 12: Cardiac Arrest in Special Situations: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):829-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/20956228/pubmed\" id=\"20956228\" target=\"_blank\">",
"        20956228",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Vonderen JJ, Siew ML, Hooper SB, et al, \"Effects of Naloxone on the Breathing Pattern of a Newborn Exposed to Maternal Opiates,\"",
"      <i>",
"       Acta Pediatr",
"      </i>",
"      , 2012, 101(7):e309-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/22372574/pubmed\" id=\"22372574\" target=\"_blank\">",
"        22372574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wampler DA, Molina DK, McManus J, et al, \"No Deaths Associated With Patient Refusal of Transport After Naloxone-Reversed Opioid Overdose,\"",
"      <i>",
"       Prehosp Emerg Care",
"      </i>",
"      , 2011, 15(3):320-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/21612385/pubmed\" id=\"21612385\" target=\"_blank\">",
"        21612385",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weber JM, Tataris KL, Hoffman JD, et al, \"Can Nebulized Naloxone Be Used Safely and Effectively by Emergency Medical Services for Suspected Opioid Overdose?\"",
"      <i>",
"       Prehosp Emerg Care",
"      </i>",
"      , 2012, 16(2):289-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?34/24/35207/abstract-text/22191727/pubmed\" id=\"22191727\" target=\"_blank\">",
"        22191727",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9678 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-9F69235DB9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35207=[""].join("\n");
var outline_f34_24_35207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2980444\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199499\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199464\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199481\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199465\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199436\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199421\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199440\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199505\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199439\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199496\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199507\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199497\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199443\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199425\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299739\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199430\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199432\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199446\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199468\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199447\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323451\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199434\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199448\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199424\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F199442\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?31/10/31907?source=related_link\">",
"      Naloxone: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?20/4/20551?source=related_link\">",
"      Naloxone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_24_35208="Diagnosis and management of retained placenta after vaginal birth";
var content_f34_24_35208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnosis and management of retained placenta after vaginal birth",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/24/35208/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35208/contributors\">",
"     Andrew Weeks, MD, MRCOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/24/35208/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35208/contributors\">",
"     Susan M Ramin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/24/35208/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35208/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/24/35208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6052582\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of retained placenta varies greatly worldwide, ranging from 0.01 to 6.3 percent of vaginal deliveries, depending on the population studied and definition used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/1\">",
"     1",
"    </a>",
"    ]. A retained or partially separated placenta interferes with normal uterine contraction, which leads to hemorrhage. In areas where access to a well-equipped hospital is readily available, mortality from hemorrhage is very low. In many parts of the developing world, however, the case fatality rate is high due to long travelling times to hospitals and lack of appropriate equipment and medications for active management of this condition in local settings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6052589\">",
"    <span class=\"h1\">",
"     DEFINITION OF RETAINED PLACENTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus worldwide as to the length of the third stage after which a placenta should be termed \"retained\" and intervention initiated. The optimum time balances the risks of leaving the placenta in situ (hemorrhage, infection) and the risks of manual removal (hemorrhage, infection, uterine trauma) versus the likelihood that the placenta will spontaneously deliver with expectant management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intrapartum guidelines produced for the National Institute for Health and Clinical Excellence (NICE) suggest intervention when the placenta has been retained for 30 minutes after birth despite active management of the third stage of labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/3\">",
"     3",
"    </a>",
"    ]. NICE intrapartum guidelines also suggest expectant management for 60 minutes when the third stage has been managed physiologically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/3\">",
"     3",
"    </a>",
"    ]. Nonphysiologic (active) management generally consists of controlled cord traction, uterine massage, and administration of a uterotonic agent prior to placenta separation.",
"   </p>",
"   <p>",
"    The World Health Organization (WHO) manual for childbirth defines retained placenta as lack of expulsion within 30 minutes of delivery of the baby [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/4\">",
"     4",
"    </a>",
"    ]. In the absence of bleeding, they recommend that the woman be observed for a further 30 minutes (or more) after the initial 30 minutes before manual removal of the placenta, but intervention should be initiated sooner in bleeding patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41639?source=see_link&amp;anchor=H7#H7\">",
"     \"Uterotonic drugs for management of the third stage of labor\", section on 'Active management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Data from trials of active versus expectant management of the third stage of labor show that only 2 percent of placentas are retained at 30 minutes with active management, but it takes about 60 minutes before only 2 percent of placentas are retained if the third stage is managed physiologically (",
"    <a class=\"graphic graphic_figure graphicRef78067 \" href=\"mobipreview.htm?28/20/29006\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/6\">",
"     6",
"    </a>",
"    ]. In a randomized trial of management of retained placenta that recruited women after 60 minutes of the third stage had elapsed, the spontaneous delivery rate over the subsequent 30 minutes in the nonintervention (control) group was 0 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The need for intervention is supported by observations that the risk of hemorrhage increases with the length of time the placenta is retained. One study of over 12,000 births&nbsp;found that the risk of hemorrhage increased after 30 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/8\">",
"     8",
"    </a>",
"    ], while another used a ROC curve to demonstrate that the optimal cut-off time for the prediction of hemorrhage was 18 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/9\">",
"     9",
"    </a>",
"    ]. Although the risk of hemorrhage begins to increase after 20 to 30 minutes, as shown above, delaying manual removal will lead to spontaneous delivery of many placentas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5282494\">",
"    <span class=\"h1\">",
"     TYPES OF RETAINED PLACENTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term retained placenta covers a number of pathologies. Some placentas are simply trapped behind a partially closed cervix (the incarcerated or trapped placenta); some are adherent to the uterine wall, but easily separated manually (placenta adherens); while others are pathologically invading the myometrium (placenta accreta).",
"   </p>",
"   <p>",
"    A prospective analysis of deliveries in Liverpool Women&rsquo;s Hospital from 2005 to 2006 found that the third stage was over 30 minutes in 3.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/10\">",
"     10",
"    </a>",
"    ]. Manual removal of the placenta was performed in 127 of the 287 cases; 81 percent of retained placentas were placenta adherens, 13 percent were trapped, and 6 percent had some areas of accreta (ie, the placenta had to be removed piecemeal), but none required hysterectomy for placenta accreta. In another series, 51 percent of placentas manually removed to prevent postpartum hemorrhage were described by the operator as trapped [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/11\">",
"     11",
"    </a>",
"    ]. The close association of placenta accreta with both previous cesarean delivery and placenta previa suggests that it is rarely encountered at vaginal delivery. We estimate that only 1 in 440 women with a retained placenta following vaginal delivery will have placenta accreta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H912257\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of retained placenta has varied between settings and over time. In a systematic review of observational studies, the median rate of retained placenta at 30 minutes in high resource settings was 2.7 percent compared to 1.5 percent in low resource settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/1\">",
"     1",
"    </a>",
"    ]. The rate of retained placenta has also been increasing: a review of historical data from nine hospitals in the British Isles reported an increase from 0.5 percent in the 1930s to 2.3 percent in the 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/1\">",
"     1",
"    </a>",
"    ]. In 2005-2006, the rate of retained placenta in our hospital was 3.3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/10\">",
"     10",
"    </a>",
"    ]. The difference in prevalence between the least and most developed countries and the observed increase in prevalence over time are probably related to differences in epidemiology and risk factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28118534\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors associated with retained placenta include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/8,12-17\">",
"     8,12-17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Previous retained placenta",
"     </li>",
"     <li>",
"      Preterm birth",
"     </li>",
"     <li>",
"      Previous curettage",
"     </li>",
"     <li>",
"      Induced or augmented labor",
"     </li>",
"     <li>",
"      Preeclampsia",
"     </li>",
"     <li>",
"      Delivery in a labor bed (rather than standing or squatting)",
"     </li>",
"     <li>",
"      Midwife delivery (possibly because midwives are more likely to use physiological rather than active management of the third stage of labor)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The strongest association is with preterm birth (particularly less than 27 weeks (RR 6 to 13) (",
"    <a class=\"graphic graphic_figure graphicRef69724 \" href=\"mobipreview.htm?36/57/37789\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/8\">",
"     8",
"    </a>",
"    ] and previous retained placenta (OR 12.6, 95% CI 3.6-44.1)) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of intravenous ergometrine may also be a risk factor for retained placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. A survey of birth centers observed that significantly more vaginal deliveries managed with methylergometrine in the third stage were complicated by retained placenta than vaginal deliveries managed with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    (2.7 versus 1.8 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/14\">",
"     14",
"    </a>",
"    ]. In addition, a randomized trial comparing intravenous ergometrine 0.5 mg with physiological management of the third stage of labor observed a large increase in the need for manual removal of the placenta with ergometrine use (relative risk 19.5, 95% CI 2.6-145.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/13\">",
"     13",
"    </a>",
"    ]. This may be a peculiarity of ergometrine which, in contrast to oxytocin, causes a powerful, continuous uterine contraction that may be more likely to trap the placenta when it detaches.",
"   </p>",
"   <p>",
"    Uterine abnormalities also appear to play a role in retained placenta. In one series of 63 pregnancies in women with M&uuml;llerian duct fusion abnormalities, 11 (17 percent) had retained placentas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/18\">",
"     18",
"    </a>",
"    ]. In another series, routine hysteroscopy of 48 women who underwent manual removal of the placenta identified an incomplete uterine septum in 15 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/19\">",
"     19",
"    </a>",
"    ]. We do not suggest routine postpartum uterine evaluation of women with a retained placenta, given the rarity of these abnormalities in the general population compared to the prevalence of retained placenta, and that detection of minor uterine anomalies after term delivery is unlikely to affect pregnancy management in subsequent pregnancies.",
"   </p>",
"   <p>",
"    Risk factors for placenta accreta (placenta previa after a previous cesarean delivery) are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=see_link&amp;anchor=H3937600#H3937600\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\", section on 'Risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6052603\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The three types of retained placenta, incarcerated or trapped placenta, placenta accreta, and placenta adherens, have different origins, pathologies, and outcomes (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65797 \" href=\"mobipreview.htm?39/21/40278\">",
"     image 1",
"    </a>",
"    ). The incarcerated or trapped placenta is simply a separated placenta that has detached completely from the uterus, but not delivered spontaneously or with light cord traction because the cervix has begun to close. Placenta accreta is due to a defect in the decidua, resulting in trophoblast invasion and abnormal attachment. A hypothesis for the origin of placenta adherens is presented below.",
"   </p>",
"   <p>",
"    Ultrasound studies have improved our understanding of both normal and abnormal third stage of labor. Four phases can be identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Latent phase: Immediately after birth, all of the myometrium contracts except for the portion beneath the placenta.",
"     </li>",
"     <li>",
"      Contraction phase: The retroplacental myometrium contracts.",
"     </li>",
"     <li>",
"      Detachment phase: Contraction of the retroplacental myometrium produces horizontal (shear) stress on the maternal surface of the placenta, causing it to detach.",
"     </li>",
"     <li>",
"      Expulsion phase: Myometrial contractions expel the detached placenta from the uterus.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Contractions occurring prior to delivery are insufficient to cause placental detachment, as the myometrium is unable to achieve the necessary strain for detachment in the presence of the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/21\">",
"     21",
"    </a>",
"    ]. The reduction of contractile strength in the retroplacental myometrium makes evolutionary sense for both the mother and fetus, as it not only prevents inadvertent placental detachment, but also allows good blood flow to the placenta to be maintained.",
"   </p>",
"   <p>",
"    These ultrasound studies also provide insight on the etiology of retained placenta and suggest that a prolonged third stage is due to contractile failure in the retroplacental area. In the cases of retained placenta that underwent serial ultrasonographic myometrial thickness measurements, the authors found universal failure of retroplacental contraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The finding that women with placenta adherens have retroplacental contractile failure may explain the observation of an association between retained placenta and dysfunctional labor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/8\">",
"     8",
"    </a>",
"    ]. In fact, an observational study found that women undergoing cesarean delivery for dysfunctional labor had to have their placenta removed manually more often than those undergoing prelabor cesarean delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/22\">",
"     22",
"    </a>",
"    ]. Another study observed less retroplacental myometrial contraction in dysfunctional labors than in normally progressing labors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/23\">",
"     23",
"    </a>",
"    ]. These findings suggest that some patients have a localized failure of myometrial contractility, resulting in both dysfunctional labor and retained placenta. If the localized contractile failure is severe, then a cesarean delivery may need to be performed for failure to progress. If localized contractile failure is not severe, then the woman may achieve vaginal delivery, but have a retained placenta.&nbsp;",
"   </p>",
"   <p>",
"    These findings also suggest that the problem of retained placenta could be solved by stimulating contractions in the retroplacental myometrium.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5286022\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF TYPE OF RETAINED PLACENTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The classic signs of placental separation are (1) lengthening of the umbilical cord, (2) a gush of blood from the vagina signifying separation of the placenta from the uterine wall, (3) change in the shape of the uterine fundus from discoid to globular with elevation of the fundal height, and (4) contraction of the fundus. If these signs are observed and the edge of the placenta is palpable through a narrow cervical os, the placenta is probably trapped. The absence of these signs and the presence of a soft and wide fundus suggest placenta adherens or placenta accreta.",
"   </p>",
"   <p>",
"    Ultrasound is helpful for differentiating between a trapped and adherent placenta, and should be performed if the diagnosis is uncertain after physical examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/20\">",
"     20",
"    </a>",
"    ]. With a trapped placenta, the myometrium is thickened all around the uterus and a clear demarcation is often seen between the placenta and the myometrium. In contrast, with an adherent placenta, the myometrium will be thickened in all areas except where the placenta is attached, where it will be very thin or even invisible (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65797 \" href=\"mobipreview.htm?39/21/40278\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Placenta accreta should be suspected in women with retained placenta and risk factors for decidual defects (eg, history of transendometrial surgery, intrauterine adhesions, submucosal leiomyoma). Focal or complete placenta accreta is usually discovered only at the time of attempted manual removal when a plane cannot be identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6052644\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the management of retained placenta have not taken into account the type of retained placenta into their",
"    <span class=\"nowrap\">",
"     inclusion/exclusion",
"    </span>",
"    criteria or in outcome data. This may partially explain why the retained placenta rate varies throughout the world, and why both uterotonic drugs and uterine relaxants can be successful. The following approach to management of retained placenta is based on our understanding of the etiology and pathophysiology of this disorder (",
"    <a class=\"graphic graphic_table graphicRef54491 \" href=\"mobipreview.htm?37/63/38907\">",
"     table 1",
"    </a>",
"    ). In patients who underwent active management of the third stage of labor, after the placenta has been retained for 30 minutes, we suggest performing an ultrasound examination to determine whether the placenta is trapped or adherent and beginning preparations for management, as appropriate for the type of retained placenta.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2373809\">",
"    <span class=\"h2\">",
"     Trapped placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use controlled cord traction (Brandt-Andrews or Cr&eacute;de maneuver) as the initial maneuver for delivery of a detached but trapped placenta. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33114?source=see_link&amp;anchor=H32#H32\">",
"     \"Management of normal labor and delivery\", section on 'Active management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the uterus is atonic, administration of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    can promote uterine contractions to help expel the placenta, but makes manual removal more difficult due to constriction of the lower uterus. Similarly, ergometrine may cause tetanic uterine contractions that may delay the expulsion of the placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If partial closure of the cervix",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a contracted lower uterine segment is inhibiting egress, glyceryl trinitrate (nitroglycerine) can be administered to relax the uterus and facilitate delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. There are no high quality data to support a specific recommendation for dose or route of administration. We use translingual glyceryl trinitrate 2 sprays (400",
"    <span class=\"nowrap\">",
"     micrograms/spray)",
"    </span>",
"    onto or under the tongue. Other options include administration of sequential bolus intravenous injections: 50 micrograms, maximum cumulative dose 200 micrograms, until sufficient uterine relaxation is achieved to allow manual removal of the placenta, or sublingual tablets: 0.6 to 1.2 milligrams. Uterine relaxation occurs within 60 seconds after the dose and lasts for one to two minutes. Blood pressure should be monitored continuously, as a drop in blood pressure always occurs, although most patients do not become hypotensive. Using sequential boluses and monitoring maternal blood pressure help to minimize occurrence of severe hypotension. General anesthesia may also be used for adequate uterine relaxation to remove trapped placenta.",
"   </p>",
"   <p>",
"    A randomized trial assigned 24 women with unspecified types of retained placenta to receive either 1 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    or placebo tablets sublingually after intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    and controlled umbilical cord traction failed to expel the placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/28\">",
"     28",
"    </a>",
"    ]. All 12 women in the nitroglycerin group had successful delivery of placenta versus only 1 of the 12 women in the placebo group (p&lt;0.0001). In those given nitroglycerin, systolic blood pressure and diastolic blood pressure dropped by a mean of 6 and 5 mmHg, respectively. Nitroglycerin treatment also reduced the mean blood loss by nearly 300 mLs.",
"   </p>",
"   <p>",
"    If these measures fail to deliver the placenta, we manually remove it. (See",
"    <a class=\"local\" href=\"#H2373846\">",
"     'Manual removal of placenta'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2373817\">",
"    <span class=\"h2\">",
"     Placenta adherens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manual removal is the most successful means of extracting placenta adherens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2373846\">",
"    <span class=\"h3\">",
"     Manual removal of placenta",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manual removal of the placenta is painful; therefore, adequate analgesia should be achieved using regional or general anesthesia, or conscious sedation. The procedure should be performed in a room (eg, cesarean delivery room) where aseptic technique is easily achieved and appropriate personnel, medications, and equipment are available to deal with any complications (eg, hemorrhage, placenta accreta, uterine perforation) that arise. Manual removal of the placenta is associated with an increased risk of endometritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. For this reason, we agree with World Health Organization (WHO) recommendations to administer a single dose of a prophylactic broad spectrum antibiotic(s), although there are no data to support or refute this practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After routine surgical preparation and bladder catheterization, one hand follows the path of the umbilical cord through the vagina, cervix, and lower uterine segment to find the maternal-placental interface, while the other hand steadies the uterine fundus through the maternal abdomens. The plane of the interface, which feels velvety and irregular, is gently dissected using a side-to-side motion of the fingers. If the cervix is tightly closed, uterine relaxation may be achieved with glyceryl trinitrate as an intravenous bolus of 50 to 200&nbsp;micrograms or with 0.6 mg sublingually. As discussed above, marked uterine relaxation occurs within 60 seconds, and the uterus recovers its tone after one to two minutes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2375270\">",
"    <span class=\"h3\">",
"     Umbilical vein injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is insufficient evidence that intraumbilical vein injection of prostaglandins is effective and fair evidence that intraumbilical vein injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is ineffective in management of retained placenta. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2375467\">",
"    <span class=\"h4\">",
"     Catheterization of the umbilical vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;One successful method for directly injecting an infusate into the umbilical vein is to use a 30 mL syringe connected to a size 10 French (infant) gastric feeding tube which has been threaded down the vein (",
"    <a class=\"graphic graphic_figure graphicRef78068 \" href=\"mobipreview.htm?6/12/6340\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/31\">",
"     31",
"    </a>",
"    ]. To insert the tube, the vein can be opened with a scalpel or the cord can be recut and the tube passed down the largest of the three exposed vessels until resistance is felt. The tube is then withdrawn by 5 cm to allow for any divisions of the vein prior to its insertion into the placenta. An umbilical vein catheter (4 to 5 French) or 18 gauge needle can also be used if a gastric tube is not available.",
"   </p>",
"   <p>",
"    A key point is to infuse a large volume of fluid. One study found that injection of less than 30 mL resulted in capillary filling of cotyledons in only 20 to 60 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/32\">",
"     32",
"    </a>",
"    ], which may explain poor success rates in studies using smaller infusate volumes. The umbilical cord is clamped after the injection to prevent backflow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20784508\">",
"    <span class=\"h4\">",
"     Umbilical vein prostaglandin injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraumbilical prostaglandin injection is a promising technique. In a meta-analysis including two small randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/7,33\">",
"     7,33",
"    </a>",
"    ], prostaglandin solution compared with saline solution alone was associated with a significant reduction in performance of manual removal of placenta (RR 0.42; 95% CI 0.22-0.82;",
"    <span class=\"nowrap\">",
"     9/31",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     14/20)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One trial that randomly assigned 28 women with retained placenta to receive an intraumbilical vein injection of prostaglandin F2&alpha; (20 mg diluted in 20 mL normal saline),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    (30 units in 20 mL normal saline), or saline alone reported the technique was successful in all 10 women who received the prostaglandin; placental expulsion typically occurred in five to eight minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/7\">",
"     7",
"    </a>",
"    ]. In the oxytocin group, 6 of 11 women had placental expulsion in 11 to 15 minutes, while all 7 women injected with saline alone required manual removal.",
"   </p>",
"   <p>",
"    Another randomized trial compared intraumbilical vein injection of dissolved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    tablets (800 mcg in 30 mLs saline) to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    (50 units in 30 mLs saline) and to saline alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/33\">",
"     33",
"    </a>",
"    ]. The success rates for misoprostol, oxytocin, and saline (control) were 57, 19, and 46 percent, respectively. Misoprostol was statistically more effective than saline alone, but oxytocin was not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2375393\">",
"    <span class=\"h4\">",
"     Umbilical vein oxytocin injection",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is hypothesized that intraumbilical vein injection allows",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    to be directed specifically to the area of myometrial contractile failure, while sparing the remainder of the uterus. However, intraumbilical vein injection of oxytocin is not recommended as there is insufficient evidence of efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/5\">",
"     5",
"    </a>",
"    ]. In a systematic review of trials of this approach, intraumbilical vein oxytocin injection had little or no effect on placental separation, possibly due to the wide range of oxytocin doses and infusion volumes used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/34\">",
"     34",
"    </a>",
"    ]. The highest quality data derive from a large, multicenter, placebo-controlled, randomized trial in which 577 women with retained placenta were given high dose oxytocin (50 units in 30 mL saline) or an equivalent volume of saline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/35\">",
"     35",
"    </a>",
"    ]. There were no differences between groups in rate of manual placental removal or frequency of adverse events.",
"   </p>",
"   <p>",
"    The reason for the lack of efficacy of the intraumbilical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    injections is not clear. The oxytocin may be deactivated by placental enzymes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6052653\">",
"    <span class=\"h3\">",
"     Systemic uterotonic drugs",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2376024\">",
"    <span class=\"h4\">",
"     Prostaglandins",
"    </span>",
"    &nbsp;&mdash;&nbsp;A double blind trial randomly assigned women with retained placentas to treatment with sulprostone 250 mcg (a prostaglandin E2 derivative) or placebo administered intravenously over 30 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/37\">",
"     37",
"    </a>",
"    ]. Significantly more patients in the sulprostone group expelled the placenta without need for manual extraction",
"    <span class=\"nowrap\">",
"     (13/24",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     4/26).",
"    </span>",
"    In a retrospective review, 40 percent of 126 consecutive patients with retained placenta expelled the placenta after receiving intravenous sulprostone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/38\">",
"     38",
"    </a>",
"    ]. These data, although promising, are insufficient evidence of efficacy.",
"   </p>",
"   <p>",
"    In low resource settings, the prostaglandin E1 analogue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    may be more suitable due to its heat stability, wide availability, and low cost. It is being evaluated in an ongoing randomized trial in Tanzania [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2376031\">",
"    <span class=\"h4\">",
"     Oxytocin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although placentas are expelled sooner after birth when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    is used than when it is not used, there is no evidence that it is an effective treatment after diagnosis of retained placenta. No randomized trials evaluating its efficacy in this setting have been performed. WHO guidelines recommend that clinicians administer 10 units of oxytocin in combination with controlled cord traction for retained placenta without bleeding, but perform manual extraction if bleeding is present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6052688\">",
"    <span class=\"h2\">",
"     Unexpected placenta accreta",
"    </span>",
"    &nbsp;&mdash;&nbsp;During manual extraction of the placenta, the clinician may note a small area where the placenta is very adherent to the uterus. This can usually be managed by slow persistent finger dissection to create a plane of separation at the maternal-placental interface. The plane of dissection is often partially through the placenta in these cases, which leaves some placenta adherent to the decidua and myometrium. This does not lead to postpartum hemorrhage as long as the uterus contracts well and there is no area of subinvolution at the site of the retained placental fragments. Sharp curettage should be avoided, if possible, as the myometrium may be very thin at the point of adherence, thus increasing the risk of perforation. Curettage of the postpartum uterus also increases the risk of forming intrauterine adhesions (Asherman syndrome). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link&amp;anchor=H2#H2\">",
"     \"Intrauterine adhesions\", section on 'Etiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/16/19719?source=see_link&amp;anchor=H1320751#H1320751\">",
"     \"Management of placenta accreta, increta, and percreta\", section on 'Focal accreta'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, a complete placenta accreta is first recognized at the time of manual removal of the placenta. In these cases, there is no plane of dissection between the uterus and placenta and, almost invariably, attempts at manual removal lead to life-threatening hemorrhage. We suggest administration of high dose uterotonic drugs and preparation for hysterectomy, which is the definitive therapy of placenta accreta.",
"   </p>",
"   <p>",
"    For young women of low parity who want to preserve their childbearing potential, interventions such as a trial of balloon tamponade or uterine artery embolization by an interventional radiologist may be useful, as long as delay in definitive surgical therapy does not result in severe coagulopathy. Conservative measures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41929?source=see_link\">",
"     \"Management of postpartum hemorrhage at vaginal delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=see_link\">",
"     \"Clinical features and diagnosis of placenta accreta, increta, and percreta\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is no vaginal bleeding following attempts to remove the placenta and uterine conservation is desired to preserve fertility, leaving the placenta in situ and awaiting spontaneous placental resorption is an option. We administer broad spectrum antibiotic prophylaxis and closely monitor the patient, in hospital initially, and then at home. Although some clinicians advocate use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , there is no evidence that this improves outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/41\">",
"     41",
"    </a>",
"    ]. Conservative management of placenta accreta carries significant risks, but is an option for well motivated, compliant women who wish to preserve their fertility and understand the significant risks of infection, hemorrhage, need for emergency hysterectomy, and mortality. Outcomes are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/16/19719?source=see_link&amp;anchor=H21108326#H21108326\">",
"     \"Management of placenta accreta, increta, and percreta\", section on 'Indications for uterine conservation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5286108\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few studies on techniques for the prevention of retained placenta, and no method has been clearly proven to be effective. As discussed above, the use of prophylactic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    reduces the mean length of the third stage, but does not affect the need for manual removal of the placenta. Likewise, timing of oxytocin administration during the third stage of labor does not significantly impact the frequency of retained placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/42\">",
"     42",
"    </a>",
"    ]. Cord drainage appears to reduce the number of placentas retained at 30 minutes after birth (one trial, n = 477, RR 0.28, 95% CI 0.10-0.73) and the length of third stage of labor (one trial, n = 147, weighted mean difference -5.46, 95% CI -8.02 to -2.90) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/43\">",
"     43",
"    </a>",
"    ]. However, a study of early versus delayed cord clamping (which would have the same effect) found no clear difference between groups in need for manual removal of the placenta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/44\">",
"     44",
"    </a>",
"    ]. The effect of cord traction is being studied in an ongoing randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35208/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2376691\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two percent of placentas are retained at 30 minutes with active management of the third stage of labor. It takes about 60 minutes before only 2 percent of placentas are retained if the third stage is managed physiologically. (See",
"      <a class=\"local\" href=\"#H6052589\">",
"       'Definition of retained placenta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The term retained placenta has been applied to placentas trapped behind a partially closed cervix (the incarcerated or trapped placenta); placentas that remain adherent to the uterine wall, but are easily separated manually (placenta adherens); as well as those that are pathologically invading the myometrium (placenta accreta). (See",
"      <a class=\"local\" href=\"#H5282494\">",
"       'Types of retained placenta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The strongest risk factor for retained placenta is gestational age less than 26 weeks (",
"      <a class=\"graphic graphic_figure graphicRef69724 \" href=\"mobipreview.htm?36/57/37789\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H28118534\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The classic signs of placental separation are (1) lengthening of the umbilical cord, (2) a gush of blood from the vagina signifying separation of the placenta from the uterine wall (3) change in the shape of the uterine fundus and (4) contraction of the fundus. If these signs are observed and the edge of the placenta is palpable through a narrow cervical os, the placenta is probably trapped. The absence of these signs and the presence of a soft and wide fundus suggest placenta adherens or placenta accreta. Placenta accreta is rare at vaginal delivery. (See",
"      <a class=\"local\" href=\"#H5286022\">",
"       'Diagnosis of type of retained placenta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Routine ultrasound evaluation is unnecessary, but an ultrasound examination is helpful for differentiating between a trapped and adherent placenta when the diagnosis is uncertain after physical examination. (See",
"      <a class=\"local\" href=\"#H5286022\">",
"       'Diagnosis of type of retained placenta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prompt intervention is indicated for women with significant bleeding. In the absence of significant bleeding, we suggest intervention when the placenta has been retained for 30 minutes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6052589\">",
"       'Definition of retained placenta'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If a trapped placenta is not expelled with controlled cord traction (pull) and the uterus is atonic, we suggest administration of intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/0/5125?source=see_link\">",
"       oxytocin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) and avoiding ergometrine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). In the absence of atony, we recommend glyceryl trinitrate (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2373809\">",
"       'Trapped placenta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest manual extraction of placenta adherens rather than uterotonic drugs (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest administering prophylactic antibiotics when performing manual extraction (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2373846\">",
"       'Manual removal of placenta'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with a small area of placenta accreta, we suggest slow persistent finger dissection to create a plane of separation at the maternal-placental interface (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6052688\">",
"       'Unexpected placenta accreta'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hysterectomy is the definitive therapy for complete placenta accreta. If placenta accreta is first recognized at delivery, there is no vaginal bleeding following attempts to remove the placenta, and uterine conservation is desired to preserve fertility, we suggest leaving the placenta in situ and awaiting spontaneous placental resorption (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Conservative management of placenta accreta carries significant risks, but is an option for well motivated, compliant women who wish to preserve their fertility and understand the significant risks of infection, hemorrhage, need for emergency hysterectomy, and mortality. (See",
"      <a class=\"local\" href=\"#H6052688\">",
"       'Unexpected placenta accreta'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/1\">",
"      Cheung WM, Hawkes A, Ibish S, Weeks AD. The retained placenta: historical and geographical rate variations. J Obstet Gynaecol 2011; 31:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/2\">",
"      Hidar S, Jennane TM, Bouguizane S, et al. The effect of placental removal method at cesarean delivery on perioperative hemorrhage: a randomized clinical trial ISRCTN 49779257. Eur J Obstet Gynecol Reprod Biol 2004; 117:179.",
"     </a>",
"    </li>",
"    <li>",
"     National Collaborating Centre for Women&rsquo;s and Children&rsquo;s Health (NCCWCH). Intrapartum Care. Care of healthy women and their babies during childbirth. RCOG Press, London 2007.",
"    </li>",
"    <li>",
"     World Health Organization (WHO). Pregnancy, childbirth, postpartum and newborn care: a guide for essential practice, 2nd ed, WHO, Genva 2006. p.B11.",
"    </li>",
"    <li>",
"     World Health Organization (WHO). WHO guidelines for the management of postpartum haemorrhage and retained placenta. WHO, Geneva 2009.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/6\">",
"      Weeks AD. The retained placenta. Best Pract Res Clin Obstet Gynaecol 2008; 22:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/7\">",
"      Bider D, Dulitzky M, Goldenberg M, et al. Intraumbilical vein injection of prostaglandin F2 alpha in retained placenta. Eur J Obstet Gynecol Reprod Biol 1996; 64:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/8\">",
"      Combs CA, Laros RK Jr. Prolonged third stage of labor: morbidity and risk factors. Obstet Gynecol 1991; 77:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/9\">",
"      Magann EF, Evans S, Chauhan SP, et al. The length of the third stage of labor and the risk of postpartum hemorrhage. Obstet Gynecol 2005; 105:290.",
"     </a>",
"    </li>",
"    <li>",
"     Khan and Weeks, AD, local audit data.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/11\">",
"      Rogers J, Wood J, McCandlish R, et al. Active versus expectant management of third stage of labour: the Hinchingbrooke randomised controlled trial. Lancet 1998; 351:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/12\">",
"      Adelusi B, Soltan MH, Chowdhury N, Kangave D. Risk of retained placenta: multivariate approach. Acta Obstet Gynecol Scand 1997; 76:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/13\">",
"      Begley CM. A comparison of 'active' and 'physiological' management of the third stage of labour. Midwifery 1990; 6:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/14\">",
"      Hammar M, Bostr&ouml;m K, Borgvall B. Comparison between the influence of methylergometrine and oxytocin on the incidence of retained placenta in the third stage of labour. Gynecol Obstet Invest 1990; 30:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/15\">",
"      Hall MH, Halliwell R, Carr-Hill R. Concomitant and repeated happenings of complications of the third stage of labour. Br J Obstet Gynaecol 1985; 92:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/16\">",
"      Owolabi AT, Dare FO, Fasubaa OB, et al. Risk factors for retained placenta in southwestern Nigeria. Singapore Med J 2008; 49:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/17\">",
"      Endler M, Gr&uuml;newald C, Saltvedt S. Epidemiology of retained placenta: oxytocin as an independent risk factor. Obstet Gynecol 2012; 119:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/18\">",
"      Green LK, Harris RE. Uterine anomalies. Frequency of diagnosis and associated obstetric complications. Obstet Gynecol 1976; 47:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/19\">",
"      Golan A, Raziel A, Pansky M, Bukovsky I. Manual removal of the placenta--its role in intrauterine adhesion formation. Int J Fertil Menopausal Stud 1996; 41:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/20\">",
"      Herman A, Weinraub Z, Bukovsky I, et al. Dynamic ultrasonographic imaging of the third stage of labor: new perspectives into third-stage mechanisms. Am J Obstet Gynecol 1993; 168:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/21\">",
"      Deyer TW, Ashton-Miller JA, Van Baren PM, Pearlman MD. Myometrial contractile strain at uteroplacental separation during parturition. Am J Obstet Gynecol 2000; 183:156.",
"     </a>",
"    </li>",
"    <li>",
"     Weeks, AD. The Retained Placenta. In: Progress in Obstetrics and Gynaecology 16, Studd J (Ed), Churchill Livingston, Edinburgh 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/23\">",
"      Weeks AD. Placental influences on the rate of labour progression: a pilot study. Eur J Obstet Gynecol Reprod Biol 2003; 106:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/24\">",
"      Dufour P, Vinatier D, Puech F. The use of intravenous nitroglycerin for cervico-uterine relaxation: a review of the literature. Arch Gynecol Obstet 1997; 261:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/25\">",
"      Chedraui PA, Insuasti DF. Intravenous nitroglycerin in the management of retained placenta. Gynecol Obstet Invest 2003; 56:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/26\">",
"      Jha S, Chiu JW, Yeo IS. Intravenous nitro-glycerine versus general anaesthesia for placental extraction--a sequential comparison. Med Sci Monit 2003; 9:CS63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/27\">",
"      Lowenwirt IP, Zauk RM, Handwerker SM. Safety of intravenous glyceryl trinitrate in management of retained placenta. Aust N Z J Obstet Gynaecol 1997; 37:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/28\">",
"      Bullarbo M, Tjugum J, Ekerhovd E. Sublingual nitroglycerin for management of retained placenta. Int J Gynaecol Obstet 2005; 91:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/29\">",
"      Ely JW, Rijhsinghani A, Bowdler NC, Dawson JD. The association between manual removal of the placenta and postpartum endometritis following vaginal delivery. Obstet Gynecol 1995; 86:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/30\">",
"      Atkinson MW, Owen J, Wren A, Hauth JC. The effect of manual removal of the placenta on post-cesarean endometritis. Obstet Gynecol 1996; 87:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/31\">",
"      Pipingas A, Gulmezoglu AM, Mitri FF, Hofmeyr GJ. Umbilical vein injection for retained placenta: clinical feasibility study of a new technique. East Afr Med J 1994; 71:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/32\">",
"      Pipingas A, Hofmeyr GJ, Sesel KR. Umbilical vessel oxytocin administration for retained placenta: in vitro study of various infusion techniques. Am J Obstet Gynecol 1993; 168:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/33\">",
"      Rogers MS, Yuen PM, Wong S. Avoiding manual removal of placenta: evaluation of intra-umbilical injection of uterotonics using the Pipingas technique for management of adherent placenta. Acta Obstet Gynecol Scand 2007; 86:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/34\">",
"      Nardin JM, Weeks A, Carroli G. Umbilical vein injection for management of retained placenta. Cochrane Database Syst Rev 2011; :CD001337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/35\">",
"      Weeks AD, Alia G, Vernon G, et al. Umbilical vein oxytocin for the treatment of retained placenta (Release Study): a double-blind, randomised controlled trial. Lancet 2010; 375:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/36\">",
"      Yamahara N, Nomura S, Suzuki T, et al. Placental leucine aminopeptidase/oxytocinase in maternal serum and placenta during normal pregnancy. Life Sci 2000; 66:1401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/37\">",
"      van Beekhuizen HJ, de Groot AN, De Boo T, et al. Sulprostone reduces the need for the manual removal of the placenta in patients with retained placenta: a randomized controlled trial. Am J Obstet Gynecol 2006; 194:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/38\">",
"      Stefanovic V, Paavonen J, Loukovaara M, et al. Intravenous sulprostone infusion in the treatment of retained placenta. Acta Obstet Gynecol Scand 2013; 92:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/39\">",
"      van Beekhuizen HJ, Pembe AB, Fauteck H, Lotgering FK. Treatment of retained placenta with misoprostol: a randomised controlled trial in a low-resource setting (Tanzania). BMC Pregnancy Childbirth 2009; 9:48.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organziation recommendations for the prevention and treatment of postpartum hemorrhage file://apps.who.int/iris/bitstream/10665/75411/1/9789241548502_eng.pdf (Accessed on September 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/41\">",
"      Palacios-Jaraquemada JM. Diagnosis and management of placenta accreta. Best Pract Res Clin Obstet Gynaecol 2008; 22:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/42\">",
"      Soltani H, Hutchon DR, Poulose TA. Timing of prophylactic uterotonics for the third stage of labour after vaginal birth. Cochrane Database Syst Rev 2010; :CD006173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35208/abstract/43\">",
"      Soltani H, Dickinson F, Symonds I. Placental cord drainage after spontaneous vaginal delivery as part of the management of the third stage of labour. Cochrane Database Syst Rev 2005; :CD004665.",
"     </a>",
"    </li>",
"    <li>",
"     McDonald, SJ, Middleton, P. Effect of timing of umbilical cord clamping of term infants on maternal and neonatal outcomes. Cochrane Database of Systematic Reviews 2008, Issue 2. Art. No.: CD004074. DOI: 10.1002/14651858.CD004074.pub2.",
"    </li>",
"    <li>",
"     G&uuml;lmezoglu, AM, Widmer, M, Merialdi, M, Qureshi, Z, Piaggio, G, Elbourne, D, et al. Active management of the third stage of labour without controlled cord traction: a randomized non-inferiority controlled trial. Reprod Health 2009; 21:6:2.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15333 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-FC043B0C43-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35208=[""].join("\n");
var outline_f34_24_35208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2376691\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6052582\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6052589\">",
"      DEFINITION OF RETAINED PLACENTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5282494\">",
"      TYPES OF RETAINED PLACENTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H912257\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28118534\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6052603\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5286022\">",
"      DIAGNOSIS OF TYPE OF RETAINED PLACENTA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6052644\">",
"      TREATMENT APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2373809\">",
"      Trapped placenta",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2373817\">",
"      Placenta adherens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2373846\">",
"      - Manual removal of placenta",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2375270\">",
"      - Umbilical vein injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2375467\">",
"      Catheterization of the umbilical vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H20784508\">",
"      Umbilical vein prostaglandin injection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2375393\">",
"      Umbilical vein oxytocin injection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6052653\">",
"      - Systemic uterotonic drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2376024\">",
"      Prostaglandins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2376031\">",
"      Oxytocin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6052688\">",
"      Unexpected placenta accreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5286108\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2376691\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/15333\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/15333|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?39/21/40278\" title=\"diagnostic image 1\">",
"      Placenta adherens and trapped placenta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/15333|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/20/29006\" title=\"figure 1\">",
"      Frequency retained placenta by 3rd stage characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/57/37789\" title=\"figure 2\">",
"      Frequency of retained placenta by gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/12/6340\" title=\"figure 3\">",
"      Pipingas technique for intraumbilical vein injection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/15333|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?37/63/38907\" title=\"table 1\">",
"      Treatment of retained placenta by etiology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/7/8311?source=related_link\">",
"      Clinical features and diagnosis of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/21/33114?source=related_link\">",
"      Management of normal labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/16/19719?source=related_link\">",
"      Management of placenta accreta, increta, and percreta",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/60/41929?source=related_link\">",
"      Management of postpartum hemorrhage at vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/42/41639?source=related_link\">",
"      Uterotonic drugs for management of the third stage of labor",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_24_35209="Etiology of hypocalcemia in infants and children";
var content_f34_24_35209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology of hypocalcemia in infants and children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/24/35209/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35209/contributors\">",
"     George S Jeha, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/24/35209/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35209/contributors\">",
"     Joseph I Wolfsdorf, MB, BCh",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/24/35209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35209/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/24/35209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 30, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A constant extracellular calcium concentration is critical for cell function and survival, and is maintained by a homeostatic system. The etiology of hypocalcemia can be related to failure of a component of this system, such as the absence or deficiency of PTH or vitamin D, or a defect of the calcium-sensing receptor.",
"   </p>",
"   <p>",
"    The etiology and pathogenesis of hypocalcemia in the infant and child, and a brief summary of calcium homeostasis will be presented here. A more detailed discussion of calcium homeostasis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=see_link\">",
"     \"Chapter 6F: Hormonal regulation of calcium and phosphate balance\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36744?source=see_link\">",
"     \"Parathyroid hormone secretion and action\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CALCIUM HOMEOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium homeostatic system consists of the following three components:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Calcium-sensing receptor (CaSR) &mdash; The CaSR of the parathyroid gland plays the role of a \"calcistat\" which continuously senses the serum ionized calcium concentration and triggers the release of parathyroid hormone (PTH) in response to even a minute decrease in the serum level of ionized calcium. PTH release is immediately suppressed when the serum ionized calcium level is high.",
"     </li>",
"     <li>",
"      Parathyroid hormone (PTH) &mdash; PTH is released from the parathyroid chief cells and increases serum calcium levels through several mechanisms:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acts directly on cells in the distal renal tubule to increase calcium reabsorption",
"     </li>",
"     <li>",
"      Mobilizes calcium from the bone",
"     </li>",
"     <li>",
"      Stimulates 1-alpha-hydroxylase in the kidney, which converts 25-hydroxyvitamin D to 1,25-dihydroxyvitamin D (the active form of vitamin D) which in turn increases intestinal and renal tubule calcium uptake",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vitamin D &mdash; 1,25-dihydroxyvitamin D, the active metabolite of vitamin D, promotes calcium and phosphorus absorption from the gastrointestinal tract and reabsorption from the renal tubules (",
"      <a class=\"graphic graphic_figure graphicRef65360 \" href=\"mobipreview.htm?20/23/20862\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another hormone that has a more minor role in calcium homeostasis is calcitonin. Calcitonin, which is synthesized in and released from the parafollicular cells of the thyroid gland, is directly regulated by the serum concentration of ionized calcium. When calcium levels are high, calcitonin is released and decreases calcium resorption from bone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary determinant of symptoms and signs in patients with hypocalcemia is the serum ionized calcium concentration. A low serum ionized calcium level results from either increased loss of ionized calcium from the circulation (deposition in tissue, loss in urine, or increased binding of calcium in serum) or decreased entry of calcium into the circulation (gastrointestinal malabsorption, decreased bone reabsorption) (",
"    <a class=\"graphic graphic_table graphicRef53781 \" href=\"mobipreview.htm?27/21/27996\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=see_link\">",
"     \"Clinical manifestations of hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Acute hypocalcemia is generally caused by a shift of calcium from the circulation or a decrease in the level of serum ionized calcium. As examples, acute hyperphosphatemia lowers the level of calcium by increasing tissue deposition, thereby removing calcium from the circulation; alkalosis decreases the level of serum ionized calcium by increasing the binding of serum ionized calcium to albumin.",
"   </p>",
"   <p>",
"    Chronic or subacute hypocalcemia usually occurs only when there is a defect in the calcium homeostatic system. In the absence of such a defect, even minute changes in serum ionized calcium concentration lead to a corrective response from the calcium homeostatic system, in which CaSR modulates PTH secretion and PTH and vitamin D act on target organs (kidneys, GI tract and bone). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Calcium homeostasis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TRANSIENT NEONATAL HYPOCALCEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient hypocalcemia is common in the newborn period, particularly in infants who are sick or have low birthweights.",
"   </p>",
"   <p>",
"    Hypocalcemia is often the result of one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Maternal factors &mdash; These include maternal vitamin D deficiency, use of anticonvulsants, diabetes (either permanent or gestational), hyperparathyroidism, and toxemia of pregnancy.",
"     </li>",
"     <li>",
"      Neonatal factors &mdash; These include prematurity, low birth weight, intrauterine growth retardation, and birth asphyxia.",
"     </li>",
"     <li>",
"      Concurrent illness &mdash; Other illnesses commonly seen in the neonate such as sepsis, respiratory distress syndrome, hypomagnesemia, hyperbilirubinemia including phototherapy, and renal failure can contribute to hypocalcemia.",
"     </li>",
"     <li>",
"      Exogenous or iatrogenic factors &mdash; The administration of excess phosphate, lipid infusions, citrated blood, and bicarbonate can cause a decrease in serum ionized calcium concentrations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Transient neonatal hypocalcemia can be divided into early and late forms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Early hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early neonatal hypocalcemia is defined by an extreme drop of serum calcium concentrations within the first 72 hours of life, with total calcium concentration &lt;7.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (1.75",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a serum ionized concentration &lt;2.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.63",
"    <span class=\"nowrap\">",
"     mmol/L).",
"    </span>",
"    It typically presents within the first 24 to 48 hours of life, and often does not result in clinical symptoms, with the exception of infants with neonatal hypocalcemia resulting from maternal hypercalcemia caused by hyperparathyroidism.",
"   </p>",
"   <p>",
"    It is associated most commonly with the following conditions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prematurity and low birth weight &mdash; It has been suggested that hypocalcemia in premature or low birthweight infants is caused by blunting of PTH secretion and elevated calcitonin secretion, as evidenced by high concentrations of calcitonin in cord blood and further rises postnatally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. However, this proposed mechanism has been refuted by several studies reporting normal PTH secretion in premature infants, with appropriate increases in PTH level in response to hypocalcemia, and suppression of PTH when high doses of calcium are administered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/2,4\">",
"       2,4",
"      </a>",
"      ]. Therefore, the current accepted hypothesis is that hypocalcemia in premature or low birth weight infants is due to delayed maturation of vitamin D pathways, resulting in decreased intestinal calcium absorption and calcium mobilization from the bones, coupled to an increase in calcium demand to support the rapidly growing skeleton.",
"      <br/>",
"      <br/>",
"      In premature infants, the total calcium stores are decreased as the calcium accretion during the third trimester is interrupted. As mentioned above, the parathyroid glands appear to respond appropriately so that the PTH concentrations are elevated by 24 hours of life and remain high for two or three days. By the third day of life, 1,25-dihydroxyvitamin D concentrations are increased. Despite the increased PTH levels, there may be peripheral resistance to PTH, accompanied by decreased calcium stores in bone.",
"     </li>",
"     <li>",
"      Birth asphyxia &mdash; In infants who suffer birth asphyxia, hypocalcemia is thought to be a result of an excessive release of phosphate from injured tissues. In addition, increased calcitonin concentrations in cord blood have been reported in these infants.",
"     </li>",
"     <li>",
"      Maternal diabetes mellitus &mdash; Almost half of the infants born to mothers with diabetes (both permanent and gestational) will develop early neonatal hypocalcemia caused by reduced PTH secretion, increased calcitonin concentrations, and a decrease in total calcium transferred from mother to infant. The risk appears to be related to the degree of maternal hyperglycemia and can be reduced with improved maternal glycemic control. Neonatal hypocalcemia also is complicated by the concurrent finding of hypomagnesemia found in babies born to diabetic mothers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Maternal hyperparathyroidism &mdash; Maternal hypercalcemia from hyperparathyroidism leads to significant suppression of PTH in the infant with blunting of the postnatal PTH surge, resulting in hypocalcemia. This also is associated with hypomagnesemia. Affected infants are often symptomatic with a range of findings that include irritability, jitteriness, poor feeding, seizures, apnea with laryngospasms, cardiac conduction defects, and tetany [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. This disorder usually resolves within two to four weeks but may last for several months.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Late hypocalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient late neonatal hypocalcemia develops after 72 hours and is attributed to the relative resistance of the immature neonatal kidney to PTH. This end-organ resistance decreases renal calcium reabsorption and phosphate excretion resulting in hypocalcemia and hyperphosphatemia.",
"   </p>",
"   <p>",
"    Infants who are fed cow's milk appear to be more likely to develop late neonatal hypocalcemia as compared to those fed human milk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/8\">",
"     8",
"    </a>",
"    ]. Cow's milk has a high phosphate content. The decrease in renal tubular response to PTH and the increased phosphate intake from cow's milk results in a high serum phosphorus concentration. This high concentration may promote increased calcium and phosphorus bone deposition, resulting in low serum calcium concentrations. Hypocalcemia may persist for one to two weeks and therapy including vitamin D and calcium may be required. Encouraging breast feeding or the use of a low phosphate formula such as Similac PM",
"    <span class=\"nowrap\">",
"     60/40",
"    </span>",
"    is useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HYPOPARATHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoparathyroidism can be classified by its pathogenesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Impaired synthesis or secretion of parathyroid hormone (PTH) on account of",
"      <span class=\"nowrap\">",
"       lack/loss",
"      </span>",
"      of parathyroid gland (tissue) or to a defect in the synthesis or release of PTH. This can be either a primary or acquired condition.",
"     </li>",
"     <li>",
"      Defect in the calcium sensing receptor (CaSR).",
"     </li>",
"     <li>",
"      End-organ resistance to PTH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Impaired synthesis/secretion",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Genetic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several genetic defects have been identified in patients with hypoparathyroidism.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An autosomal dominant mutation in the signal peptide sequence of preproPTH has been described, which impairs the normal processing of preproPTH to PTH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several families with autosomal recessive hypoparathyroidism have been identified [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/10-13\">",
"       10-13",
"      </a>",
"      ]. Two had a point mutation in the signal peptide [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/10,12\">",
"       10,12",
"      </a>",
"      ]; these mutations also affect the processing of preproPTH. In one kindred with autosomal recessive hypoparathyroidism, the underlying defect was homozygous loss of function of the GCMB gene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/14\">",
"       14",
"      </a>",
"      ]. In mice, the Gcmb gene, which is expressed exclusively in the parathyroid gland, encodes a transcription factor that is essential for parathyroid gland development [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      X-linked recessive hypoparathyroidism caused by a deletion-insertion rearrangement involving chromosomes Xq27.1 and 2p25.3 has been described in two related kindreds [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/15,16\">",
"       15,16",
"      </a>",
"      ]. Affected male infants develop hypocalcemia with seizures because of an isolated defect in the development of the parathyroid gland.",
"     </li>",
"     <li>",
"      An autosomal dominant form of hypoparathyroidism associated with sensorineural deafness and renal dysplasia (HDR syndrome) has been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/17,18\">",
"       17,18",
"      </a>",
"      ]. Mutations in GATA3, a gene localized to the chromosome region 10p14-15, have been detected in families affected by the syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/19,20\">",
"       19,20",
"      </a>",
"      ]. GATA3 is a transcription factor that is involved in the embryonic development of the parathyroid glands, kidneys, inner ears, thymus, and central nervous findings. Similar clinical findings were reported in families with an apparent autosomal recessive mode of inheritance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/11,21\">",
"       11,21",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Barakat described two sets of brothers with hypoparathyroidism, sensorineural deafness, and steroid-resistant nephrotic syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/22\">",
"       22",
"      </a>",
"      ]. This was termed Barakat's syndrome, but it shares many of the same clinical manifestations as HDR syndrome. It is unclear whether these disorders are the same entity.",
"     </li>",
"     <li>",
"      In DiGeorge syndrome, one of the components is hypoparathyroidism resulting from parathyroid aplasia or hypoplasia. DiGeorge syndrome is a result of abnormal development of the third and fourth branchial pouches. Other features include thymic aplasia or hypoplasia, cardiac defect affecting the outflow tract, developmental delay, and a characteristic facial appearance (prominent nose, squared nasal root). Most cases are sporadic but familial cases with autosomal dominant inheritance have been reported. Most patients have deletion of the region of chromosome 22q11.2. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=see_link\">",
"       \"DiGeorge syndrome: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The Sanjad-Sakati syndrome and the autosomal recessive form of Kenney-Caffey syndrome (Kenney-Caffey type 1) share the same clinical features including congenital hypoparathyroidism, mental retardation, facial dysmorphism and severe growth failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/23,24\">",
"       23,24",
"      </a>",
"      ]. Patients with Kenney-Caffey type 1 also have osteosclerosis and immunodeficiency [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/25\">",
"       25",
"      </a>",
"      ]. Sanjad-Sakati syndrome has been reported almost exclusively in Arab families. Both disorders map to 1q42-q43 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/26\">",
"       26",
"      </a>",
"      ] and are caused by mutations in TBCE (tubulin specific chaperone E gene), which encodes a protein involved in tubulin folding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/27\">",
"       27",
"      </a>",
"      ]. This finding suggests the two disorders are likely allelic or constitute different reports of the same condition.",
"     </li>",
"     <li>",
"      Mitochondrial disorders have been associated with hypoparathyroidism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. These include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Kearns Sayre syndrome (KSS), characterized by ophthalmoplegia, pigmentary degeneration of the retina, and cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/15/20726?source=see_link&amp;anchor=H3#H3\">",
"       \"Myopathies affecting the extraocular muscles in children\", section on 'Kearns-Sayre syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      MELAS syndrome, characterized by mitochondrial encephalopathy, lactic acidosis and stroke-like episode.",
"     </li>",
"     <li>",
"      Mitochondrial trifunctional protein deficiency syndrome (MTPDS), is a fatty acid oxidation disorder characterized by peripheral neuropathy and pigmentary retinopathy. Mothers of an affected fetus have acute liver degeneration during pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Autoimmune",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoparathyroidism is part of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) syndrome, also known as autoimmune polyglandular syndrome type 1 (APS1). In these patients, immunologic destruction of the parathyroid gland occurs in association with destruction of other endocrine glands. APECED appears to be a result of mutations in AIRE (autoimmune regulator gene), which is expressed in the thymus, lymph nodes, pancreas, adrenal cortex, and fetal liver.",
"   </p>",
"   <p>",
"    The three principal findings include hypoparathyroidism, primary adrenal insufficiency, and chronic mucocutaneous candidiasis. Hypoparathyroidism or candidiasis are typically the first manifestations to appear during childhood or adolescence. Because of these associations, a child with hypoparathyroidism should be examined frequently for other endocrinopathies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22553?source=see_link&amp;anchor=H571991#H571991\">",
"     \"Chronic mucocutaneous candidiasis\", section on 'Autoimmune regulator (AIRE) deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    APS1 or APECED syndrome is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link&amp;anchor=H3#H3\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Polyglandular autoimmune syndrome type I'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Acquired",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoparathyroidism can be acquired in the following clinical settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During thyroid surgery, as a result of manipulation of the blood supply to or removal of one or more parathyroid glands. In most cases, the hypoparathyroidism and hypocalcemia are transient.",
"     </li>",
"     <li>",
"      Parathyroidectomy to remove a parathyroid adenoma or hyperplastic gland (eg, in patients with end-stage renal failure and hyperparathyroidism). The pre-surgical hypercalcemia suppresses PTH from the remaining glands or tissue, resulting in transient hypoparathyroidism and hypocalcemia immediately after surgery. In addition, some patients may develop the hungry bone syndrome because of an increase in bone resorption, which increases the severity of hypocalcemia post-operatively. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Hungry bone syndrome'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=see_link\">",
"       \"Indications for parathyroidectomy in end-stage renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Iron deposition in the parathyroid gland in patients requiring chronic transfusions (eg, beta thalassemia major) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/30\">",
"       30",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7802?source=see_link\">",
"       \"Treatment of beta thalassemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Copper deposition in patients with Wilson's disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/31\">",
"       31",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=see_link\">",
"       \"Epidemiology and pathogenesis of Wilson disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Gram-negative sepsis, toxic shock syndrome, and AIDS. The etiology of the hypoparathyroidism in ill children is unknown but may be related to macrophage-generated cytokines, which can affect PTH and vitamin D secretion and action.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Calcium-sensing receptor defect",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Autosomal dominant hypoparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autosomal dominant hypoparathyroidism (ADHH) is a rare form of hypocalcemia caused by an activating mutation in the calcium-sensing receptor (CaSR). This causes hypocalcemia by shifting the set point of CaSR, such that PTH is not released at serum calcium concentrations that normally trigger PTH release. Renal calcium reabsorption in these patients is also lower than anticipated because of the absence of PTH secretion.",
"   </p>",
"   <p>",
"    Although patients with ADHH can present in the neonatal period, it is not uncommon for subjects to be asymptomatic with mild to moderate hypocalcemia. However, during periods of stress such as a febrile illness, patients can become symptomatic with seizures, and neuromuscular irritability (tetany). It is the authors' experience that some of these patients escape detection by being mislabeled as children with febrile seizures, hence the importance of screening serum calcium in any child presenting with seizures.",
"   </p>",
"   <p>",
"    ADHH is uncommon in the general population but it is often confused with the diagnosis of isolated primary hypoparathyroidism. Unlike patients with primary hypoparathyroidism, patients with ADHH have hypocalcemia with an inappropriately normal PTH concentration and an inappropriately normal urinary",
"    <span class=\"nowrap\">",
"     Ca/Cr",
"    </span>",
"    (relative hypercalcuria).",
"   </p>",
"   <p>",
"    The genetic defect, diagnosis, and treatment of autosomal dominant hypocalcemia are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=see_link\">",
"     \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     End-organ resistance/pseudohypoparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohypoparathyroidism (PHP) refers to a group of heterogeneous disorders defined by targeted organ (kidney and bone) unresponsiveness to PTH. PTH resistance is characterized by [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypocalcemia",
"     </li>",
"     <li>",
"      Hyperphosphatemia",
"     </li>",
"     <li>",
"      Elevated PTH concentrations",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PHP has been divided into two types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with pseudohypoparathyroidism (PHP) type 1, there is a diminished urinary cyclic AMP response to exogenous PTH administration. There are several subtypes of PHP type 1 caused by mutations of GNAS1, a gene encoding the alpha subunit of the G protein, coupled to the PTH receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/35\">",
"     35",
"    </a>",
"    ]. These gene mutations result in the G protein's inability to activate adenyl cyclase upon the binding of PTH to its receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Activation of adenyl cyclase is required for signal transduction that produces the end-organ response to PTH. Failure of signal transduction results in the unresponsiveness of the end organ.",
"   </p>",
"   <p>",
"    GNAS1 is imprinted in humans so that expression of the allele for a specific tissue is dependent on whether the allele is maternally or paternally inherited; therefore, the disease manifestations also differ depending on the parent of origin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/39\">",
"     39",
"    </a>",
"    ]. As an example, renal expression of GNAS1 appears to be determined only by the maternal allele so that a defect only in the maternal allele of GNAS1 will result in unresponsiveness of the renal tubule to PTH binding. This difference in tissue expression, based upon parental transmission and whether the underlying mutation is a GNAS1 structural or expression defect, appears to contribute to the differences in the variants of PHP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11300164\">",
"    <span class=\"h4\">",
"     Type 1a",
"    </span>",
"    &nbsp;&mdash;&nbsp;PHP type 1a is an autosomal dominant disease with a loss-of-function mutation of the GNAS1 gene, leading to an inability to activate adenyl cyclase when PTH binds to its receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/40\">",
"     40",
"    </a>",
"    ]. Maternal transmission of the mutation is required for expression of PHP type 1a [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/41\">",
"     41",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    Patients with PHP type 1a have a constellation of findings known as Albright's hereditary osteodystrophy (AHO) that includes round facies, short stature, short fourth metacarpal bones, obesity, subcutaneous calcifications, and developmental delay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/32,42\">",
"     32,42",
"    </a>",
"    ]. In addition, the PTH resistance of the renal tubule leads to hyperphosphatemia and hypocalcemia, and secondary hyperparathyroidism and hyperparathyroid bone disease (osteitis fibrosa).",
"   </p>",
"   <p>",
"    In humans, GNAS1 also is predominantly expressed from the maternal allele in the thyroid, gonads and pituitary glands. As a result, patients with PHP type 1a show resistance to various other G-protein coupled hormones including thyroid-stimulating hormone, luteinizing hormone, follicular-stimulating hormone, and gonadotropin-releasing hormone as well as blunted response to beta-adrenergic agonists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7817?source=see_link&amp;anchor=H3107659#H3107659\">",
"     \"Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)\", section on 'Gs alpha subunit gene mutations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11300222\">",
"    <span class=\"h4\">",
"     Pseudo-pseudohypoparathyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;By contrast to patients with maternally transmitted mutations that result in loss of GNAS1 function, those with paternally transmitted mutations have the phenotype of Albright's hereditary osteodystrophy (AHO) but with normal serum calcium concentrations and without renal tubular resistance to PTH; this pattern is termed &ldquo;pseudo-pseudohypoparathyroidism&rdquo;. [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In these patients, the paternal transmission of a mutated GNAS1 gene results in AHO but the normal maternal allele results in the maintenance of renal responsiveness to PTH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. As a result, these patients have normal calcium homeostasis with normal concentrations of calcium, phosphate, and PTH.",
"   </p>",
"   <p>",
"    Paternally inherited inactivating GNAS1 mutations can cause a related autosomal dominant disorder, progressive osseous heteroplasia, characterized by extensive dermal ossification during childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11300173\">",
"    <span class=\"h4\">",
"     Type 1b",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the type 1b disease have hypocalcemia but do not have the phenotypic abnormalities of AHO. It has been suggested that PTH resistance is confined to the kidney in this disorder, leading to only hypocalcemia, hyperphosphatemia, and secondary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This rare autosomal dominant disorder appears to be caused by mutations that affect the regulatory elements of GNAS1, rather than mutations in GNAS1 itself [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/51-54\">",
"     51-54",
"    </a>",
"    ]. Type 1b is maternally transmitted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11300191\">",
"    <span class=\"h4\">",
"     Type 1c",
"    </span>",
"    &nbsp;&mdash;&nbsp;PHP type 1c refers to a subgroup of mutations that affect the coupling of G protein to the PTH receptor. The ability to stimulate adenyl cyclase remains intact but is no longer coupled to the binding of PTH and its receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients with PHP type 1c are phenotypically the same as type 1a.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PHP type 2 do not have the features of AHO. &nbsp;They have normal or even elevated urinary cyclic AMP concentrations in response to exogenous PTH administration but without a concomitant increase in phosphate excretion. The molecular defect in this disorder has not been identified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HYPOVITAMINOSIS D",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disruption of vitamin D metabolism results in decrease concentrations of its most active metabolite, 1,25-dihyroxyvitamin D. This can occur as a result of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Decreased intake or production of vitamin D",
"     </li>",
"     <li>",
"      Increased catabolism of vitamin D and its metabolites by the liver",
"     </li>",
"     <li>",
"      Decreased 25-hydroxylation by the liver",
"     </li>",
"     <li>",
"      Decreased 1-hydroxylation by the kidney",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, there can be end-organ (gastrointestinal tract and kidney) resistance to the action of 1,25-dihydroxyvitamin D [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=see_link\">",
"     \"Metabolism of vitamin D\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Reduced intake or production",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, most vitamin D is derived from foods that have a high content of the vitamin (fatty fishes) or are fortified with the vitamin (milk and related products and cereals). The remainder is synthesized in the skin from 7-dehydrocholesterol under the influence of ultraviolet light (",
"    <a class=\"graphic graphic_figure graphicRef63249 \" href=\"mobipreview.htm?1/10/1198\">",
"     figure 2",
"    </a>",
"    ). Hence, vitamin D deficiency can occur in children whose dietary intake is low",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    who live without sun exposure. These children frequently have a low calcium intake as well, and in the most severe cases can lead to hypocalcemic rickets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link\">",
"     \"Etiology and treatment of calcipenic rickets in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a survey of 618 Asian children (&lt;2 years of age) living in the United Kingdom, 27 percent had low serum 25-hydroxyvitamin D concentrations defined as &lt;10",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    (25",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/60\">",
"     60",
"    </a>",
"    ]. Serum 25-hydroxyvitamin D concentrations were correlated with ingestion of vitamin D supplements in these children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vitamin D deficiency also is caused by decreased absorption from the gastrointestinal tract because of gastrectomy, celiac disease, malabsorption, extensive bowel surgery, inflammatory bowel disease, or pancreatic insufficiency as seen in cystic fibrosis.",
"   </p>",
"   <p>",
"    In infants who are exclusively breastfed, vitamin D deficiency can occur if vitamin D supplementation is not provided especially in dark-skinned infants during the winter months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Hepatic",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the liver, vitamin D undergoes 25-hydroxylation to produce 25-hydroxyvitamin D. This conversion can be impaired in patients with severe liver disease. Drugs such as anticonvulsants (eg,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?28/63/29689?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/19/33082?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?5/36/5706?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?37/24/38278?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?23/49/24344?source=see_link\">",
"     theophylline",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?16/52/17225?source=see_link\">",
"     rifampin",
"    </a>",
"    ) that increase the activity of P-450 enzymes increase the 25-hydroxylation but also the catabolism of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D to inactive metabolites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Renal",
"    </span>",
"    &nbsp;&mdash;&nbsp;The final step in vitamin D metabolism is the 1-hydroxylation of 25-hydroxyvitamin D in the kidney to produce 1,25-dihydroxyvitamin D, the most biologically active metabolite of vitamin D. This reaction is stimulated by PTH and hypophosphatemia, but inhibited by calcium and phosphate. In patients with renal failure, 1,25-dihydroxyvitamin D production is low, mostly because of loss of the enzyme (1-hydroxylase) and as a consequence of hyperphosphatemia. The result is hypocalcemia, hyperparathyroidism, and bone disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=see_link\">",
"     \"Pathogenesis of renal osteodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term vitamin D-dependent rickets defines two syndromes that present in childhood. Both are inherited as autosomal recessive traits and are characterized by hypocalcemia, hypophosphatemia, and rickets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/62\">",
"     62",
"    </a>",
"    ]. Type 1 vitamin D dependent rickets is caused by an inherited defect in vitamin D synthesis. Type 2 vitamin D-dependent rickets is caused by end-organ resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Defective vitamin D hydroxylation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vitamin D-dependent rickets type I, also called pseudovitamin D deficient rickets, is characterized by an inability to produce 1,25-dihydroxyvitamin D. This disease is a result of an inactivating mutation in the 1-hydroxylase gene CYP27B1, which maps to chromosome region12q13.1-13.3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. The defect results in an inability of the mutated 1-hyroxylase to bind to either the substrate 25-hydroxyvitamin D or the heme group required for catalyzing the biochemical reaction. In affected patients, the gene defect results in hypocalcemia, hypophosphatemia, and high PTH and alkaline phosphatase concentrations. This disorder can be treated with small doses of oral 1,25-dihydroxyvitamin D (calcitriol). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link&amp;anchor=H12#H12\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Vitamin D dependent rickets type I'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Vitamin D resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hereditary vitamin D-resistant rickets (HVDRR) is a form of vitamin D resistance and was previously called type 2 vitamin D-dependent rickets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/66\">",
"     66",
"    </a>",
"    ]. It is caused by end-organ resistance to 1,25-dihydroxyvitamin D, most often because of mutations in the gene encoding the vitamin D receptor (VDR), located in chromosome region 12q13-14 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/67-69\">",
"     67-69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical findings of HVDRR are similar to those in type 1 vitamin D-dependent rickets (hypocalcemia, hypophosphatemia, and high PTH and alkaline phosphatase concentrations), except that serum 1,25-dihyroxyvitamin D concentrations are high, not low. Many of the patients also have alopecia. Therapy with pharmacological doses of 1,25-dihyroxyvitamin D and 25-hydroxyvitamin D are ineffective in most but not all cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/70\">",
"     70",
"    </a>",
"    ]. The rickets can be improved with long-term, high-dose intravenous calcium therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/71,72\">",
"     71,72",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=see_link&amp;anchor=H16#H16\">",
"     \"Etiology and treatment of calcipenic rickets in children\", section on 'Hereditary vitamin D resistant rickets'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     HYPOMAGNESEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnesium is required for PTH release and may be required for PTH effect on target organs. Hypomagnesemia can lead to hypocalcemia through the following mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      End-organ unresponsiveness to PTH",
"     </li>",
"     <li>",
"      Impaired release of PTH",
"     </li>",
"     <li>",
"      Impaired formation of 1,25-dihydroxyvitamin D, likely secondary to both of the above effects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with hypomagnesemia present with carpopedal spasm, tetany",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizures, muscle weakness, anorexia, and hypokalemia, as well as tachycardia with prolonged QT and PR intervals. Tetany can occur in the absence of hypocalcemia and is thought to be secondary to a depression in the threshold of nerve excitation. Hypomagnesemia can be a primary disorder or secondary to other diseases. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link\">",
"     \"Signs and symptoms of magnesium depletion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Primary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypomagnesemia with secondary hypocalcemia (HSH) is an autosomal recessive disease that affects the TRPM6 gene located at chromosome 9q22 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. TRPM6 is expressed in the intestinal mucosa and the kidney. It encodes for a protein with dual functions, protein kinase and a calcium and magnesium ion channel. In affected patients, there is an isolated defect of intestinal magnesium absorption with normal renal excretion of magnesium.",
"   </p>",
"   <p>",
"    Patients present at 1 month of age with seizures with both hypomagnesemia and hypocalcemia. Patients require large doses of magnesium, up to 20 times the usual daily requirement. These high doses rarely lead to normalization of magnesium concentrations but completely corrects hypocalcemia with resolution of symptoms. One of the side effects of magnesium is diarrhea, which can increase the intestinal loss of magnesium. Early diagnosis and treatment can help avoid sequelae of prolonged seizures caused by hypocalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypomagnesemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Secondary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnesium homeostasis is not hormonally regulated and depends on the balance between intestinal absorption and renal excretion. As a result, the major causes of secondary hypomagnesemia in children are either decreased intake or increased urinary and gastrointestinal losses. Gastrointestinal losses are seen in any disorder associated with acute or chronic diarrhea, steatorrhea, or malabsorption. Renal losses may be because of diuretic use, nephrotoxins (such as aminoglycoside), and renal tubular dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15000?source=see_link\">",
"     \"Causes of hypomagnesemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Pancreatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypocalcemia is common in patients with acute pancreatitis. It is primarily caused by precipitation of calcium soaps in the abdominal cavity; glucagon-stimulated calcitonin release and decreased PTH secretion also may play a role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Citrated products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Administration of intravenous fluids that contain citrate may decrease the serum ionized calcium concentration through increased binding of calcium into calcium-citrate complexes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Hungry bone syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;After a prolonged period of calcium resorption from bone, a rebound phase characterized by avid uptake of calcium by bones results in hypocalcemia. A parallel increase in bone resorption of magnesium leading to hypomagnesemia may increase the severity of hypocalcemia by decreasing PTH secretion and action. The hungry bone syndrome can be seen following parathyroidectomy or thyroidectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=see_link&amp;anchor=H6#H6\">",
"     \"Signs and symptoms of magnesium depletion\", section on 'Parathyroid hormone resistance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Hyperphosphatemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endogenous or exogenous sources of phosphate can create a phosphate load sufficient to exceed the renal capacity for phosphate excretion. The ensuing hyperphosphatemia may result in calcium-phosphate precipitation in the tissues leading to symptomatic hypocalcemia.",
"   </p>",
"   <p>",
"    Acute hyperphosphatemia is seen in the setting of massive tissue breakdown (eg, tumor lysis and rhabdomyolysis) or with excessive phosphate intake. The repeated use of phosphate containing enemas or the use of adult size enemas in children may cause hyperphosphatemia. This is especially a problem in children with poor intestinal motility, such as those with chronic constipation or neuromuscular dysfunction including cerebral palsy or neurodegenerative disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Fluoride poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, excess intake of fluoride can cause hypocalcemia; this effect is presumably mediated by inhibition of bone resorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35209/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A constant extracellular ionized calcium concentration is critical for cell function and survival and is maintained by a calcium homeostatic system consisting of calcium sensing receptor, parathyroid hormone, and vitamin D. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Calcium homeostasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The primary determinant of symptomatic hypocalcemia is the serum ionized calcium concentration. In patients with acute hypocalcemia, there is a shift of calcium from the circulation (eg, hyperphosphatemia) or increased binding of ionized calcium resulting in a decrease in the serum ionized concentration (eg, administration of bicarbonate or citrate). In patients with chronic or subacute hypocalcemia, there is usually a defect in the calcium homeostatic system. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Transient neonatal hypocalcemia is not uncommon particularly in newborn infants admitted to the neonatal intensive care unit and can present within the first 72 hours of life (early) or after 72 hours (late). There are a number of contributing factors including those associated with the mother (eg, maternal diabetes mellitus), the infant (eg, premature), concurrent illnesses, and iatrogenic factors. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Transient neonatal hypocalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypoparathyroidism, a major cause of pediatric hypocalcemia, is caused by impaired secretion or production of parathyroid hormone (PTH), a defect in the calcium sensing receptor that regulates PTH secretion, or end-organ resistance to PTH. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Hypoparathyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disruption of vitamin D metabolism results in decrease concentrations of its most active metabolite 1,25-dihydroxyvitamin D and subsequent hypocalcemia. End-organ (gastrointestinal tract and kidney) resistance to the action of vitamin D also results in hypocalcemia. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Hypovitaminosis D'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5898037\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. John Kirkland, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/1\">",
"      Venkataraman PS, Tsang RC, Chen IW, Sperling MA. Pathogenesis of early neonatal hypocalcemia: studies of serum calcitonin, gastrin, and plasma glucagon. J Pediatr 1987; 110:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/2\">",
"      Salle BL, David L, Chopard JP, et al. Prevention of early neonatal hypocalcemia in low birth weight infants with continuous calcium infusion: effect on serum calcium, phosphorus, magnesium, and circulating immunoreactive parathyroid hormone and calcitonin. Pediatr Res 1977; 11:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/3\">",
"      David L, Salle BL, Putet G, Grafmeyer DC. Serum immunoreactive calcitonin in low birth weight infants. Description of early changes; effect of intravenous calcium infusion; relationships with early changes in serum calcium, phosphorus, magnesium, parathyroid hormone, and gastrin levels. Pediatr Res 1981; 15:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/4\">",
"      Mumm S, Whyte MP, Thakker RV, et al. mtDNA analysis shows common ancestry in two kindreds with X-linked recessive hypoparathyroidism and reveals a heteroplasmic silent mutation. Am J Hum Genet 1997; 60:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/5\">",
"      Banerjee S, Mimouni FB, Mehta R, et al. Lower whole blood ionized magnesium concentrations in hypocalcemic infants of gestational diabetic mothers. Magnes Res 2003; 16:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/6\">",
"      Kaplan EL, Burrington JD, Klementschitsch P, et al. Primary hyperparathyroidism, pregnancy, and neonatal hypocalcemia. Surgery 1984; 96:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/7\">",
"      Ertel NH, Reiss JS, Spergel G. Hypomagnesemia in neonatal tetany associated with maternal hyperparathyroidism. N Engl J Med 1969; 280:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/8\">",
"      Specker BL, Tsang RC, Ho ML, et al. Low serum calcium and high parathyroid hormone levels in neonates fed 'humanized' cow's milk-based formula. Am J Dis Child 1991; 145:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/9\">",
"      Arnold A, Horst SA, Gardella TJ, et al. Mutation of the signal peptide-encoding region of the preproparathyroid hormone gene in familial isolated hypoparathyroidism. J Clin Invest 1990; 86:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/10\">",
"      Parkinson DB, Thakker RV. A donor splice site mutation in the parathyroid hormone gene is associated with autosomal recessive hypoparathyroidism. Nat Genet 1992; 1:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/11\">",
"      Shaw NJ, Haigh D, Lealmann GT, et al. Autosomal recessive hypoparathyroidism with renal insufficiency and developmental delay. Arch Dis Child 1991; 66:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/12\">",
"      Sunthornthepvarakul T, Churesigaew S, Ngowngarmratana S. A novel mutation of the signal peptide of the preproparathyroid hormone gene associated with autosomal recessive familial isolated hypoparathyroidism. J Clin Endocrinol Metab 1999; 84:3792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/13\">",
"      G&uuml;nther T, Chen ZF, Kim J, et al. Genetic ablation of parathyroid glands reveals another source of parathyroid hormone. Nature 2000; 406:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/14\">",
"      Ding C, Buckingham B, Levine MA. Familial isolated hypoparathyroidism caused by a mutation in the gene for the transcription factor GCMB. J Clin Invest 2001; 108:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/15\">",
"      Thakker RV, Davies KE, Whyte MP, et al. Mapping the gene causing X-linked recessive idiopathic hypoparathyroidism to Xq26-Xq27 by linkage studies. J Clin Invest 1990; 86:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/16\">",
"      Bowl MR, Nesbit MA, Harding B, et al. An interstitial deletion-insertion involving chromosomes 2p25.3 and Xq27.1, near SOX3, causes X-linked recessive hypoparathyroidism. J Clin Invest 2005; 115:2822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/17\">",
"      Bilous RW, Murty G, Parkinson DB, et al. Brief report: autosomal dominant familial hypoparathyroidism, sensorineural deafness, and renal dysplasia. N Engl J Med 1992; 327:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/18\">",
"      Hasegawa T, Hasegawa Y, Aso T, et al. HDR syndrome (hypoparathyroidism, sensorineural deafness, renal dysplasia) associated with del(10)(p13). Am J Med Genet 1997; 73:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/19\">",
"      Van Esch H, Groenen P, Nesbit MA, et al. GATA3 haplo-insufficiency causes human HDR syndrome. Nature 2000; 406:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/20\">",
"      Muroya K, Hasegawa T, Ito Y, et al. GATA3 abnormalities and the phenotypic spectrum of HDR syndrome. J Med Genet 2001; 38:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/21\">",
"      Yumita S, Furukawa Y, Sohn HE, et al. Familial idiopathic hypoparathyroidism and progressive sensorineural deafness. Tohoku J Exp Med 1986; 148:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/22\">",
"      Barakat AY, D'Albora JB, Martin MM, Jose PA. Familial nephrosis, nerve deafness, and hypoparathyroidism. J Pediatr 1977; 91:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/23\">",
"      Sanjad SA, Sakati NA, Abu-Osba YK, et al. A new syndrome of congenital hypoparathyroidism, severe growth failure, and dysmorphic features. Arch Dis Child 1991; 66:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/24\">",
"      Tahseen K, Khan S, Uma R, et al. Kenny-Caffey syndrome in six Bedouin sibships: autosomal recessive inheritance is confirmed. Am J Med Genet 1997; 69:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/25\">",
"      Bergada I, Schiffrin A, Abu Srair H, et al. Kenny syndrome: description of additional abnormalities and molecular studies. Hum Genet 1988; 80:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/26\">",
"      Kelly TE, Blanton S, Saif R, et al. Confirmation of the assignment of the Sanjad-Sakati (congenital hypoparathyroidism) syndrome (OMIM 241410) locus to chromosome lq42-43. J Med Genet 2000; 37:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/27\">",
"      Parvari R, Hershkovitz E, Grossman N, et al. Mutation of TBCE causes hypoparathyroidism-retardation-dysmorphism and autosomal recessive Kenny-Caffey syndrome. Nat Genet 2002; 32:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/28\">",
"      Zupanc ML, Moraes CT, Shanske S, et al. Deletion of mitochondrial DNA in patients with combined features of Kearns-Sayre and MELAS syndromes. Ann Neurol 1991; 29:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/29\">",
"      Dionisi-Vici C, Garavaglia B, Burlina AB, et al. Hypoparathyroidism in mitochondrial trifunctional protein deficiency. J Pediatr 1996; 129:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/30\">",
"      De Sanctis V, Vullo C, Bagni B, Chiccoli L. Hypoparathyroidism in beta-thalassemia major. Clinical and laboratory observations in 24 patients. Acta Haematol 1992; 88:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/31\">",
"      Carpenter TO, Carnes DL Jr, Anast CS. Hypoparathyroidism in Wilson's disease. N Engl J Med 1983; 309:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/32\">",
"      Albright, F, Burnett, CH, Smith, PH, Parson, W. Pseudo-hypoparathyroidism--an example of 'Seabright-Bantam syndrome': report of three cases. Endocrinology 1942; 30:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/33\">",
"      Chase LR, Fedak SA, Aurbach GD. Activation of skeletal adenyl cyclase by parathyroid hormone in vitro. Endocrinology 1969; 84:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/34\">",
"      Chase LR, Melson GL, Aurbach GD. Pseudohypoparathyroidism: defective excretion of 3',5'-AMP in response to parathyroid hormone. J Clin Invest 1969; 48:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/35\">",
"      Bastepe M, J&uuml;ppner H. GNAS locus and pseudohypoparathyroidism. Horm Res 2005; 63:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/36\">",
"      Spiegel AM, Weinstein LS, Shenker A. Abnormalities in G protein-coupled signal transduction pathways in human disease. J Clin Invest 1993; 92:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/37\">",
"      Shapira H, Mouallem M, Shapiro MS, et al. Pseudohypoparathyroidism type Ia: two new heterozygous frameshift mutations in exons 5 and 10 of the Gs alpha gene. Hum Genet 1996; 97:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/38\">",
"      Ahmed SF, Dixon PH, Bonthron DT, et al. GNAS1 mutational analysis in pseudohypoparathyroidism. Clin Endocrinol (Oxf) 1998; 49:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/39\">",
"      Hayward BE, Kamiya M, Strain L, et al. The human GNAS1 gene is imprinted and encodes distinct paternally and biallelically expressed G proteins. Proc Natl Acad Sci U S A 1998; 95:10038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/40\">",
"      Farfel Z, Brickman AS, Kaslow HR, et al. Defect of receptor-cyclase coupling protein in psudohypoparathyroidism. N Engl J Med 1980; 303:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/41\">",
"      Nakamoto JM, Sandstrom AT, Brickman AS, et al. Pseudohypoparathyroidism type Ia from maternal but not paternal transmission of a Gsalpha gene mutation. Am J Med Genet 1998; 77:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/42\">",
"      Farfel Z, Friedman E. Mental deficiency in pseudohypoparathyroidism type I is associated with Ns-protein deficiency. Ann Intern Med 1986; 105:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/43\">",
"      Levine MA, Downs RW Jr, Moses AM, et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. Am J Med 1983; 74:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/44\">",
"      Carlson HE, Brickman AS. Blunted plasma cyclic adenosine monophosphate response to isoproterenol in pseudohypoparathyroidism. J Clin Endocrinol Metab 1983; 56:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/45\">",
"      ALBRIGHT F, FORBES AP, HENNEMAN PH. Pseudo-pseudohypoparathyroidism. Trans Assoc Am Physicians 1952; 65:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/46\">",
"      Fitch N. Albright's hereditary osteodystrophy: a review. Am J Med Genet 1982; 11:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/47\">",
"      Germain-Lee EL, Groman J, Crane JL, et al. Growth hormone deficiency in pseudohypoparathyroidism type 1a: another manifestation of multihormone resistance. J Clin Endocrinol Metab 2003; 88:4059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/48\">",
"      Mantovani G, Maghnie M, Weber G, et al. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type ia: new evidence for imprinting of the Gs alpha gene. J Clin Endocrinol Metab 2003; 88:4070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/49\">",
"      Shore EM, Ahn J, Jan de Beur S, et al. Paternally inherited inactivating mutations of the GNAS1 gene in progressive osseous heteroplasia. N Engl J Med 2002; 346:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/50\">",
"      Murray TM, Rao LG, Wong MM, et al. Pseudohypoparathyroidism with osteitis fibrosa cystica: direct demonstration of skeletal responsiveness to parathyroid hormone in cells cultured from bone. J Bone Miner Res 1993; 8:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/51\">",
"      Ishikawa Y, Bianchi C, Nadal-Ginard B, Homcy CJ. Alternative promoter and 5' exon generate a novel Gs alpha mRNA. J Biol Chem 1990; 265:8458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/52\">",
"      Swaroop A, Agarwal N, Gruen JR, et al. Differential expression of novel Gs alpha signal transduction protein cDNA species. Nucleic Acids Res 1991; 19:4725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/53\">",
"      Bastepe M, Fr&ouml;hlich LF, Hendy GN, et al. Autosomal dominant pseudohypoparathyroidism type Ib is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. J Clin Invest 2003; 112:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/54\">",
"      Bastepe M, Fr&ouml;hlich LF, Linglart A, et al. Deletion of the NESP55 differentially methylated region causes loss of maternal GNAS imprints and pseudohypoparathyroidism type Ib. Nat Genet 2005; 37:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/55\">",
"      Farfel Z, Brothers VM, Brickman AS, et al. Pseudohypoparathyroidism: inheritance of deficient receptor-cyclase coupling activity. Proc Natl Acad Sci U S A 1981; 78:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/56\">",
"      Rodriguez HJ, Villarreal H Jr, Klahr S, Slatopolsky E. Pseudohypoparathyroidism type II: restoration of normal renal responsiveness to parathyroid hormone by calcium administration. J Clin Endocrinol Metab 1974; 39:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/57\">",
"      Drezner M, Neelon FA, Lebovitz HE. Pseudohypoparathyroidism type II: a possible defect in the reception of the cyclic AMP signal. N Engl J Med 1973; 289:1056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/58\">",
"      Malloy PJ, Feldman D. Vitamin D resistance. Am J Med 1999; 106:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/59\">",
"      Thacher TD, Fischer PR, Pettifor JM, et al. A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N Engl J Med 1999; 341:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/60\">",
"      Lawson M, Thomas M. Vitamin D concentrations in Asian children aged 2 years living in England: population survey. BMJ 1999; 318:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/61\">",
"      Ziegler EE, Hollis BW, Nelson SE, Jeter JM. Vitamin D deficiency in breastfed infants in Iowa. Pediatrics 2006; 118:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/62\">",
"      Scriver CR, Reade TM, DeLuca HF, Hamstra AJ. Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease. N Engl J Med 1978; 299:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/63\">",
"      Kitanaka S, Takeyama K, Murayama A, et al. Inactivating mutations in the 25-hydroxyvitamin D3 1alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets. N Engl J Med 1998; 338:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/64\">",
"      Yoshida T, Monkawa T, Tenenhouse HS, et al. Two novel 1alpha-hydroxylase mutations in French-Canadians with vitamin D dependency rickets type I1. Kidney Int 1998; 54:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/65\">",
"      Wang JT, Lin CJ, Burridge SM, et al. Genetics of vitamin D 1alpha-hydroxylase deficiency in 17 families. Am J Hum Genet 1998; 63:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/66\">",
"      Brooks MH, Bell NH, Love L, et al. Vitamin-D-dependent rickets type II. Resistance of target organs to 1,25-dihydroxyvitamin D. N Engl J Med 1978; 298:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/67\">",
"      Labuda M, Fujiwara TM, Ross MV, et al. Two hereditary defects related to vitamin D metabolism map to the same region of human chromosome 12q13-14. J Bone Miner Res 1992; 7:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/68\">",
"      Baker AR, McDonnell DP, Hughes M, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci U S A 1988; 85:3294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/69\">",
"      Hughes MR, Malloy PJ, Kieback DG, et al. Point mutations in the human vitamin D receptor gene associated with hypocalcemic rickets. Science 1988; 242:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/70\">",
"      Marx SJ, Spiegel AM, Brown EM, et al. A familial syndrome of decrease in sensitivity to 1,25-dihydroxyvitamin D. J Clin Endocrinol Metab 1978; 47:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/71\">",
"      Balsan S, Garab&eacute;dian M, Larchet M, et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986; 77:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/72\">",
"      Hochberg Z, Tiosano D, Even L. Calcium therapy for calcitriol-resistant rickets. J Pediatr 1992; 121:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/73\">",
"      Walder RY, Shalev H, Brennan TM, et al. Familial hypomagnesemia maps to chromosome 9q, not to the X chromosome: genetic linkage mapping and analysis of a balanced translocation breakpoint. Hum Mol Genet 1997; 6:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/74\">",
"      Walder RY, Landau D, Meyer P, et al. Mutation of TRPM6 causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 2002; 31:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/75\">",
"      Marraffa JM, Hui A, Stork CM. Severe hyperphosphatemia and hypocalcemia following the rectal administration of a phosphate-containing Fleet pediatric enema. Pediatr Emerg Care 2004; 20:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/76\">",
"      Wason S, Tiller T, Cunha C. Severe hyperphosphatemia, hypocalcemia, acidosis, and shock in a 5-month-old child following the administration of an adult Fleet enema. Ann Emerg Med 1989; 18:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35209/abstract/77\">",
"      Gessner BD, Beller M, Middaugh JP, Whitford GM. Acute fluoride poisoning from a public water system. N Engl J Med 1994; 330:95.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5846 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-F5F47B5EFB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35209=[""].join("\n");
var outline_f34_24_35209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CALCIUM HOMEOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TRANSIENT NEONATAL HYPOCALCEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Early hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Late hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HYPOPARATHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Impaired synthesis/secretion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Genetic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Autoimmune",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Acquired",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Calcium-sensing receptor defect",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Autosomal dominant hypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      End-organ resistance/pseudohypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11300164\">",
"      Type 1a",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11300222\">",
"      Pseudo-pseudohypoparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11300173\">",
"      Type 1b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11300191\">",
"      Type 1c",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HYPOVITAMINOSIS D",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Reduced intake or production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Hepatic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Renal",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Defective vitamin D hydroxylation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Vitamin D resistance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HYPOMAGNESEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Primary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Secondary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MISCELLANEOUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Pancreatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Citrated products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Hungry bone syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Fluoride poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5898037\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5846\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5846|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/23/20862\" title=\"figure 1\">",
"      Vit D metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?1/10/1198\" title=\"figure 2\">",
"      Vitamin D synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5846|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?27/21/27996\" title=\"table 1\">",
"      Causes hypocalcemia children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/36/2631?source=related_link\">",
"      Chapter 6F: Hormonal regulation of calcium and phosphate balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/1/22553?source=related_link\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/50/36646?source=related_link\">",
"      Clinical manifestations of hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/37/32343?source=related_link\">",
"      DiGeorge syndrome: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13910?source=related_link\">",
"      Epidemiology and pathogenesis of Wilson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/37/28248?source=related_link\">",
"      Etiology and treatment of calcipenic rickets in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/15/9462?source=related_link\">",
"      Metabolism of vitamin D",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/15/20726?source=related_link\">",
"      Myopathies affecting the extraocular muscles in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/56/36744?source=related_link\">",
"      Parathyroid hormone secretion and action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/40/7817?source=related_link\">",
"      Pathogenesis and causes of spontaneous primary ovarian insufficiency (premature ovarian failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/50/18218?source=related_link\">",
"      Pathogenesis of renal osteodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/37/42580?source=related_link\">",
"      Signs and symptoms of magnesium depletion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_24_35210="Treatment of pulmonary hypertension in adults";
var content_f34_24_35210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of pulmonary hypertension in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/24/35210/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35210/contributors\">",
"     William Hopkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35210/contributors\">",
"     Lewis J Rubin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/24/35210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35210/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?34/24/35210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?34/24/35210/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?34/24/35210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 12, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early identification and treatment of pulmonary hypertension (PH) is generally suggested because advanced disease may be less responsive to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Treatment begins with a baseline assessment of disease severity, followed by primary therapy. Primary therapy is directed at the underlying cause of the PH.",
"   </p>",
"   <p>",
"    Some patients progress to advanced therapy, which is therapy directed at the PH itself, rather than the underlying cause of the PH. It includes treatment with prostanoids, endothelin receptor antagonists, phosphodiesterase 5 inhibitors, or, rarely, certain calcium channel blockers.",
"   </p>",
"   <p>",
"    Assessment of disease severity, primary therapy, and advanced therapy will be reviewed here. The definition, classification, epidemiology, etiology, pathogenesis, clinical manifestations, diagnosis, natural history and prognosis of PH are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link\">",
"     \"Overview of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7304?source=see_link\">",
"     \"Pathogenesis of pulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NOMENCLATURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The World Health Organization (WHO) classifies patients with PH into five groups based upon etiology. Patients in the first group are considered to have pulmonary arterial hypertension (PAH), whereas patients in the remaining four groups are considered to have PH (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"mobipreview.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). When all five groups are discussed collectively, PH is generally used. We adhere to this nomenclature in the discussion that follows. The WHO classification system is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     BASELINE ASSESSMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The baseline severity of PH should be determined prior to the initiation of therapy. This assessment is essential because the response to therapy will be measured as the change from baseline. Functional impairment and hemodynamic derangement are the key determinants of disease severity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The functional significance of the PH is determined by measuring exercise capacity. From the exercise capacity, the patient's World Health Organization (WHO) functional class can be determined (",
"      <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"       table 2",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pulmonary artery systolic pressure and right ventricular function can be estimated by echocardiography, and then used to make a presumptive diagnosis of PH. Right heart catheterization must be performed to accurately measure the hemodynamic parameters and confirm that PH exists. However, right heart catheterization is often deferred until advanced therapy is indicated because it is an invasive procedure. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Advanced therapy'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Once the severity of the patient's pulmonary hypertension has been determined, primary therapy can be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRIMARY THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary therapy refers to treatment that is directed at the underlying cause of the PH. It is warranted in nearly all patients with PH. The disease severity should be reassessed following primary therapy, in order to determine whether advanced therapy is indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Group 1 PAH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with group 1 pulmonary arterial hypertension (PAH) have idiopathic pulmonary arterial hypertension (IPAH, formerly called primary pulmonary hypertension), hereditary PAH, or PAH due to diseases that localize to small pulmonary arterioles, such as connective tissue diseases, HIV infection, portal hypertension, congenital heart disease, schistosomiasis, chronic hemolytic anemia, and drug use (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"mobipreview.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no effective primary therapies for most types of group 1 PAH. As a result, advanced therapy is often needed. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Advanced therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Group 2 PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with group 2 PH have PH secondary to left heart disease with chronic left atrial and pulmonary venous hypertension, including systolic dysfunction, diastolic dysfunction, and valvular heart disease (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"mobipreview.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary therapy for group 2 PH consists of treatment of the underlying heart disease, which is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=see_link\">",
"     \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=see_link\">",
"     \"Treatment and prognosis of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=see_link\">",
"     \"Course and management of chronic aortic regurgitation in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=see_link\">",
"     \"Overview of the management of chronic mitral regurgitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=see_link\">",
"     \"Medical management and indications for intervention in mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=see_link\">",
"     \"Medical management of asymptomatic aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Group 3 PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with group 3 PH have PH secondary to various causes of hypoxemia, such as chronic obstructive pulmonary disease, interstitial lung disease, other pulmonary diseases with a mixed restrictive and obstructive pattern, sleep-disordered breathing, or alveolar hypoventilation disorders (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"mobipreview.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary therapy for group 3 PH consists of treatment of the underlying cause of hypoxemia and correction of the hypoxemia with supplemental oxygen. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=see_link\">",
"     \"Management of stable chronic obstructive pulmonary disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/60/34762?source=see_link\">",
"     \"Treatment of idiopathic pulmonary fibrosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Oxygen is the only modality with proven mortality benefit in some patients with group 3 PH. This has been established by two large trials studying patients with COPD, the most common cause of group 3 PH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial randomly assigned 87 patients with COPD, a history of right ventricular dysfunction, and a PaO2 below 60 mmHg to receive either oxygen therapy for 15 hours per day or no oxygen therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/5\">",
"       5",
"      </a>",
"      ]. Oxygen therapy decreased five-year mortality (46 versus 67 percent), but the survival advantage did not appear until after 500 days of therapy. Pulmonary vascular resistance did not increase in the oxygen group, but increased in the group without oxygen (",
"      <a class=\"graphic graphic_figure graphicRef67353 \" href=\"mobipreview.htm?18/33/18973\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The Nocturnal Oxygen Therapy Trial (NOTT) compared continuous (19 hours per day) to nocturnal (12 hours per day) oxygen administration [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/6\">",
"       6",
"      </a>",
"      ]. The population included 203 patients with COPD and either a PaO2 below 55 mmHg or a PaO2 below 60 mmHg with coexisting polycythemia, leg edema, or cor pulmonale on the electrocardiogram. The three-year mortality rate was lower with continuous oxygen than nocturnal oxygen (22 versus 42 percent) (",
"      <a class=\"graphic graphic_figure graphicRef82598 \" href=\"mobipreview.htm?38/49/39709\">",
"       figure 2",
"      </a>",
"      ). Oxygen therapy was also associated with a slight reduction of pulmonary vascular resistance.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, continuous oxygen therapy improves survival in patients with COPD and a PaO2 below 55 mmHg, despite seemingly mild effects on pulmonary hemodynamics. Predictors of a long-term response to continuous supplemental oxygen therapy include a decrease of the mean pulmonary artery pressure greater than 5 mmHg after 24 hours of 28 percent oxygen therapy and a high peak oxygen consumption (VO2) after symptom-limited exercise (&gt;6.5",
"    <span class=\"nowrap\">",
"     cc/kg",
"    </span>",
"    per min as determined by a 30 second collection of expired gas in an airtight collection bag) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Group 4 PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with group 4 PH have PH due to thromboembolic occlusion of the proximal or distal pulmonary vasculature (eg, chronic thromboembolic disease) (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"mobipreview.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anticoagulation is primary medical therapy for patients with group 4 PH. The value of anticoagulant therapy for group 4 PH is an extrapolation of the clinical evidence that anticoagulation prevents recurrent pulmonary embolism. Data suggesting that anticoagulation is beneficial in patients with group 4 PH are lacking.",
"   </p>",
"   <p>",
"    Surgical thromboendarterectomy is primary surgical therapy for selected patients with thromboembolic obstruction of the proximal pulmonary arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/8\">",
"     8",
"    </a>",
"    ]. Perioperative mortality for this procedure is less than 10 percent when performed in selected centers and the hemodynamic response may be dramatic and sustained. Prior to proceeding with this invasive approach, a three-month period of anticoagulation is required and patients must remain severely incapacitated due to PH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10503?source=see_link&amp;anchor=H2#H2\">",
"     \"Chronic thromboembolic pulmonary hypertension: Surgical treatment\", section on 'Indications for pulmonary thromboendarterectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10503?source=see_link&amp;anchor=H9#H9\">",
"     \"Chronic thromboembolic pulmonary hypertension: Surgical treatment\", section on 'Pulmonary thromboendarterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Group 5 PH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Group 5 PH is uncommon and includes PH with unclear multifactorial mechanisms. Examples include PH caused by hematologic disorders (eg, myeloproliferative disorders), systemic disorders (eg, sarcoidosis), metabolic disorders (eg, glycogen storage disease), and miscellaneous causes (",
"    <a class=\"graphic graphic_table graphicRef66348 \" href=\"mobipreview.htm?42/38/43628\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=see_link&amp;anchor=H3#H3\">",
"     \"Overview of pulmonary hypertension in adults\", section on 'Classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary therapy is directed at the underlying cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     All groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several therapies should be considered in all patients with PH. They include diuretic, oxygen, anticoagulant, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    therapy, as well as exercise.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Diuretics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diuretics are used to treat fluid retention due to PH because diuresis will diminish hepatic congestion and peripheral edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/9\">",
"     9",
"    </a>",
"    ]. However, they should be administered with caution to avoid decreased cardiac output (due to decreased right",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    left ventricular preload), arrhythmias induced by hypokalemia, and metabolic alkalosis. Fluid can also be removed by dialysis or ultrafiltration if necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Oxygen therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuous oxygen administration remains the cornerstone of therapy in patients with group 3 PH, as discussed above. It is inferred that oxygen may benefit other groups of patients with PH and resting, exercise-induced, or nocturnal hypoxemia. However, long-term data do not exist.",
"   </p>",
"   <p>",
"    Oxygen should be considered for all patients with PH plus hypoxemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ]. The flow of oxygen needed to correct hypoxemia should be determined by measurement of the oxygen saturation. Oxygen is generally administered at 1 to 4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    via nasal prongs and adjusted to maintain the oxygen saturation above 90 percent at rest and, if possible, with exercise and sleep [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=see_link\">",
"     \"Long-term supplemental oxygen therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Supplemental oxygen will not significantly improve the oxygen saturation of patients who have congenital heart disease with a right-to-left shunt (Eisenmenger physiology).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PH are at increased risk for intrapulmonary thrombosis and thromboembolism, due to sluggish pulmonary blood flow, dilated right heart chambers, venous stasis, and a sedentary lifestyle. Even a small thrombus can produce hemodynamic deterioration in a patient with a compromised pulmonary vascular bed that is unable to dilate or recruit unused vasculature.",
"   </p>",
"   <p>",
"    It is generally accepted that anticoagulation is indicated in patients with IPAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1,9,10\">",
"     1,9,10",
"    </a>",
"    ], hereditary pulmonary artery hypertension (PAH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1,9\">",
"     1,9",
"    </a>",
"    ], drug-induced PAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1,9\">",
"     1,9",
"    </a>",
"    ], or group 4 PH. Limited experience with newer anticoagulants makes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    the anticoagulant of choice, with a therapeutic goal of an international normalized ratio (INR) of approximately two.",
"   </p>",
"   <p>",
"    Support for the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    in patients with PH largely comes from observational studies of patients with IPAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1,12-14\">",
"     1,12-14",
"    </a>",
"    ]. In a systematic review of seven observational studies that evaluated the effect of warfarin in patients with group 1 PAH, five studies found a mortality benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of bleeding on vitamin K antagonists may differ among patients with different types of PH. As an example, a retrospective study of 198 patients with PH receiving anticoagulation reported major bleeding events in 23 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/16\">",
"     16",
"    </a>",
"    ]. Compared to idiopathic PAH and chronic thromboembolic disease-associated PAH, connective tissue disease-related PAH had a higher bleeding event rate (19 versus 5.4 and 2.4 events per 100 patient-years, respectively). This suggests that differences in bleeding risk may alter the risk-benefit ratio of anticoagulation in PH subtypes. Prospective studies with subset analysis are required to accurately assess whether increases in bleeding risk offset the apparent benefit of anticoagulation in these patient groups. &nbsp;",
"   </p>",
"   <p>",
"    Patients with pulmonary hypertension frequently have other risk factors for thromboembolism (eg, atrial fibrillation, severe left heart failure) that may warrant anticoagulation. These conditions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=see_link\">",
"     \"Indications for antithrombotic therapy in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Digoxin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     Digoxin",
"    </a>",
"    therapy has been shown to have both beneficial effects and drawbacks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      improves the right ventricular ejection fraction of patients with group 3 PH due to COPD and biventricular failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/17\">",
"       17",
"      </a>",
"      ]. However, these patients may be more sensitive than most patients to digitalis toxicity and require close monitoring.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      helps control the heart rate of patients who have supraventricular tachycardias associated with right ventricular dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/18\">",
"       18",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"       Verapamil",
"      </a>",
"      is preferred for multifocal atrial tachycardia, unless there is concurrent left ventricular failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    No data are available on the long-term effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    in patients with group 1 PAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Exercise",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise training appears to be beneficial for patients with PH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/19-23\">",
"     19-23",
"    </a>",
"    ]. A crossover trial randomly assigned 30 patients who were receiving advanced therapy for severe PH to either an exercise training group or a sedentary control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/19\">",
"     19",
"    </a>",
"    ]. After 15 weeks, the mean six-minute walk distance increased in the exercise training group and decreased in the sedentary group (+96 versus -15 meters). Following crossover, the sedentary group also improved their mean six-minute walk distance (+74 meters). The improved distances exceed those described for all types of advanced therapy. Exercise training improved the WHO functional class and peak oxygen consumption. Despite the functional benefits, exercise training did not improve hemodynamic abnormalities, measured as the Doppler-derived pulmonary artery systolic pressure. This study suggests that skeletal muscle training may play a major role in the treatment of patients with PH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     ADVANCED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced therapy is directed at the PH itself, rather than the underlying cause of the PH. It includes treatment with prostanoids, endothelin receptor antagonists, phosphodiesterase 5 inhibitors, or, rarely, certain calcium channel blockers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced therapy is considered for patients who have evidence of persistent PH and a World Health Organization (WHO) functional class II, III, or IV despite adequate primary therapy (",
"    <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1,24\">",
"     1,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Primary therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Two issues deserve emphasis before selecting a patient for advanced therapy. First, the evidence supporting advanced therapy comes primarily from studies that included patients with idiopathic PAH or scleroderma-related PAH. Extrapolation to other patient populations must be done with caution. Second, most clinicians agree that patients should be selected and administered advanced therapy only at specialized centers where clinicians are experienced in the evaluation and management of patients with PH.",
"   </p>",
"   <p>",
"    There are special considerations for each group of pulmonary hypertension.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Group 1 PAH &ndash; Advanced therapy is often needed for patients with group 1 PAH because there are no effective primary therapies.",
"     </li>",
"     <li>",
"      Group 2 PH &ndash; There are a few situations in which advanced therapy may be considered for group 2 PH (eg, patients with persistent PH due to mitral stenosis who have undergone mitral valve replacement). However, for most patients with group 2 PH, advanced therapy should be avoided because it may be harmful.",
"      <br/>",
"      <br/>",
"      This was illustrated by a trial that randomly assigned 471 patients with PH and severe left ventricular dysfunction to receive standard therapy with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      (a component of advanced therapy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/3\">",
"       3",
"      </a>",
"      ]. The trial was terminated early because the epoprostenol group had a nonstatistically significant increase in mortality at three months (30 versus 24 percent) and six months (48 versus 37 percent). Possible explanations for the detrimental impact of epoprostenol include its significant positive inotropic effect and the inability of a compromised left heart to handle the increased flow across a newly dilated pulmonary vascular bed [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Group 3 PH &ndash; Advanced therapy is not approved by the United States Food and Drug Administration (FDA) for patients with group 3 PH and several guideline panels recommend against its use in this population, except in the context of a clinical trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/9,25\">",
"       9,25",
"      </a>",
"      ]. Despite this, it is occasionally considered for patients who remain WHO functional class III or IV (",
"      <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"       table 2",
"      </a>",
"      ) despite correction of hypoxemia and optimization of the underlying disease, especially if the severity of the PH is out of proportion to the severity of the parenchymal lung disease. Advanced therapy for patients with group 3 PH should only be initiated at specialized centers and administered cautiously due to its potential to worsen ventilation-perfusion mismatch and increase hypoxemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The tendency of advanced therapy to worsen ventilation-perfusion mismatch and increase hypoxemia in patients with group 3 PH may be formulation- and disease-specific:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evidence of a formulation-specific effect &ndash; Small trials suggest that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      increases hypoxemia in patients who have pulmonary fibrosis; however, inhaled nitric oxide, inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      , and oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      do not appear to have this effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. All of the agents decrease the pulmonary vascular resistance.",
"     </li>",
"     <li>",
"      Evidence of a disease-specific effect &ndash; In small trials, oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      did not appear to worsen hypoxemia in patients with group 3 PH due to pulmonary fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/26\">",
"       26",
"      </a>",
"      ], but was associated with worsened hypoxemia in patients with group 3 PH due to chronic obstructive pulmonary disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/28\">",
"       28",
"      </a>",
"      ]. In both diseases, oral sildenafil decreased the pulmonary artery pressure.",
"     </li>",
"     <li>",
"      Group 4 PH &ndash; Advanced therapy can be considered for patients with group 4 PH who remain WHO functional class III or IV (",
"      <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"       table 2",
"      </a>",
"      ) even after anticoagulation or thromboendarterectomy. Pharmacologic therapy can also act as a bridge to surgical intervention. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14837?source=see_link&amp;anchor=H1663229#H1663229\">",
"       \"Chronic thromboembolic pulmonary hypertension: Medical treatment\", section on 'Indications for pulmonary hypertension-specific therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Group 5 PH &ndash; Small studies have addressed the role of advanced therapy for patients with PH related to sarcoidosis. One series of eight patients described a favorable response to intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      in most patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/29\">",
"       29",
"      </a>",
"      ], while another study reported that carefully selected patients can be transitioned from prostanoid infusion to oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     General approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with PH who are selected for advanced therapy should undergo an invasive hemodynamic assessment prior to the initiation of advanced therapy. It is recommended that patients with group 1 PAH also undergo a vasoreactivity test with intravenous adenosine, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    , or inhaled nitric oxide (patients with IPAH and anorexigen-induced PAH are the most likely to respond ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with a positive vasoreactivity test can be given a trial of oral calcium channel blocker therapy with a dihydropyridine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    . In contrast, patients with a negative vasoreactivity test require advanced therapy with a prostanoid, endothelin receptor antagonist, or phosphodiesterase 5 inhibitor. Combination advanced therapy may be appropriate in refractory cases, although data are limited. Some patients are refractory to all medical interventions. In such cases, lung transplantation or creation of a right to left shunt by atrial septostomy may be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/8\">",
"     8",
"    </a>",
"    ]. An algorithm for advanced therapy is shown in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef71168 \" href=\"mobipreview.htm?7/25/7583\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The discussion that follows will address the following issues: the acute vasoreactivity test; the various therapeutic agents that are available to treat PH; and the clinical trials that support the use of the various agents (most included only patients with group 1 PAH). Finally, we describe selection of a pharmacologic agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Vasoreactivity test",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is recommended that patients with group 1 PAH undergo a vasoreactivity test (patients with IPAH and anorexigen-induced PAH are the most likely to respond). This involves the administration of a short-acting vasodilator and then measurement of the hemodynamic response using a right heart catheter. Agents commonly used for vasoreactivity testing include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    , adenosine, and inhaled nitric oxide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/31\">",
"     31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       Epoprostenol",
"      </a>",
"      is infused at a starting rate of 1 to 2",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per min and increased by 2",
"      <span class=\"nowrap\">",
"       ng/kg",
"      </span>",
"      per min every 5 to 10 minutes until a clinically significant fall in blood pressure, an increase in heart rate, or adverse symptoms (eg, nausea, vomiting, headache) develop (",
"      <a class=\"graphic graphic_table graphicRef50798 \" href=\"mobipreview.htm?26/54/27500\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Adenosine is administered intravenously in doses of 50",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min and increased every two minutes until uncomfortable symptoms develop or a maximal dose of 200 to 350",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per min is reached.",
"     </li>",
"     <li>",
"      Inhaled nitric oxide administered at 10 to 20 ppm is selective for the pulmonary vasculature. Thus, it is often better tolerated than the intravenous agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/32-36\">",
"       32-36",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/4/38982?source=see_link\">",
"       \"Inhaled nitric oxide in adults with pulmonary hypertension\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An acute vasoreactivity test is considered positive if mean pulmonary artery pressure decreases at least 10 mmHg and to a value less than 40 mmHg, with an increased or unchanged cardiac output, and a minimally reduced or unchanged systemic blood pressure. Patients with a positive vasoreactivity test are candidates for a trial of CCB therapy with a dihydropyridine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. In contrast, patients with a negative vasoreactivity test should be treated with an alternative agent because CCBs have not been shown to be beneficial in these patients and may be harmful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with portopulmonary hypertension are rarely vasoreactive and are at increased risk for adverse sequelae from pure vasodilator therapy. Therefore, neither vasoreactivity testing nor calcium channel blocker therapy is indicated in this group. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35064?source=see_link\">",
"     \"Portopulmonary hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Calcium channel blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients who are vasoreactive and receive CCB therapy with a dihydropyridine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    can achieve prolonged survival, sustained functional improvement, and hemodynamic improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/12,37-39\">",
"     12,37-39",
"    </a>",
"    ]. This was illustrated by an observational study of 64 patients with IPAH that compared vasoreactive patients who received CCB therapy (primarily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    ) to a combined group that included patients who were not vasoreactive plus historical controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/12\">",
"     12",
"    </a>",
"    ]. None of the patients in the combined group received a CCB. Five year survival was greater among patients who received CCB therapy (94 versus 55 percent).",
"   </p>",
"   <p>",
"    A more recent observational study of 557 patients with IPAH found that only 13 percent had a positive vasoreactivity test and only 54 percent of the vasoreactive patients with IPAH who received CCB therapy maintained functional improvement after one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/39\">",
"     39",
"    </a>",
"    ]. Responders were more vasoreactive (ie, had a greater decrease of mean pulmonary arterial pressure during the vasoreactivity test) and had less severe disease at baseline.",
"   </p>",
"   <p>",
"    The evidence suggesting that CCB therapy is beneficial is limited by the absence of randomized trials comparing such therapy to no therapy in vasoreactive patients only. Without such trials, it is uncertain whether the vasoreactive patients who received CCB therapy in the observational trials truly benefited from the therapy or were predisposed to a better outcome, with vasoreactivity potentially being a marker of a better prognosis.",
"   </p>",
"   <p>",
"    CCB therapy can be initiated with either long-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    (120",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    then increased to the maximal tolerated dose (",
"    <a class=\"graphic graphic_table graphicRef50798 \" href=\"mobipreview.htm?26/54/27500\">",
"     table 3",
"    </a>",
"    ). Short-acting nifedipine should NOT be used. Systemic blood pressure, heart rate, and oxygen saturation should be carefully monitored during titration. Sustained release preparations of both nifedipine and diltiazem are available. Their use minimizes the adverse effects of therapy, especially systemic hypotension.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     Amlodipine",
"    </a>",
"    , a long-acting dihydropyridine, is a useful alternative for patients who are intolerant of the other agents. Patients who respond to CCB therapy with a dihydropyridine or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    (defined as asymptomatic or minimal symptoms) should be reassessed after three to six months of treatment.",
"   </p>",
"   <p>",
"    Adverse effects are common among patients with PH who are administered CCBs. In an observational study evaluating 12 patients with PH due to obliterative pulmonary vascular diseases who were administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    , severe short- and long-term side effects occurred in 11 of the 12 patients who received verapamil or nifedipine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/40\">",
"     40",
"    </a>",
"    ]. Many of the adverse effects are a result of the potent vasodilatory properties of CCBs. Systemic vasodilation may cause hypotension, while pulmonary vasodilation may reduce hypoxic vasoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Loss of hypoxic vasoconstriction can worsen ventilation-perfusion mismatch and hypoxemia. CCBs may also be associated with deterioration of right ventricular (RV) function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=see_link\">",
"     \"Major side effects and safety of calcium channel blockers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prostanoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prostanoid formulations used to treat PH include intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    (prostacyclin), intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    , subcutaneous treprostinil, inhaled treprostinil, and inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. All of the prostanoid formulations have the limitations of a short half-life and a heterogeneous response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Epoprostenol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    (Flolan) is the advanced therapy that has been best studied. It improves hemodynamic parameters, functional capacity, and survival in patients with IPAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/45-49\">",
"     45-49",
"    </a>",
"    ]. In patients with other types of group 1 pulmonary arterial hypertension (PAH), intravenous epoprostenol improves hemodynamic parameters and functional capacity; however, survival has not been adequately evaluated due to limited sample sizes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/50-53\">",
"     50-53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    was illustrated by a trial that randomly assigned 81 patients with severe (ie, World Health Organization [WHO] class III or IV) IPAH to receive intravenous epoprostenol or standard therapy for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/47\">",
"     47",
"    </a>",
"    ]. Intravenous epoprostenol improved quality of life, mean pulmonary arterial pressure (-8 versus +3 percent), pulmonary vascular resistance (-21 versus +9 percent), and exercise capacity, as measured by a six-minute walk test (+47 versus -66 meters). Eight patients died during the trial, all of whom were in the standard therapy group.",
"   </p>",
"   <p>",
"    We believe that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    should be considered the first-line agent in patients with severe disease (ie, WHO class IV) because only a small number of such patients were included in the clinical trials of the alternative agents. In less severe disease (ie, WHO class II or III), numerous choices exist, as discussed below.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     Epoprostenol",
"    </a>",
"    is delivered continuously through a permanently implanted central venous catheter using a portable infusion pump. It is usually initiated at doses of 1 to 2",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min and increased by 1 to 2",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min every one to two days as tolerated. The rate at which the dose can be increased varies from patient to patient and depends to a large extent on how well the drug is tolerated. Once an initial level of 6 to 10",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min is achieved (usually within one to two weeks), most patients require dose increases of 1 to 2",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min every two to four weeks to sustain the clinical effect (",
"    <a class=\"graphic graphic_table graphicRef50798 \" href=\"mobipreview.htm?26/54/27500\">",
"     table 3",
"    </a>",
"    )(",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/10/14497?source=see_link\">",
"     calculator 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A maximal dose has not been established. Patients who have been receiving therapy for many years may receive doses as high as 150 to 200",
"    <span class=\"nowrap\">",
"     ng/kg",
"    </span>",
"    per min with sustained clinical and hemodynamic benefit. Excess doses may produce high output cardiac states. In this situation, the dose should be reduced, while monitoring for rebound pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects include jaw pain, diarrhea, and arthralgias. More severe adverse effects are usually attributable to the complex delivery system including thrombosis, pump malfunction, and interruption of the infusion. Central venous catheter infection can also contribute to the morbidity and mortality of continuous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/55,56\">",
"     55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most insurers in the United States now reimburse the cost of continuous intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    for IPAH and group 1 PAH due to connective tissue diseases, portal hypertension, HIV infection, anorectic drug therapy, or congenital heart disease. In each of these conditions, the following criteria must be met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pulmonary hypertension has progressed despite medical or surgical treatment of the underlying disorder, AND",
"     </li>",
"     <li>",
"      The mean pulmonary artery pressure is greater than 25 mmHg at rest or greater than 30 mmHg with exertion, AND",
"     </li>",
"     <li>",
"      Symptoms from PH are present, AND",
"     </li>",
"     <li>",
"      Acute vasoreactivity testing was negative, CCB therapy with a dihydropyridine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      failed, or treatment with a CCB is contraindicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     Epoprostenol",
"    </a>",
"    may also be reimbursed for the treatment of patients with other types of PH, if the clinician can demonstrate that the PH is out of proportion to the associated disease (eg, parenchymal lung disease) or is the major cause of symptoms. This is also true for the other pharmacologic agents used for advanced therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Treprostinil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"     Treprostinil",
"    </a>",
"    (Remodulin) can be given intravenously or subcutaneously, although subcutaneous administration is uncommon due to severe pain at the injection site (",
"    <a class=\"graphic graphic_table graphicRef50798 \" href=\"mobipreview.htm?26/54/27500\">",
"     table 3",
"    </a>",
"    ). Inhaled treprostinil (Tyvaso) has more recently been approved, specifically for patients with group 1 PAH who are WHO functional class III (",
"    <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Intravenous and subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    improve hemodynamic parameters, symptoms, exercise capacity, and possibly survival in patients with group 1 PAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/44,57-59\">",
"     44,57-59",
"    </a>",
"    ]. It has not been evaluated in patients with other types of PH.",
"   </p>",
"   <p>",
"    Trials comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"     epoprostenol",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    have not been performed. Advantages of parenteral treprostinil, compared to epoprostenol, include the option of continuous subcutaneous delivery, a longer half-life that may make interruption of the infusion less immediately life threatening, and no need for refrigeration. All of these advantages allow more flexibility and easier administration. For patients who desire the advantages associated with treprostinil administration, it can be offered as first line therapy. Based upon preliminary results, patients who are already receiving epoprostenol generally can be transitioned to treprostinil (subcutaneous or intravenous) without a significant loss of clinical efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. Reciprocally, epoprostenol can be given if the desired effect is not achieved with treprostinil.",
"   </p>",
"   <p>",
"    Oral formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"     treprostinil",
"    </a>",
"    are not commercially available, but have been examined in clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. As an example, 349 patients with PAH, not on other advanced therapy, were randomly assigned to gradually increasing doses of treprostinil or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/63\">",
"     63",
"    </a>",
"    ]. After 12 weeks, the treprostinil group experienced a statistically significant but not clinically impressive increase in six minute walk distance. No significant effect was noted on the incidence of clinical worsening, but the overall rate of clinical worsening was low. The combination of oral treprostinil with other agents is described below. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Iloprost",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    (Ventavis) has theoretical advantages in targeting the lung vasculature and does not require intravenous administration (",
"    <a class=\"graphic graphic_table graphicRef50798 \" href=\"mobipreview.htm?26/54/27500\">",
"     table 3",
"    </a>",
"    ). The main disadvantage is the need for frequent administration (six to nine times per day).",
"   </p>",
"   <p>",
"    A trial randomly assigned 203 patients with PH (including a variety of types) who were WHO Class III or IV to receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     iloprost",
"    </a>",
"    (2.5 to 5 mcg, six to nine times per day) or placebo for 12 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/64\">",
"     64",
"    </a>",
"    ]. The primary endpoint (improvement in WHO class and &gt;10 percent improvement in the six-minute walk test) was greater in the iloprost group compared to the placebo group (17 versus 5 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Endothelin receptor antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelin-1 is a potent vasoconstrictor and smooth muscle mitogen. High concentrations of endothelin-1 have been recorded in the lungs of patients with both IPAH and other etiologies of group 1 PAH, including scleroderma and congenital cardiac shunt lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/65\">",
"     65",
"    </a>",
"    ]. Endothelin receptor antagonism emerged as an initial therapy for group 1 PAH in the late 1990s.",
"   </p>",
"   <p>",
"    A meta-analysis of 12 randomized trials (1471 patients) evaluated the impact of endothelin receptor antagonists (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    or sitaxsentan) on patients with PAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/66\">",
"     66",
"    </a>",
"    ]. The endothelin receptor antagonists improved exercise capacity, dyspnea, and hemodynamic measures (pulmonary artery pressure, pulmonary vascular resistance, and cardiac index).",
"   </p>",
"   <p>",
"    There is some evidence that the magnitude of the response to endothelin receptor antagonists may vary according to gender and race; namely, an observational study of 1130 patients that used data extracted from randomized trials found that women had significantly greater improvement in their six-minute walk test than men (+29.7 m) and white individuals had a trend toward greater improvement in their six-minute walk test than black individuals (+43.6 m) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/67\">",
"     67",
"    </a>",
"    ]. While the data are too preliminary to alter current clinical practice, further investigation is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Bosentan",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     Bosentan",
"    </a>",
"    (Tracleer), a nonselective endothelin receptor antagonist, improves hemodynamics and exercise capacity in patients with group 1 PAH and delays clinical worsening (",
"    <a class=\"graphic graphic_table graphicRef50798 \" href=\"mobipreview.htm?26/54/27500\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. The mortality of bosentan-treated IPAH patients appears favorable compared to historical controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/65,70\">",
"     65,70",
"    </a>",
"    ]. Mortality has not been studied in patients with other types of PH. The major advantage of bosentan is its oral administration.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     Bosentan",
"    </a>",
"    appears to be effective in patients with severe group 1 PAH (WHO functional class III or IV) and may also be effective in patients with moderate group 1 PAH (WHO functional class II):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a double-blind trial (BREATHE-1 trial), 213 patients with severe group 1 PAH were randomly assigned to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      (62.5 mg) or placebo twice daily for four weeks, followed by either of two doses of bosentan (125 or 250 mg) twice daily for a minimum of 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/69\">",
"       69",
"      </a>",
"      ]. Bosentan improved symptoms, the six-minute walking distance, and the WHO functional class (",
"      <a class=\"graphic graphic_figure graphicRef75744 \" href=\"mobipreview.htm?13/50/14126\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Another double-blind trial randomly assigned 185 patients with moderate group 1 PAH to receive",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      or placebo twice daily for six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/2\">",
"       2",
"      </a>",
"      ]. The bosentan was administered at a dose of 62.5 mg twice daily for four weeks and then increased to 125 mg twice daily. Bosentan improved pulmonary vascular resistance and the mean six-minute walk distance, although the latter was not statistically significant. A limitation of this trial was its failure to follow the principle of intention to treat.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Selective agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/60/29637?source=see_link\">",
"     Ambrisentan",
"    </a>",
"    (Letaris) and sitaxsentan (Thelin) are selective type A endothelin-1 receptor antagonists that are administered orally. The evidence (eg, the ARIES-1 and ARIES-2 trials) suggests that ambrisentan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/72-74\">",
"     72-74",
"    </a>",
"    ] and sitaxsentan [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/75-78\">",
"     75-78",
"    </a>",
"    ] improve exercise tolerance, WHO functional class, hemodynamics, and quality of life in patients with PAH. Only ambrisentan is currently available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main adverse effect of some endothelin receptor antagonists is hepatotoxicity, which appears to be more severe at higher doses. Sitaxsentan was withdrawn from the European Union, Canada, and Australia in 2010 following several fatal cases of hepatoxicity (the drug was never approved in the United States) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/79\">",
"     79",
"    </a>",
"    ]. Ambrisentan is a safe and effective alternative for patients who previously discontinued bosentan or sitaxsentan due to abnormal liver function test results according to one observational study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/80\">",
"     80",
"    </a>",
"    ], suggesting the hepatotoxicity may differ among the endothelin receptor antagonists. Liver function tests should be monitored monthly during treatment with bosentan. The monitoring of liver function tests is no longer required for patients treated with ambrisentan. Careful consideration should be given to the use of endothelin receptor antagonists in patients with moderate or severe hepatic dysfunction, or in conjunction with cyclosporine or glyburide.",
"   </p>",
"   <p>",
"    Peripheral edema is the most common side effect that requires attention. Mild cases can be managed with diuretics, but more severe cases warrant discontinuation of the medication. Endothelin receptor antagonists are also potent teratogens, requiring meticulous contraception if used by women who have childbearing potential.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     PDE5 inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     Sildenafil",
"    </a>",
"    (Viagra, Revatio),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    (Cialis, Adcirca), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    (Levitra) are orally administered cyclic GMP phosphodiesterase type 5 (PDE5) inhibitors that prolong the vasodilatory effect of nitric oxide and are also used to treat erectile dysfunction.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      improves pulmonary hemodynamics and exercise capacity in patients with group 1 PAH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/81-84\">",
"       81-84",
"      </a>",
"      ]. However, its effect on mortality has not been adequately evaluated. An illustrative trial (the SUPER-1 trial) randomly assigned 277 patients with group 1 PAH to receive sildenafil (20, 40, or 80 mg) or placebo three times daily for 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/83\">",
"       83",
"      </a>",
"      ]. The sildenafil group demonstrated significant improvement in hemodynamics and six-minute walk distances, which persisted during one year of follow up. Mortality was not reported. Patients who completed the SUPER-1 trial were eligible to participate in an uncontrolled, open-label, three-year extension called the SUPER-2 trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/85\">",
"       85",
"      </a>",
"      ]. The trial enrolled 259 patients and, at the end of three years of therapy, found persistent improvement in the six-minute walk distance and WHO functional class of 46 and 29 percent of patients, respectively, compared with the baseline values measured prior to the SUPER-1 trial. The estimated three year survival rate was 79 percent. The effect of sildenafil on patients with other types of PH is uncertain.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"       Tadalafil",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"       vardenafil",
"      </a>",
"      also appear to improve outcomes in patients with group 1 PAH. The PHIRST trial randomly assigned 405 such patients to receive tadalafil (2.5, 10, 20, or 40 mg) or placebo once daily for 16 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/86\">",
"       86",
"      </a>",
"      ]. Tadalafil (40 mg) significantly increased the six-minute walk distance and the time to clinical worsening, while decreasing the incidence of clinical worsening and improving health related quality of life. This improvement of the six-minute walk distance was sustained for an additional 52 weeks in the PHIRST -2 trial, an uncontrolled extension trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/87\">",
"       87",
"      </a>",
"      ]. Similarly, another trial randomly assigned 66 patients with group 1 PAH to receive vardenafil (5 mg once daily for four weeks, then twice daily) or placebo for 12 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/88\">",
"       88",
"      </a>",
"      ]. Vardenafil increased the mean six minute walking distance and cardiac index, while decreasing the mean pulmonary arterial pressure, pulmonary vascular resistance, and number of clinical worsening events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that combining pharmacologic agents with different mechanisms of action may produce an additive effect or may induce the same effect at lower doses of each agent. Clinical studies have begun to evaluate combination therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       Bosentan",
"      </a>",
"      added to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      &ndash; Limited experience suggests that bosentan can be used safely and effectively added to epoprostenol or subcutaneous treprostinil therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/59,89\">",
"       59,89",
"      </a>",
"      ]. A trial (BREATHE-2 trial) randomly assigned 22 patients with group 1 PAH who were receiving epoprostenol to have either bosentan or placebo added for 16 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/89\">",
"       89",
"      </a>",
"      ]. Epoprostenol improved hemodynamic parameters, exercise capacity, and functional class, compared to baseline. The addition of bosentan improved these outcomes to a greater degree than the addition of placebo, although the difference was not statistically significant.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"       Treprostinil",
"      </a>",
"      added to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      &ndash; The addition of inhaled treprostinil may improve the exercise capacity and quality of life of patients with persistent symptoms despite bosentan or sildenafil therapy. This was demonstrated by the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) trial [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/90\">",
"       90",
"      </a>",
"      ]. In the trial, 235 patients with group 1 PAH, a WHO functional class III or IV, and a six minute walking distance (6MWD) of only 200 to 450 meters despite bosentan or sildenafil therapy were randomly assigned to receive either inhaled treprostinil or placebo for 12 weeks. The treprostinil group had a larger improvement in their six minute walking distance and quality of life, but there were no differences in the time to clinical worsening, dyspnea, or WHO functional class.",
"     </li>",
"     <li>",
"      Oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      added to an endothelin receptor antagonist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a phosphodiesterase-5 inhibitor &ndash; The addition of oral treprostinil in patients with group 1 PAH already on an endothelin receptor antagonist",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a phosphodiesterase-5 inhibitor did not improve the 6MWD at 16 weeks in the FREEDOM-C Study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/62\">",
"       62",
"      </a>",
"      ]. The 354 subjects were randomly assigned to oral treprostinil or placebo for 16 weeks. The dose of treprostinil was increased at intervals according to protocol to a median dose of 3 mg twice daily. A study drug discontinuation rate of 22 percent was noted in the treprostinil group and was attributed to the high incidence (&gt;40 percent) of side effects of headache, nausea, vomiting, diarrhea, flushing, and jaw pain. Significant improvements were noted in the secondary end-points of median dyspnea fatigue index score and combined 6MWD and Borg dyspnea score.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      added to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      &ndash; The addition of sildenafil to long-term epoprostenol therapy improves clinical outcomes. A trial randomly assigned 267 patients with group 1 PAH who were receiving epoprostenol to have sildenafil or placebo added for 16 weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/91\">",
"       91",
"      </a>",
"      ]. Most patients were WHO functional class III at the beginning of the trial. Sildenafil improved hemodynamic parameters, exercise capacity, quality of life, and time to clinical worsening, compared to placebo. There was no difference in dyspnea. Headache and dyspepsia were more common in the sildenafil group.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      added to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      &ndash; The benefits of adding sildenafil to bosentan therapy are more certain among patients with IPAH than those with scleroderma-associated PAH. A prospective cohort study followed 25 patients with group 1 PAH who were initially treated with bosentan monotherapy, but developed clinical deterioration and had sildenafil added [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/92\">",
"       92",
"      </a>",
"      ]. Clinical improvement occurred after the addition of sildenafil, as measured by symptoms, exercise capacity, and WHO functional classification. Improvement was more frequent and of greater magnitude in patients with IPAH, compared to patients with scleroderma-associated PAH.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       Sildenafil",
"      </a>",
"      added to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      &ndash; The combination of iloprost plus sildenafil may improve outcomes compared to either agent alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/93,94\">",
"       93,94",
"      </a>",
"      ]. This was illustrated by a prospective cohort study of 73 patients with group 1 PAH who were receiving long-term inhaled iloprost [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/93\">",
"       93",
"      </a>",
"      ]. Clinical deterioration occurred in 14 patients, prompting the addition of sildenafil for 9 to 12 months. Among those patients who had sildenafil added to their iloprost regimen, there was improvement in exercise capacity, WHO functional class, and hemodynamics.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       Bosentan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      &ndash; The effect of combining bosentan with iloprost is less clear. Early observational studies suggested that the combination was both safe and effective when bosentan was added to preexisting inhaled iloprost therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/95\">",
"       95",
"      </a>",
"      ]. However, a subsequent trial that randomly assigned 40 patients with IPAH to receive bosentan alone or bosentan plus iloprost for 12 weeks, demonstrated no difference in the six-minute walking distance, the trial's primary endpoint [",
"      <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/96\">",
"       96",
"      </a>",
"      ]. The results of the trial may have been skewed by three outliers in the combination therapy group. Thus, larger trials are needed to adequately evaluate the efficacy of bosentan and iloprost combination therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Selection of an agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of pharmacologic agents available for advanced therapy continues to increase, making selection of an appropriate agent increasingly complex. The following strategy categorizes the initial choice of agents according to WHO functional class (",
"    <a class=\"graphic graphic_table graphicRef62080 \" href=\"mobipreview.htm?24/47/25339\">",
"     table 2",
"    </a>",
"    ). It is just one reasonable approach to selecting an agent. However, it is supported by moderate and high quality evidence. It is also consistent with the algorithm developed during the 4th World Symposium on Pulmonary Hypertension (",
"    <a class=\"graphic graphic_algorithm graphicRef71168 \" href=\"mobipreview.htm?7/25/7583\">",
"     algorithm 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1\">",
"     1",
"    </a>",
"    ]. Clinicians with expertise in the treatment of patients with advanced PH may deviate from this algorithm based on their clinical experience.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      WHO functional class II &ndash; Preferred agents include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/60/29637?source=see_link\">",
"       ambrisentan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      WHO functional class III &ndash; Preferred agents include",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/60/29637?source=see_link\">",
"       ambrisentan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      , intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      , intravenous or subcutaneous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      , inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      WHO functional class IV &ndash; Patients with severe PH who are WHO functional class IV should be treated with an intravenous prostanoid. Most clinicians consider intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      to be the preferred agent. Intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      is considered a reasonable alternative by some. Inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      can be considered for patients who refuse or cannot receive intravenous therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Combination therapy is appropriate in cases refractory to monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. It should consist of two agents with different mechanisms of action. In other words, it should consist of agents from any two of the following three classes: prostanoids, endothelin receptor antagonists, and PDE5 inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should ideally be seen every three months (or more frequently) if they are receiving parenteral or combination therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The same is true of patients who have advanced symptoms, right heart failure, or advanced hemodynamic abnormalities. Less ill patients should be seen every three to six months. Such frequent reassessment is necessary because of the complex nature of the disease and its treatments. Patient logistics may dictate alternative forms of follow-up, such as frequent telephone contact.",
"   </p>",
"   <p>",
"    Follow-up visits should ideally include a thorough history to assess symptoms of right heart failure, exercise tolerance, and medication side effects; physical examination for signs of right heart failure; and resting and ambulatory oximetry. The frequency of follow-up testing with a brain natriuretic peptide (BNP), six minute walk test (6MWT), echocardiogram, and invasive hemodynamic assessment (right heart catheterization) should be determined on a case by case basis. We usually obtain a 6MWT at each visit and an echocardiogram every 12 months, or sooner if clinically indicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     RIGHT TO LEFT SHUNT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Creation of a right to left shunt is not routinely recommended as therapy for the treatment of pulmonary arterial hypertension (PAH). However, in adults with severe symptomatic PAH, such a procedure can be considered. Procedures that have been used to generate a right to left shunt in adults with PAH are atrial septostomy and placement of a Potts shunt via a transcatheter approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/97-107\">",
"     97-107",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with severe PAH face significant morbidity and mortality due to progressive right heart failure. Severely high pulmonary vascular resistance leads to a reduction in left ventricular preload and consequently, systemic pressure, that can precipitate significant syncope and death (from obstructive shock). The purpose of right to left shunting is to avoid these undesirable outcomes by diverting blood flow to bypass the pulmonary vascular bed and enter the systemic circulation, thereby elevating systemic blood flow and maintaining tissue perfusion, albeit with less oxygenated blood. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3758506\">",
"    <span class=\"h2\">",
"     Atrial septostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Atrial septostomy is a right to left shunt that connects right and left atrial cavities. As a direct result of high right atrial pressures; the right-to-left shunting and consequent arterial desaturation that follow the procedure are offset in some patients by increased cardiac output and augmentation of systemic oxygen delivery by up to 27 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/97,100\">",
"     97,100",
"    </a>",
"    ]. However, procedure-related mortality may be as high as 15 to 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/97,103\">",
"     97,103",
"    </a>",
"    ]. It is difficult to predict which patients will benefit and which will deteriorate after this therapy.",
"   </p>",
"   <p>",
"    Atrial septostomy may be considered in individuals with refractory severe pulmonary arterial hypertension (PAH) and right heart failure, despite aggressive advanced therapy and maximal diuretic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/104,108\">",
"     104,108",
"    </a>",
"    ]. It may also be considered in patients who have signs of impaired systemic blood flow (such as syncope) due to reduced left heart filling. Stepwise balloon dilatation is the procedure of choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with the most advanced PAH appear more likely to die or get worse with atrial septostomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/104\">",
"     104",
"    </a>",
"    ]. This includes patients with markedly elevated mean right atrial pressure (eg, greater than 20 mmHg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/8\">",
"     8",
"    </a>",
"    ], extremely low cardiac output, and a resting arterial oxyhemoglobin saturation less than 80 percent. In addition, older age and impaired renal function were associated with early adverse outcomes in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3758513\">",
"    <span class=\"h2\">",
"     Transcatheter Potts Shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical placement of a right to left shunt between the left pulmonary artery and the descending aorta (Potts shunt), has been described as a palliative measure in children with pulmonary artery hypertension (PAH). However, mortality from general anesthesia and surgery in adult patients with severe PAH is considerably higher. Placement of a transcatheter Potts shunt (TPS) under fluoroscopic guidance has been performed in one pilot study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/107\">",
"     107",
"    </a>",
"    ]. TPS involves retrograde needle perforation of the aorta, with subsequent placement of a covered stent between the aorta and left pulmonary artery. Of four patients studied (18 to 47 years old), two died and two survived at four and ten months with symptomatic improvement. The use of TPS should be reserved for patients enrolled in clinical trials until further studies confirm its safety and efficacy in this population. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transplantation has been performed in patients with idiopathic pulmonary arterial hypertension (IPAH) and is considered by some to be the final effective treatment for selected patients with IPAH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/8,109\">",
"     8,109",
"    </a>",
"    ]. Bilateral lung or heart-lung transplantation is the procedure of choice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The timing of transplantation is critical, since survival from severe IPAH refractory to medical therapy is poor and the availability of suitable organs for transplantation is limited. The three year survival of patients who had a lung or heart-lung transplant for IPAH is approximately 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/104,110\">",
"     104,110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Guidelines for when to refer a patient for transplant evaluation are as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/111\">",
"     111",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      World Health Organization (WHO) functional class III or IV",
"     </li>",
"     <li>",
"      Mean right atrial pressure &gt;10 mmHg",
"     </li>",
"     <li>",
"      Mean pulmonary arterial pressure &gt;50 mmHg",
"     </li>",
"     <li>",
"      Cardiac index &lt;2.5",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      per m",
"      <sup>",
"       2",
"      </sup>",
"     </li>",
"     <li>",
"      Failure to improve functionally despite medical therapy",
"     </li>",
"     <li>",
"      Rapidly progressive disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hyperbilirubinemia is a late manifestation of pulmonary hypertension caused by chronic passive hepatic congestion and cardiac cirrhosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/97\">",
"     97",
"    </a>",
"    ]. An elevated bilirubin has been associated with a high postoperative mortality in heart-lung transplant recipients and the likelihood of successful transplantation is poor if the bilirubin elevation persists after the patient's cardiopulmonary status is optimized.",
"   </p>",
"   <p>",
"    Post-transplantation management for IPAH is similar to management for other conditions requiring transplantation, although the incidence of obliterative bronchiolitis appears to be higher in IPAH patients undergoing transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?34/24/35210/abstract/112\">",
"     112",
"    </a>",
"    ]. Recurrence of IPAH after transplantation has not been reported. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=see_link\">",
"     \"Lung transplantation: Procedure and postoperative management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The World Health Organization (WHO) classifies patients with pulmonary hypertension (PH) into five groups based upon etiology. Patients in the first group are considered to have pulmonary arterial hypertension (PAH), whereas patients in the remaining four groups are considered to have PH (",
"      <a class=\"graphic graphic_table graphicRef66348 \" href=\"mobipreview.htm?42/38/43628\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nomenclature'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial therapy should be directed at the underlying cause of the PH. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Primary therapy'",
"      </a>",
"      above.) In addition, the need for diuretic, oxygen, and anticoagulant therapy should be assessed:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with fluid retention due to PH, we suggest diuretics (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diuretics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with idiopathic pulmonary arterial hypertension (IPAH), hereditary PAH, drug-induced (eg, anorexigens) PAH, or group 4 PH, we suggest anticoagulant therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Anticoagulation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with group 3 PH and resting or exercise hypoxemia, we recommend supplemental oxygen&nbsp;(",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with other types of PH, we suggest supplemental oxygen if resting, exercise, or nocturnal hypoxemia exists (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Oxygen therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Group 3 PH'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with persistent PH whose WHO functional class is II, III, or IV despite treatment of the underlying cause of the PH should be referred to a specialized center to be evaluated for advanced therapy. Advanced therapy is treatment that is directed at the PH itself, rather than the underlying cause of the PH. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Advanced therapy is widely accepted for many patients with group 1 PAH. In contrast, it must be considered on a case-by-case basis for patients with group 3 PH, group 4 PH, or group 5 PH, after carefully weighing the risks versus the benefits. Advanced therapy should NOT be administered to most patients with group 2 PH. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients selected for advanced therapy should undergo right heart catheterization and most of those who have group 1 PAH should also undergo vasoreactivity testing. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Vasoreactivity test'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who have a positive vasoreactivity test, we suggest a trial of calcium channel blocker (CCB) therapy with a dihydropyridine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      prior to the initiation of therapy with prostanoids, endothelin receptor antagonists, or phosphodiesterase 5 inhibitors (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Patients who respond to such therapy should be reassessed after three to six months of treatment. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with idiopathic pulmonary arterial hypertension (IPAH) who have a negative vasoreactivity test or fail CCB therapy with a dihydropyridine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      , we recommend advanced therapy with a non-CCB agent (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). For patients with another type of group 1 PAH who have a negative vasoreactivity test or fail CCB therapy with a dihydropyridine or diltiazem, we suggest advanced therapy with a non-CCB agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Non-CCB agents include prostanoids, endothelin receptor antagonists, and phosphodiesterase 5 inhibitors. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'General approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred non-CCB agent is related to the functional severity of disease. For patients who are WHO functional class IV, we suggest intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/22/359?source=see_link\">",
"       epoprostenol",
"      </a>",
"      , rather than any alternative agent (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). For patients who are WHO functional class II or III, acceptable first-line non-CCB agents include oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/60/29637?source=see_link\">",
"       ambrisentan",
"      </a>",
"      , oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"       bosentan",
"      </a>",
"      , intravenous epoprostenol, inhaled",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"       iloprost",
"      </a>",
"      , oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"       sildenafil",
"      </a>",
"      , oral",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"       tadalafil",
"      </a>",
"      , intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/52/25414?source=see_link\">",
"       treprostinil",
"      </a>",
"      , or subcutaneous treprostinil (",
"      <a class=\"graphic graphic_algorithm graphicRef71168 \" href=\"mobipreview.htm?7/25/7583\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H31\">",
"       'Selection of an agent'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Atrial septostomy and lung transplantation are reserved for patients refractory to medical therapy. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Right to left Shunt'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/1\">",
"      Barst RJ, Gibbs JS, Ghofrani HA, et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/2\">",
"      Gali&egrave; N, Rubin Lj, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371:2093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/3\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53:1573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/4\">",
"      Badesch DB, Champion HC, Sanchez MA, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:S55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/5\">",
"      Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/6\">",
"      Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/7\">",
"      Ashutosh K, Dunsky M. Noninvasive tests for responsiveness of pulmonary hypertension to oxygen. Prediction of survival in patients with chronic obstructive lung disease and cor pulmonale. Chest 1987; 92:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/8\">",
"      Keogh AM, Mayer E, Benza RL, et al. Interventional and surgical modalities of treatment in pulmonary hypertension. J Am Coll Cardiol 2009; 54:S67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/9\">",
"      Gali&egrave; N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30:2493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/10\">",
"      McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009; 119:2250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/11\">",
"      Hildenbrand FF, Bloch KE, Speich R, Ulrich S. Daytime measurements underestimate nocturnal oxygen desaturations in pulmonary arterial and chronic thromboembolic pulmonary hypertension. Respiration 2012; 84:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/12\">",
"      Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/13\">",
"      Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/14\">",
"      Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of outcome in idiopathic pulmonary arterial hypertension. Am J Cardiol 2005; 95:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/15\">",
"      Johnson SR, Mehta S, Granton JT. Anticoagulation in pulmonary arterial hypertension: a qualitative systematic review. Eur Respir J 2006; 28:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/16\">",
"      Henkens IR, Hazenoot T, Boonstra A, et al. Major bleeding with vitamin K antagonist anticoagulants in pulmonary hypertension. Eur Respir J 2013; 41:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/17\">",
"      Mathur PN, Powles P, Pugsley SO, et al. Effect of digoxin on right ventricular function in severe chronic airflow obstruction. A controlled clinical trial. Ann Intern Med 1981; 95:283.",
"     </a>",
"    </li>",
"    <li>",
"     Paraskos JA. Pulmonary heart disease including pulmonary embolism. In: Cardiology, Parmley WW, Chatterjee K (Eds), JB Lippincott, Philadelphia 1987.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/19\">",
"      Mereles D, Ehlken N, Kreuscher S, et al. Exercise and respiratory training improve exercise capacity and quality of life in patients with severe chronic pulmonary hypertension. Circulation 2006; 114:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/20\">",
"      de Man FS, Handoko ML, Groepenhoff H, et al. Effects of exercise training in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2009; 34:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/21\">",
"      Gr&uuml;nig E, Lichtblau M, Ehlken N, et al. Safety and efficacy of exercise training in various forms of pulmonary hypertension. Eur Respir J 2012; 40:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/22\">",
"      Chan L, Chin LM, Kennedy M, et al. Benefits of intensive treadmill exercise training on cardiorespiratory function and quality of life in patients with pulmonary hypertension. Chest 2013; 143:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/23\">",
"      Weinstein AA, Chin LM, Keyser RE, et al. Effect of aerobic exercise training on fatigue and physical activity in patients with pulmonary arterial hypertension. Respir Med 2013; 107:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/24\">",
"      Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007; 131:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/25\">",
"      Hoeper MM, Barber&agrave; JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009; 54:S85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/26\">",
"      Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/27\">",
"      Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/28\">",
"      Blanco I, Gimeno E, Munoz PA, et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/29\">",
"      Fisher KA, Serlin DM, Wilson KC, et al. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130:1481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/30\">",
"      Steiner MK, Preston IR, Klinger JR, et al. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest 2006; 130:1471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/31\">",
"      Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:35S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/32\">",
"      Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 1991; 338:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/33\">",
"      Morales-Blanhir J, Santos S, de Jover L, et al. Clinical value of vasodilator test with inhaled nitric oxide for predicting long-term response to oral vasodilators in pulmonary hypertension. Respir Med 2004; 98:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/34\">",
"      Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/35\">",
"      Ricciardi MJ, Knight BP, Martinez FJ, Rubenfire M. Inhaled nitric oxide in primary pulmonary hypertension: a safe and effective agent for predicting response to nifedipine. J Am Coll Cardiol 1998; 32:1068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/36\">",
"      Atz AM, Adatia I, Lock JE, Wessel DL. Combined effects of nitric oxide and oxygen during acute pulmonary vasodilator testing. J Am Coll Cardiol 1999; 33:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/37\">",
"      Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987; 76:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/38\">",
"      Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351:1425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/39\">",
"      Sitbon O, Humbert M, Ja&iuml;s X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111:3105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/40\">",
"      Packer M, Medina N, Yushak M. Adverse hemodynamic and clinical effects of calcium channel blockade in pulmonary hypertension secondary to obliterative pulmonary vascular disease. J Am Coll Cardiol 1984; 4:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/41\">",
"      Palevsky HI, Fishman AP. Chronic cor pulmonale. Etiology and management. JAMA 1990; 263:2347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/42\">",
"      Melot C, Hallemans R, Naeije R, et al. Deleterious effect of nifedipine on pulmonary gas exchange in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/43\">",
"      Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:56S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/44\">",
"      Tapson VF, Gomberg-Maitland M, McLaughlin VV, et al. Safety and efficacy of IV treprostinil for pulmonary arterial hypertension: a prospective, multicenter, open-label, 12-week trial. Chest 2006; 129:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/45\">",
"      Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994; 121:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/46\">",
"      Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/47\">",
"      Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/48\">",
"      Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/49\">",
"      Higenbottam T, Butt AY, McMahon A, et al. Long-term intravenous prostaglandin (epoprostenol or iloprost) for treatment of severe pulmonary hypertension. Heart 1998; 80:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/50\">",
"      Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159:1925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/51\">",
"      McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/52\">",
"      Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/53\">",
"      Humbert M, Sanchez O, Fartoukh M, et al. Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study. Eur Respir J 1999; 13:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/54\">",
"      Rich S, McLaughlin VV. The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension. J Am Coll Cardiol 1999; 34:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/55\">",
"      Oudiz RJ, Widlitz A, Beckmann XJ, et al. Micrococcus-associated central venous catheter infection in patients with pulmonary arterial hypertension. Chest 2004; 126:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/56\">",
"      Kitterman N, Poms A, Miller DP, et al. Bloodstream infections in patients with pulmonary arterial hypertension treated with intravenous prostanoids: insights from the REVEAL REGISTRY&reg;. Mayo Clin Proc 2012; 87:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/57\">",
"      Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/58\">",
"      Barst RJ, Galie N, Naeije R, et al. Long-term outcome in pulmonary arterial hypertension patients treated with subcutaneous treprostinil. Eur Respir J 2006; 28:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/59\">",
"      Benza RL, Rayburn BK, Tallaj JA, et al. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest 2008; 134:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/60\">",
"      Vachi&eacute;ry JL, Hill N, Zwicke D, et al. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/61\">",
"      Gomberg-Maitland M, Tapson VF, Benza RL, et al. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 2005; 172:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/62\">",
"      Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012; 142:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/63\">",
"      Jing ZC, Parikh K, Pulido T, et al. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Circulation 2013; 127:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/64\">",
"      Olschewski H, Simonneau G, Gali&egrave; N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/65\">",
"      Channick RN, Sitbon O, Barst RJ, et al. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:62S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/66\">",
"      Liu C, Chen J, Gao Y, et al. Endothelin receptor antagonists for pulmonary arterial hypertension. Cochrane Database Syst Rev 2013; 2:CD004434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/67\">",
"      Gabler NB, French B, Strom BL, et al. Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension. Chest 2012; 141:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/68\">",
"      Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/69\">",
"      Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/70\">",
"      McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/71\">",
"      Sitbon O, Badesch DB, Channick RN, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/72\">",
"      Gali&eacute; N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/73\">",
"      Gali&egrave; N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117:3010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/74\">",
"      Oudiz RJ, Gali&egrave; N, Olschewski H, et al. Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54:1971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/75\">",
"      Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/76\">",
"      Wittbrodt ET, Abubakar A. Sitaxsentan for treatment of pulmonary hypertension. Ann Pharmacother 2007; 41:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/77\">",
"      Seligman BG, Ribeiro RA, Kuchenbecker Rde S, et al. Critical steps in fluoroquinolones and carbapenems prescriptions: results from a prospective clinical audit. Int J Clin Pract 2007; 61:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/78\">",
"      Benza RL, Barst RJ, Galie N, et al. Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival. Chest 2008; 134:775.",
"     </a>",
"    </li>",
"    <li>",
"     Thelin (sitaxentan) to be withdrawn due to cases of unpredictable serious liver injury. European Medicines Agency. file://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/12/WC500099707.pdf (Accessed on December 15, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/80\">",
"      McGoon MD, Frost AE, Oudiz RJ, et al. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities. Chest 2009; 135:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/81\">",
"      Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 2000; 84:E4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/82\">",
"      Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/83\">",
"      Gali&egrave; N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353:2148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/84\">",
"      Pepke-Zaba J, Gilbert C, Collings L, Brown MC. Sildenafil improves health-related quality of life in patients with pulmonary arterial hypertension. Chest 2008; 133:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/85\">",
"      Rubin LJ, Badesch DB, Fleming TR, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest 2011; 140:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/86\">",
"      Gali&egrave; N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119:2894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/87\">",
"      Oudiz RJ, Brundage BH, Galie N. Tadalafil for the Treatment of Pulmonary Arterial Hypertension. J Am Coll Cardiol 2012; Epub ahead of print.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/88\">",
"      Jing ZC, Yu ZX, Shen JY, et al. Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study. Am J Respir Crit Care Med 2011; 183:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/89\">",
"      Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/90\">",
"      McLaughlin VV, Benza RL, Rubin LJ, et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. J Am Coll Cardiol 2010; 55:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/91\">",
"      Simonneau G, Rubin LJ, Gali&egrave; N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/92\">",
"      Mathai SC, Girgis RE, Fisher MR, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007; 29:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/93\">",
"      Ghofrani HA, Rose F, Schermuly RT, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/94\">",
"      Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/95\">",
"      Hoeper MM, Taha N, Bekjarova A, et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/96\">",
"      Hoeper MM, Leuchte H, Halank M, et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006; 28:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/97\">",
"      Reichenberger F, Pepke-Zaba J, McNeil K, et al. Atrial septostomy in the treatment of severe pulmonary arterial hypertension. Thorax 2003; 58:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/98\">",
"      Kerstein D, Levy PS, Hsu DT, et al. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995; 91:2028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/99\">",
"      Nihill MR, O'Laughlin MP, Mullins CE. Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease. Cathet Cardiovasc Diagn 1991; 24:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/100\">",
"      Rich S, Dodin E, McLaughlin VV. Usefulness of atrial septostomy as a treatment for primary pulmonary hypertension and guidelines for its application. Am J Cardiol 1997; 80:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/101\">",
"      Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/102\">",
"      Rothman A, Sklansky MS, Lucas VW, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999; 84:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/103\">",
"      Sandoval J, Rothman A, Pulido T. Atrial septostomy for pulmonary hypertension. Clin Chest Med 2001; 22:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/104\">",
"      Doyle RL, McCrory D, Channick RN, et al. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004; 126:63S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/105\">",
"      Kurzyna M, Dabrowski M, Bielecki D, et al. Atrial septostomy in treatment of end-stage right heart failure in patients with pulmonary hypertension. Chest 2007; 131:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/106\">",
"      Sandoval J, Gaspar J, Pe&ntilde;a H, et al. Effect of atrial septostomy on the survival of patients with severe pulmonary arterial hypertension. Eur Respir J 2011; 38:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/107\">",
"      Esch JJ, Shah PB, Cockrill BA, et al. Transcatheter Potts shunt creation in patients with severe pulmonary arterial hypertension: Initial clinical experience. J Heart Lung Transplant 2013; 32:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/108\">",
"      Barst RJ. Role of atrial septostomy in the treatment of pulmonary vascular disease. Thorax 2000; 55:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/109\">",
"      Pasque MK, Trulock EP, Kaiser LR, Cooper JD. Single-lung transplantation for pulmonary hypertension. Three-month hemodynamic follow-up. Circulation 1991; 84:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/110\">",
"      Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/111\">",
"      Orens JB, Estenne M, Arcasoy S, et al. International guidelines for the selection of lung transplant candidates: 2006 update--a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?34/24/35210/abstract/112\">",
"      Kshettry VR, Kroshus TJ, Savik K, et al. Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients. Chest 1996; 110:704.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8250 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-9CEA1CDAAA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35210=[""].join("\n");
var outline_f34_24_35210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NOMENCLATURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      BASELINE ASSESSMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRIMARY THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Group 1 PAH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Group 2 PH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Group 3 PH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Group 4 PH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Group 5 PH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      All groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Diuretics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Digoxin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Exercise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      ADVANCED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      General approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Vasoreactivity test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prostanoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Epoprostenol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Treprostinil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Iloprost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Endothelin receptor antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Bosentan",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Selective agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PDE5 inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Selection of an agent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      RIGHT TO LEFT SHUNT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3758506\">",
"      Atrial septostomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3758513\">",
"      Transcatheter Potts Shunt",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8250\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8250|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?7/25/7583\" title=\"algorithm 1\">",
"      Treatment of PH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8250|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/33/18973\" title=\"figure 1\">",
"      Benefit of LTOT in MRC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/49/39709\" title=\"figure 2\">",
"      Benefit of LTOT in NOTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/50/14126\" title=\"figure 3\">",
"      Bosentan in PAH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8250|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/38/43628\" title=\"table 1\">",
"      WHO pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/47/25339\" title=\"table 2\">",
"      Classification PH function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/54/27500\" title=\"table 3\">",
"      Drugs for PH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?14/10/14497?source=related_link\" title=\"calculator 1\">",
"      Calculator: Epoprostenol (Flolan) Infusion Rate Calculator",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/31/14837?source=related_link\">",
"      Chronic thromboembolic pulmonary hypertension: Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10503?source=related_link\">",
"      Chronic thromboembolic pulmonary hypertension: Surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/29/25050?source=related_link\">",
"      Course and management of chronic aortic regurgitation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/56/7048?source=related_link\">",
"      Indications for antithrombotic therapy in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/4/38982?source=related_link\">",
"      Inhaled nitric oxide in adults with pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/14/42215?source=related_link\">",
"      Long-term supplemental oxygen therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/50/38697?source=related_link\">",
"      Lung transplantation: Procedure and postoperative management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/12/32966?source=related_link\">",
"      Major side effects and safety of calcium channel blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/26/39338?source=related_link\">",
"      Management of stable chronic obstructive pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/37/4697?source=related_link\">",
"      Medical management and indications for intervention in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/62/2025?source=related_link\">",
"      Medical management of asymptomatic aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/47/19193?source=related_link\">",
"      Overview of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/51/33593?source=related_link\">",
"      Overview of the management of chronic mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/8/7304?source=related_link\">",
"      Pathogenesis of pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/15/35064?source=related_link\">",
"      Portopulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/60/34762?source=related_link\">",
"      Treatment of idiopathic pulmonary fibrosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f34_24_35211="Adenovirus serotypes";
var content_f34_24_35211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F63104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F63104&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adenovirus serotypes and associated diseases",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Subgroup",
"       </td>",
"       <td class=\"subtitle1\">",
"        Serotypes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        Infantile gastroenteritis*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        B",
"       </td>",
"       <td>",
"        3, 7, 21",
"       </td>",
"       <td>",
"        Upper respiratory disease, pneumonia, pharyngoconjunctival fever",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11, 34, 35",
"       </td>",
"       <td>",
"        Hemorrhagic cystitis, interstitial nephritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        1, 2, 5",
"       </td>",
"       <td>",
"        Upper respiratory disease, pneumonia, hepatitis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        D",
"       </td>",
"       <td>",
"        8, 19, 37",
"       </td>",
"       <td>",
"        Epidemic keratoconjunctivitis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Upper respiratory disease, pneumonia",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        F",
"       </td>",
"       <td>",
"        40, 41",
"       </td>",
"       <td>",
"        Infantile gastroenteritis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Remaining serotypes are infrequently isolated or not clearly associated with disease.",
"    <div class=\"footnotes\">",
"     * Association with gastroenteritis not as firmly established as with types 40 and 41.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35211=[""].join("\n");
var outline_f34_24_35211=null;
var title_f34_24_35212="Perioperative thrombotic risk";
var content_f34_24_35212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F86930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F86930&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Perioperative thrombotic risk",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Risk stratum",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Indication for VKA therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Mechanical heart valve",
"       </td>",
"       <td class=\"subtitle2\">",
"        Atrial fibrillation",
"       </td>",
"       <td class=\"subtitle2\">",
"        VTE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High thrombotic risk*",
"       </td>",
"       <td>",
"        <p>",
"         Any mitral valve prosthesis",
"        </p>",
"        <p>",
"         Any caged-ball or tilting disc aortic valve prosthesis",
"        </p>",
"        Recent (within six months) stroke or transient ischemic attack",
"       </td>",
"       <td>",
"        <p>",
"         CHADS",
"         <sub>",
"          2",
"         </sub>",
"         score of 5 or 6",
"        </p>",
"        <p>",
"         Recent (within three months) stroke or transient ischemic attack",
"        </p>",
"        Rheumatic valvular heart disease",
"       </td>",
"       <td>",
"        <p>",
"         Recent (within three months) VTE",
"        </p>",
"        Severe thrombophilia (eg, deficiency of protein C, protein S, or antithrombin; antiphospholipid antibodies; multiple abnormalities)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate thrombotic risk",
"       </td>",
"       <td>",
"        Bileaflet aortic valve prosthesis and one or more of the of following risk factors: atrial fibrillation, prior stroke or transient ischemic attack, hypertension, diabetes, congestive heart failure, age &gt;75 years",
"       </td>",
"       <td>",
"        CHADS",
"        <sub>",
"         2",
"        </sub>",
"        score of 3 or 4",
"       </td>",
"       <td>",
"        <p>",
"         VTE within the past 3 to 12 months",
"        </p>",
"        <p>",
"         Nonsevere thrombophilia (eg, heterozygous factor V Leiden or prothrombin gene mutation)",
"        </p>",
"        <p>",
"         Recurrent VTE",
"        </p>",
"        Active cancer (treated within six months or palliative)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low thrombotic risk",
"       </td>",
"       <td>",
"        Bileaflet aortic valve prosthesis without atrial fibrillation and no other risk factors for stroke",
"       </td>",
"       <td>",
"        CHADS",
"        <sub>",
"         2",
"        </sub>",
"        score of 0 to 2 (assuming no prior stroke or transient ischemic attack)",
"       </td>",
"       <td>",
"        VTE &gt;12 months previous and no other risk factors",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     VKA: vitamin K antagonist; VTE: venous thromboembolism; CHADS",
"     <sub>",
"      2",
"     </sub>",
"     : congestive heart failure, hypertension, age &ge;75 years, diabetes mellitus, and stroke or transient ischemic attack.",
"     <br/>",
"     * High risk patients may also include those with a prior stroke or transient ischemic attack occurring &gt;3 months before the planned surgery and a CHADS",
"     <sub>",
"      2",
"     </sub>",
"     score &lt;5, those with prior thromboembolism during temporary interruption of VKAs, or those undergoing certain types of surgery associated with an increased risk for stroke or other thromboembolism (eg, cardiac valve replacement, carotid endarterectomy, major vascular surgery).",
"    </div>",
"    <div class=\"reference\">",
"     From: Douketis JD, Spyropoulos AC, Spencer FA, et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141(2 Suppl):e326S. Copyright &copy; 2012. Reproduced with permission from the American College of Chest Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35212=[""].join("\n");
var outline_f34_24_35212=null;
var title_f34_24_35213="Criteria for thyroid storm";
var content_f34_24_35213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F60908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F60908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for thyroid storm*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Thermoregulatory dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\">",
"            Temperature (&deg;F | &deg;C)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            99 to 99.9 | 37.2&nbsp;to 37.7",
"           </td>",
"           <td>",
"            5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            100&nbsp;to 100.9 | 37.8&nbsp;to 38.2",
"           </td>",
"           <td>",
"            10",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            101&nbsp;to 101.9 | 38.3&nbsp;to 38.8",
"           </td>",
"           <td>",
"            15",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            102&nbsp;to 102.9 | 38.9&nbsp;to 39.4",
"           </td>",
"           <td>",
"            20",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            103&nbsp;to 103.9 | 39.4&nbsp;to 39.9",
"           </td>",
"           <td>",
"            25",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            &ge;104.0 | &gt;40.0",
"           </td>",
"           <td>",
"            30",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Central nervous system effects",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Mild",
"           </td>",
"           <td rowspan=\"2\">",
"            10",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Agitation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Moderate",
"           </td>",
"           <td rowspan=\"4\">",
"            20",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Delirium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Psychosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Extreme lethargy",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Severe",
"           </td>",
"           <td rowspan=\"3\">",
"            30",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Seizure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Coma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Gastrointestinal-hepatic dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Moderate",
"           </td>",
"           <td rowspan=\"4\">",
"            10",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Nausea/vomiting",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Abdominal pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Severe",
"           </td>",
"           <td rowspan=\"2\">",
"            20",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Unexplained jaundice",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Cardiovascular dysfunction",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\" colspan=\"2\">",
"            Tachycardia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            99&nbsp;to 109",
"           </td>",
"           <td>",
"            5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            110&nbsp;to 119",
"           </td>",
"           <td>",
"            10",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            120&nbsp;to 129",
"           </td>",
"           <td>",
"            15",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            130&nbsp;to 139",
"           </td>",
"           <td>",
"            20",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            &ge;140",
"           </td>",
"           <td>",
"            25",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            <strong>",
"             Atrial fibrillation",
"            </strong>",
"           </td>",
"           <td>",
"            10",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Heart failure",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Mild",
"           </td>",
"           <td rowspan=\"2\">",
"            5",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pedal edema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Moderate",
"           </td>",
"           <td rowspan=\"2\">",
"            10",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Bibasilar rales",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_left\">",
"            Severe",
"           </td>",
"           <td rowspan=\"2\">",
"            15",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pulmonary edema",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1\" colspan=\"2\">",
"            Precipitant history",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Negative",
"           </td>",
"           <td>",
"            0",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Positive",
"           </td>",
"           <td>",
"            10",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A score of 45 or more is highly suggestive of thyroid storm; a score of 25 to 44 supports the diagnosis; and a score below 25 makes thyroid storm unlikely.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Burch HB, Wartofsky L. Life-threatening thyrotoxicosis. Thyroid storm. Endocrinol Metab Clin North Am 1993; 22:263.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35213=[""].join("\n");
var outline_f34_24_35213=null;
var title_f34_24_35214="Rx in the setting of loss of response to TNF antagonist agents";
var content_f34_24_35214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F87503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F87503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 579px\">",
"   <div class=\"ttl\">",
"    Proposed treatment algorithm in the setting of loss of response",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 559px; height: 341px; background-image: url(data:image/gif;base64,R0lGODlhLwJVAcQAAP///wAAACMfIIiIiLu7u0RERCIiIt3d3ZmZmWZmZjMzMxEREczMzO7u7lVVVXd3d6qqql9fXz8/P9/f35+fn8/Pzy8vL+/v76+vrw8PD7+/vx8fH39/fxEPEE9PTwAAACH5BAAAAAAALAAAAAAvAlUBAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJFVApSVlpeYmZqbnJSSn6ChSAJXpKKnqKk3ppOqrq+wKKxUs7G2t6G1Urq4vb6KvEMHBgEDKcG/ycp/yAAIBj4PBSvNy9bXdM3PPg7GKtXY4eJq2tAjAwEBCgwAD+kBDAgL6d4iBPMLCAjvB8fj/wDZlBvBAB6ABNMCQBhR4MGJBcbkNShQT1bAixjHDBSxDQABaAOIJWhAQEGAAuxE/xwI0A8AS4rUMsqcqWUjgILsHEwbkW+EgwQkIAIYsGBixRPgaCpdWkTbu2Lo1DFoME/dxHQGUtrDhwAAzG9Mw4odVWqs2bM/kipRi7atW4tW2L6d+1buEbt0847F21Sv378A+BIRDLgwQMJCEBtefK3WAIosHaRT0ICByQAOXF7uei9AzwKXgcqjB0Cy1RKKGav+5dgAgaGUASgYMEABiWJDFwAQKrHANAIvHYqo3UD20dSrk9tyvDPB0wQHJCvoGuA18JUtXxrDXvIkA+fvgJJArry8KubDY5cI6fL1A2hCiRoFgN1nAuJwzesfh16E6QAIRAWgS1hZx5VX272EVf9O73Q13n4QhkNYdUCQF+GFjUz4WloYduiLhTyA6OGIg4iog4kkptgHijiwqOKLd7hog4ww1hgHjTTgaOOOa3Ti449AZsLjkMsEQOSRaBmJ5JJhKcnkkzM5CeWUAUlJ5ZXhWInllspoyeWXuHgJ5piviEnmmSI8peaabLbp5ptwxinnnHTWaeedeOapJ5xoKmJmnyf8Cagfgg46QqGG6oGooYsmekejgELqKB2SolnppHFcSqammLrBKZifdrpGqFySKioZFUSggUsAaBBBBZ2muqqRrsJ66h0bBGCBrgFscGquu+7q6613UKAmBaca+xSyxNpxQQbvZHDBqc9GO23/s3ZE8E4ExGqbDrfY2jHBOxMQO2465YZrhwQBSIAtu+6qawcGAWCALb32yruuuvHq6++/GQUpMJAkDmywjwDftYSOSzGMVMJGOPzgiBKjBnFfaxXcRMX+chyYxkx4LG8twAUg3g0lHwfyCCWfjENUG44gsrokm3PQOwrEHMN9FlNcwkckQGCySk8JJ4JJLZ3gWs8XJ/azzQmI55xWMPA8sYc1k+BbUfSx5JECmXm0wGwpLH110xU+PULUPj0AHHD7vLbNAZdReJDKPpMANNEMGNBVfTcFUFwCDnTkTjopmS0z2k7rDfXJjwGXoNzQOGBbeyJYvXjeLNtc21DTAN4e/1UQUPWaQiUoLsLM4Wad+ckOuK3kSpQD4HeaG2q++sr22EwMP4AX1MA+4Q0lUnG26/wx42k7vrbULAF3aFcFVJ5ZQbnjjbXaHgkuQkP1lQRUQ/Z4L0JPyTPNfA+u3zwZO9IPNxk0fQdATPbqY+g64SPIs9I7CdKKAYgyGeSpbnnrYx/3bFCQlugOgR1qHw8OyDpskSwdLntByXCTsvxd6IJD0wHMPJjAFi2Md0moYLM8pkL+bKyECswY52QIwxOdcIYprOEOWIhCsugwBwcLIiYKJsQiVuKHTzAVlpSIxCUwkUpPbCISogglKkqxCFZkUhavKIQtIsmLXPwBGIk0xv8w8qCMPEKjGXOgRhu1cY02eCOM5AjHGdBRRXdczZ72yMc++vGPgAzkUwohSEGmKI9uQeQVFLkCRv7DkWaB5BQkGahDTomSUcBkCTRpDU4qxZNNACWrSCRKmZRSCaI8ZS9UeRFWHiGVlqwiIbXgSlvU8pGzzMItYbFLcfSyi7TskKxYVashDZNWrwoELDsELF4Na0jNFJYglokhZb2DWUOyZjqw+QdqXqha6ZDWkcAZAHEqM5ge8lYAwHUkdbITEN680LkCkK4jzbOe8ESnh+D1JH4OIp4XwteTBPpPfe5zSv2apkHriC2AtsWIEPXEYSJK0Yh+waFoqWALmdGjiy7/1C0aDchGgehRXeolpIfpqBcwehaU/mOkJlzpRx/6BJjywaYzKikWfimIWrzjgCeACYXi9wKc6kEuBcAN7WQQP6KSVKYmzYtPu0KUF9hNBkbNA1KJcYClxsCpIdLpIk+6ya40MCrruIpnEAQeABlpgAAgHd0wSMLGwKAACCnAUk1DmbmmgwD/s8rvXPNWY5DuI+lwkAuyWsmo0mWqB8mKQRACHOQhCHPSYw97fkKfBVCNsTG6awIkVx38zMZyuBvBSiDQVCNpFj5dgYBuiipWK/A0ED5dUEeA5g6hCNU6RjLddGz3FMVCUBxIBYppCNBWk92uPQxIamJbG9cFlAQB/4FNR9JYANpNzjSjZSWIQXQi3gMIdSHxS4ABuMbZh6X0BXjtWmnVU5rrVScBtmkAgCrbvcyttzjoi0F3b/Pdlob3HO/b4PiMAZ59EM0bfvXa5l4q2sxR6D8IqN/9OkMMBDTAJIR9cO+wAoMBH6rAZnGpC3/QQB92gaUprqlIe7DBowymtlW4LSBUjFyVvhjFe5Hxe9Ng4jQBWSw8llANrjqUxO5ghNzFMRV0zFEnFFkOGiLBAFwmNPFk12iykbDSYrY3E1wZxkG28oxpwOQta60AXAsf2LZCNhQorsx1Hatj51LRIq55bQ3ySmjoUzeduZlvtwue9whnuHckjsw2y/+zbY9cHirvGAX49cpvIrOTNkPONo/pWtKqQzrTuWQhJFja7wAo6RxTWjmWrvI5qgINmGDnuZ4ewapZoujhPcd4JjMgpPPDBTSbJ9Z+mMVq21HrBEXHvoYWD3+98gA5j084096Ng+4c6bNtwdiV/kstpGuAZou6fiaJdubC5owFZDeAuibgadLXO2J/+9XJQfaKnpxBHQDVvT/ec4f0fdMnO1mEf23BmfGtR3H7uNgMVw3B93DlKEN1p7EkKzmkPMmMS/Xh9xY4hiZ+VJBHPAkkf0TK8dBnTnSg5ZvguBRW3gialymXGCdUIXfO85773I+OsLkMwC0HoavA6EcPOs7/9dwHpKPA6U9XOiGInilCdVPqBRV5HqBuAq53HesK1ToevE5gq3vq50AvA9XhQPYTm70Nqrzt2t/QdiO/nQ1xN8PcPXX3PZA872o/Odz7rii6B5wMex9806/Od4gHXuyPIvzWDe94xAse75IfO+VDbnnI26Huo1x84zk/hsRjXvSoPz3pxWD6UWU+8qO//MxlrwbQgz70qqc9FFpvhmO2Kpl18H0x7VABD8wKAKni5hiED/wpMN9WXHi+FKSPK15Js/rB6lUe2JUr7qchmtq3Avif2YXxU8H8eNBmAJQ/B/Wzv/1q4kAa3H8F+n/B/lLAv7OgFc5r7d9aepAr7+B//2ZATuZUBQZIgFyQgFTAgHngTnoAgXrAAduyBhJ4BRf4BRkoBRsoLuSiB/e0B/O0KmoQglhggmCAglOggnjgT3rgghGoK20Ag1dAg19gg1KAg/NSL3xAUHugAevXBj6IBUMIBkU4BUfYgn6QUHvAhGrghDVoBlA4BVPIUFZoBjCXhVrYDFvYhTF3DF4YhkZUVGEIRGUYBGI4I2cYVhQHFkTmhm24WEOAHDQiI3WYU43DhiXnD2/Ih3GocHP4VGiYh82TI4EYQ3tob2XAhfsmh4RYA3c4iI8oYIeoh1oFh2fAiAXniJK4CpXIIZNYYp9oQ38IcJmIiZfIiYWIh50Iiv+tiFWjKIipqIhkoImlGBOhCIu5SIqvSIm7CImbSIsagYpvkFTKc1zEiIisuIo+EImG+IvPmIimiIXJyAYroQD9xhbOuIyu2I3e6Iu9GFN3ZWPfQ45PoFdmVo1iYIsvEGon4I5T8BiyZVm7o4rfOAOKAVat5onQiIs1oI/eJovtlg4oEVQV4Y5fUQRfkZAk8ACW8wCXM2HT2HXH6ATEozzseBOXMVwmAI/9BTpH4I4eGRRdAVcB6YclwDbiyI3f42XVAZAAKZHNiGn9ho8s6RUuSQAw+ScmMgv6tRANUDgGqWU7wZBDYJQnsA87cZISuWvFwGRDYDdQeT6TIWm1oAD/wnFo67GUHzmSQuCVJSARxrOPMvk8AhmNWpOTKRCT9ciMZrmSulgC8dU1FVk+6giMI6BfFeFgBzE+oRFYCDFopVFAb+NWhKkO9sMOUZEVS/UMxAMgMCEg7OCQ2BiRbTmRRDWVQaCZQVGVTHmZssGVjQkS6yVYWBESxBAbi8kOAGIA6rUgmuFkiDUgcIUd4RFqs2kMc+lVoFmNKik/UiFbJCA8E2mTJrCbL2kkEaaTiOlZ6RiOfall7yOc4kWPZSmKx5mT0rOcwGESzkmW4MgR0jUSfMk2BWBfDICQm3YApjUAkkMCqwUcOeEADOCcDjmal4Ug2HOc29WbAZmZm0Fo/3T1GOjwmEAREvMQG3zla6/TVnuVDrN1kVZZAt9BkAyAnyHRAA0wQPETEgdAFRlmn5mBGanjELhRVT0hnLXJEiI5DUJBNGriMtpIk+LFDgihX/FgAOzJbuDpj1qjJsxZGpeTnK8xl595lq9TowdRADj6DDsqjPb4PUAqPajVHm+Dk89piSTwYQ9QnguWJgFSlM7WXKOlJNHVIB3qN0+hoxSyDQs5AB0BiChpl2liDJsFFAfgWSGhM/vQABm6obQRG7PhpZjTHh4qp1CKXxhalGU6HDvhN49pP5jTAG0FFEPFEmoyDM7WoqJjcYiakiezW9AwG9NBOOZIh0GlnW/lIP/JmaQ9apwm8Juiahyl2g1Q+qkMoaq2w6pBGp2vqooEUJAf5p68ho2XJTTseTm2xqL0lV75tV9Kgo31STUDUj3UVo77iaselJm1s2thyhF1w56MSqaEKpXMVZPFKZMciRAuQT0gETr5wF/u6DfTehty4z3GSiHvoW1p2WTJ6qi7YY7pmq6/iROlMQ1EARQL8J1ZepPIGaQOAG3plY25WLDjhbALoLAM+6sk9LBUKrFK8pvXyY8q8R9hk1RjMz6sVp8ms6z9gGFNNQ8dtkEK0A8CcqDz4wyJFZmO5qMNS6eYsw3tBbC24xDIGmp5GiDNWqyWimqlpaPa6m2How42m7P/ApIZH2Y/80pVxUMhfuWaBGI/1jFY3YOYB8Cy9/EbVSGwI0uwT0EAaMUO+7mvt0pb2Uk0QaphreqrRwqXgPYOcPs+geMe3da3PtuSeCs9eturIuufJPsEbHmPZcmtzgANESauwMlVV+sfgYayxgoeSyVdszWnHLuZdemWpKuMeCkDLXa4WjqTqxsDrXuXaOkEkQu7dWsDYIm6bYtKpyu5A8uLN6kCNRa1OxSL2KlBrOapx3uLpesCuwu8yBhaUaq6tYu70oukdgudw5sNtPsFGcly28u74Zm9j2u+33u+2uu9qTuM7dsCnMkDtxu7rvu6sEq+6yu8cYm/12sH4VuL/+n7dL+rA2AVlO9gosv7U3U5o1rjDb9Fv7VLXdHLvNibnw/cv+P7kZnFleWbv1gWwFzwvy4QvzsAVgoQGyXRrgAgNMUxIFUVvPljlCRcv+ULVhNMwwIpwwMMwtNowxycvM0rjT+7iKjYVtQzaMupNYIpXUxamPvwO+BhG4FFGU5FnLdBVbM1ILNruBL5mAhAEQ66oIX5GBD6vPkzWNcRHrNJPY/hN2vLxbHrxWDMD2JcHcUgumZ8XGiMqRi0xghSPaOBG72bI2K4CQFQyJrwDWJ4yGtIsLbhG90THZ2mM5B8HX86G+/pEgymo7wZn1KCZ2kyGRsyIOqVuzL5ppjTnv/vmW1w7LMSvBMpqhug0Q/kM8RaisoUosocZD55fEF26Y6xLGi0DGaDzHqvFzHrQWuXdWu82sCippJbRrnuWB1nOl1SssXtWp9OC5sw7G24/BpkSlS9pT3c+MryxQ9f0R0FWczc+M3u08dOMs69/DNKssHnrF3pbBLr7LiPxweKpGyos68uG7GD68zY8acc6iS5PMmZpl8IYMI1+zUqLFusaVzdfMrCcV6wYVlgtcWoqjfek1mXE2D5aR+tfL/Xelmogx9AKwIeXc4h7VojbVxGObTTq3fHjDEMgRXmhh3oxmQu6xUESRIK/RrTrJMyC60lYF4QaqIO4qEDAsK1QDz/X8xg2gWz9Vw8Jz2nWRtiaDub5ibUibnV5UvVMAG6WF0+dEXW3tbVijsPo0W2C8nN/Nx5/ixkzvu++ovBQYy+3Wu8fZ0GtofXQszDKM3Xe22/il29i23XfkfYs0jBFYzYHqy+1gvEfi1zdfDPjQjYib2/mX3Yl53Bk30Gg61mwSjZo93Bq13Zlk3arV16OX1jqY3Drq3aje23sW3buo3TqXdDeW3Kfw3buf3agc3axR0Gp/1CtW3YoE3Zvf3Zx43Zpe3bd21liKwJL5fdl0CGXmiG342GjYxV440Gy33dird6yq175j3bc/B3hyfbnrfZ7l10m8feTsB7gl3fVRd7//Ot3lPGeOg94K5XefKdc789efwNBoDn2JO24P5deBHOdAdO4Y+d4Aqe3vgdShvezxeO4WQwAemiJCJeBSU+SifOBSdO4vjkBCsuAimueSAOe2lwAe2CL+yigFBg4xKA4wGg41jA4z4O5Esg5PWS4x+e5Ep+Bur0LRioJu/EBU2+TlQw5VFO40ue4WlQAWoCfVTA5U/h5dHX5V9O5lmO5WdeBruSDhaQBWsug2Hw5m1eBXI+4/QN4VxgTe+Xf9ckBnpuBX9O4Fqe5mUALRmwBYZOBol+BYsu6DJu52RAgfKnBZIe6QEw6VZQ6ZD+3gK+BuPS4lbw6SFOTydI6ptu3/943gUkuAWrPgatbgWvLuGO/uhXGHazjub/cMOhgJSofuuf5wXSZdE3MMM4ENUOBpa6LgTBfkY7PAPXkTnTwOu83t++fuddMO1L1uxx5CB8iQLJruxsa0fa/lUSxq4pgO33LevVTgUwARzEsACm4RAIahVTXBymkbH8sJnc7lq/sWrGk5rWaQTtbj+eEe/Gk6ANUO+D6RkOSmPlHu12+g7RLpicfuq9zgUD/xoGMA3HbgAaapJdAwGHmlpdpCYguQAOkVk6CqJLkPG2w/Gu5fGAqloKMfKF6vBPAfEFsRChVsliRu2Ebu0YbwzxM/AgiZPVDCAiS+zDvu+gEz78LgL/z5UERn9Z9oz00qX0LsP0TPXwCNIRPe9slJLqubcFVW/0SJsPDQ0gNo86XeT0oRYfUb+rLU/0SoL28IoAax8gUJsmqObwDqTzF7vMP892ZF/gGG/N5dhfm8th1VrGoKvvHBH1xEMMRz/1RxDsRW/3TZYOmeH41AP52gX40H5Z4LHxhN+f6T7o6o4G304F7OEFrw8FNo3rtB70YTD7TxAV1vUFut/yk6H6Qt/6xF/rh7/fx2/8Gl78t48F8wsFz+/8oBT9to77Fb8F1N8E2V8F248E3Z/8pt3pWfD9SUD+UWD+RID+zP/r4A8EfuUA2zloBgo6BVo8qHka9975WQED//cOAkQAHEoQJAByosBQDMHBKo1oLozLMoRxIgDCIbFoHJZODhHJ1FqdUq8YtDUw/GoAx2mxCxh0R2IysByVU1UpLLB2YQNabsAbA4vH+j2/7z+O/AkOEhb6BRomKi7yITI+GjkUDDE5pBzkDK00XBEQbV4dNCwghAoxZD44CJoCVF5mCoEaeCIFQIh4FiQwBNQCkAJAeDFKUo5YksSqBHDSfjaHjpYaHJymrvIZC70q583+MjuLkrai6qhCqis6rru/G7XDz7/L0xcaBHGP/LAgIDiR8UJWwAMDAeRLkEIWCzCCFB5D2PBfwYMMCvhjAkAhAgO2GlpblC9iPyAAWf8YnKSiosqEC5mx8Mhn5D6J/k6eSEkQ5UGXmhrKvCd0iL2hRgcVPaq0T9KlY7a5QvYS4QNhAltWhXBVSD5zy1hVq5lsiIGsWzcqANDAjUaFvX4FUwe1G1mzOqlavds1LIBzguZKJVI2b0+7PamF9OtUaNPFjgE0frw4suQyZ5rwPPHj7p3NhwFgrPOlhaDQC5iUEaj5LIEFYNgGgngnQI9+QRVZRl1xNWfen02PnjomN5rdr3sf/90luGR3lJsbfQ59qPTp1q9jz659u5Dq3B95/84ovPjy5s+jP08+/Z/17A+9jy9/Pn3H7usXuY+fiP79/v8DaF5/+w1IYID5HVj/XoEJarcgfQ4+yGB36UE4mYASElJhfBpuiCGH9RioIIZIjdheiSZK+KFzIYqnIoUnMgVjjCm+iJ+L48nYSI563KiehzXW1yM7O/JIJCBGHkkjekLSw6QhTn4H5XZSTvnjkixGiWQ8WvLHZZdK+mjjhVpWEIEGkAGgQQQV7FjmmSOoyWabZqIZp39u1rnmdnjCqWd6fKbpp3WA2knkBgFYgGgAGxh5aKKJMtqoopAC6KiikW5nKaXvabqodp1iuiMFDQVAgZGjNmTqqaSq6h+qLLSq3asnxIrerKXKyiqSF2TAQgYXGMmrr8AG2+sJvwIo7LHEbqdsAMi+5yy02EnL/yyREbAQgZbYnqDtttkeyG0A3n4nLrnvmctdulpOwMIE7LrLZbsnvBvgvAHU+929+b63L3f+cilBABJ4KTDBBQ/MoMHnLUxfw9w9rCUGAWDg5cQVW0wxgxefxzF9HnMHcsBeCnEwySYniHJ5KsvHsnYukxyzzDPTXLNkAuCcs84789yzzz8DzXMfQRNdtNFHI530zkUo3bTTTwvAB9RTI70H1U4XcrXWQB+xddKPRW1e2FbbLMTYZjN4dtfnqc20Y20Pzfbai8FtVN3Z3T1E3lyqvfd8e/s9Xd6Bv0M4EYbfPLdTiK/D+Ntxl9132lLLrYfjjzh++eKKL6U5I54r5f836BhKniDglY8xuiGZo37446+XJ3rZAJR+4Olik0131q3rDfvmuFPOx0FCDc+IRqu73ZwvhQcfe+7wLM/5H6oPBTf1gITjuu99JEBD9vTIXkRHJyhAQPH0nK/I8btrP0T35H9fz/capd986viw4EBI9wxeBANOKEAf2Fsff+JHO/YNoiT6q570/kc+AcaDAAQkigGvRwjEQWQjtLEb5IagFX0kYAD1e8cICzFBQdROCBnsXh7mET0inHB69vvDSA5QAAM0QCj9I4ICquIC4Rghhi9M3iAcV8Mb5pB/0uuhEAYAxCIIsYJgG0QGt1AVNxggAQYYAAlkkBoDzlB6DvD/4RCukIUc2kYHcgCCK0qCGdKUkQWTgMENE9CSINAhAFxEghMu8wYEuEaPDjRD+9BGhCqO8QthKEIaVBBILtJhATMgXw598QbbDKQ1dQiCGeWQRENaDh8CXAAufOGG5XWkjSxA4BJVIoRhEKEXa/GBZrawnDW6gYgoFOUQSJmLU3oilbQ8ASt7x0NXCoMYp2iGL2xjS9HgEoIH3B4fqjgQQiKEizM4gAPSAhkwPi+URCiANKURF65ckYtXAEZVuoGJPLzFBXNUgDXsyJVSSBI0exQCYKDRgAKQcQDe1OU03feSF/hFFZOUQTLeCdAy8sUWEPjmT2wQiIEsgIuAHMc0/wopPT/QRJ8i0CYqPbKAdoZnh0NgwPsKwIC1MKAjBlmFL+gXUT3CgaB+MKIAYTDSLgbTpCgtJihP0dKX0kamA6CpBC96U3XepqC/+wMir1iLLXbxADQZ4i5nOJYy3rEB72tBSbcZFZuwURYyGQgMVHjHDLaVLAJkAk5kQAATuJSbcoBgCjfykjFWwSGCmchdA+DSKl7EH9+s6wHoVwCzQkYvfA1jH0Lqy0DMIKhmjWE4jXC3BKRFAQJFQAIcwMWaxmYqJdVpBwVh2VIKIbMqqIYMznrBj7ovtKMt7WmbqkLVBpW1HHzIQrpnjejtYgfcXEU8ierZImhljyE8zCYAoP+AFKw2ozvYwhN7oQNjxHWdraFGAxqA1SH0czBa2d9X12nM9/5WhTJQTCSeaIlWgFYtuWymXUSQQ4yqcwGcuKNHn0uII3rkeLm8ITDUmdLOBtCtLlhAChaQCdT+96bBLXBraRgEGyYYEQs2qYOdq7YIb2QSA6AwMC7c1Azvb7UcHi5VaSCG6IlgjQdgwA9+AE5xdnbCJyiA+e5YhixSNJVQ+MEba+s+8s1xj1qVAyka4ITzxraPTOiMDEIThtlM1qNjVYAYZiOc1NhQMzowjSZ/EARfcFkUJtjiJDQZjM/AF7czyV8Oj3cHBXhkyQ8GshAeQANrxPMBMvGFlR0CHBn/53mn+FNCnxHx50CvxsRFMDT5EL08RXeHAI32yKM3HOmjWHAPvdhfETtMwqhCwrzSbJxw8XO7o7i31YQOnXPRB2tXS5XX1HRHjnGKPMo+4g6ncc6QlThjWyPbHcr+sZ6LKmxdE68L1DZwrZ2tO+AFWWZ9/c+txaPSzvUab9X29lTNDeyYjds/5f7Oua/dVedxG93DTkQJFRG+PVw3Q9veA0aQaYQp7xMS8d7PvBfR70TUG9XpLsTDj91t4Rlchvs2RP3iGtd779oIACkEVwkxjEr6dtMZx9zF/xZtiq/c4wmXdMhpDHJGdHyPH9d4y2tykOJx9tk6XEfO/f1uskxU/+AOR+YETQuPhUM73PyO+cyxvW7wTZwQRYf41Y3w85Uffegw7AcC/rmcYQ7gDQMZ6z/80dY/q9EJ0vz3EWaQxAI44RJOIGN35K7KBef9jQlY6AqGGZQqFN4NcAdNP25YB1YTNNXXmfcwyw4ctKt9EmxH/NvJF/e0njr0Yrf63y1/9n6knQVs0KBJ3O5gOXw+lxxum2iJMEYRLDSEcajBlnf/SdGPXgjBGIZ/e1l1UCAzvzL3boohA9WW580HQyhAnRnK3GUTJcDACAIsqR8VbsKCAQdBrRHa+lPm29P7hc/mrr3mfqjNcPinaYbxRR6N5Kdl+Ru0J05zbW2mvV/RFP+T/BWf8B3f/R1S/uncAKDfJPRfVFmPEaRDcuXAlqmEOSFA75HDrEkez3URSBhaRkHWSvCEigUSqS1gKrVRkkFg2EmfELTVNtEEORXQ95GKDZHUlPnD+KXcOHGRRqig9JlfIOxcz53I2SxUToTgAIwgYw3EitWSzAWhR0Da/7ncR6DEEjYhSwiZo6WgTEhfFQbb/w1DKSgALFlgE91RGiIEB04REZzTSsmAdqETYTzWLQAAqD2UPjGfMYgh3R0c/elTVjkAcw3Rp5kUBMUgQ00FDxbg9P1gIPRhlNlWEQpdjqhNHC4TJuyTel3FDEyUHvoQDEwiCxohuAnfrK0aHeL/xXq9ACjmIamNIgNukB+amhXCjYUZxAKswpZ502GwYUgBH7v9HS2onis8UpyxlWZgmht0HuyZ4iWOYREYQNIt4gGUAd9BhmZ4guEN4jahGQ+Omg/a1heQ2SBqhCUOo4yojeEVWwpokh4p4xwxI0wgwDOe4x+SGxTZxjsi4wmIkG/QIxg04z2+Xj7e4jTCjTGsRRAwASqgADCOAJ5J4zx0IPO83EoYyUXGB0fSmrzxjhUy0MZhByAeQcDtiEeyh0oq3D6i4jo+3Rvim9SRDEuih01+jkvOZEVi5Lft5P1EjriF5BX+pEgGn74VZb7tQcXRgzoawh7W3EZCR9BNo3zg/6QeUGUE+gFV3py90VvYEQFTzoM6Rk/JHcEogNNVJuU6sCEUNYZaEuM7tCUMvWXX1URLkuTkgSVYSQZZDhwRPMATweQR4trKZaVOEo9h1qVSYmWBwOVgNodJFsFsqJjn5SEPNJLtUdIgrcJssJRitVUajZVshUYBWBQOiAEsRSWRwE02ylMM7A+n0UbtodcD4J7qEQdq2uVQuuYUONllnsD/JNztyQBuatkafcWp3Q1xwMQTPBJnrqYOBaD7hV08IdT+OWDScZc3lJEWiJZAyeH3KF/CDUZZmg8OWdkA5AJoLMQM0GRKHkEh9sVpdEJ+aOcEVlgPTKRKAIYuPNFjWv9kfF7feWYPHhbaKlCgfsoTP7nSeiYXY1blFjSoI2wCVIJnRs6O0KngC0whHKCAeU3Ek+EmFwSQCjbRCeqTWB2jeWaQE7VFezYFgG4H3MxgKWTcFXxoGQoUGu7nPUWEX+3mS/ooaNio1/1AAjSAjp6hFwTjXKUWbt1NSNFVQRRWXpHorEHm7OTNJJZiLyHAV4WlFkxmGEQPLOph6uVQwBkonKHnFr3oKylTkI7IQhpikelBMOjiivXiRHpTPwEphFqlgPYFnIHd9rXYLu6pC/TphMYXhN5NetkFeh3Urxllhl7c+yhAZcLeKFASmmkmEIDZaCQWQerTkaXA+5DmkFn/VKMG5ntiYt3t3YISAad6koTql0OOAEQO3nE26ikmZW8aHK3OwSQ05FnpKnP+KWstJ6/GmZeJn2IBpaViaIKgpauy41AGqpBGaFxKK6COCFRGq5fIKOnRx7h25bZiXbdaK5KYa0lia0cOJYC2K8NpqVBqa7Ympbyq67pKJby963vMK7Dp676GK80ErOD860rGa15268Fqh8NGZsKmB8QWbKWmK8F6q7ja61rCq7YOLMYC4HSK7MjijLiR7NWQ28lSTdeorNCA7MvCbMzK7MzSbM3a7M3ibM7q7M7ybM/67M8CbdAK7dASbdEa7dEibdIq7dIybdM67dNCbdRK7dRSCW3VWu3V8mwIAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Additional information is required about the optimal cut-off values for ADL and CZP.",
"    <div class=\"footnotes\">",
"     ADA: antidrug antibody; IFX: infliximab; ADL: adalimumab; CZP: certolizumab.",
"     <br/>",
"     * [IFX], &lt;3 microg/mL; [ADL], &lt;8 microg/mL; [CZP], &lt;27.5 microg/mL.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     [IFX], 3 to 7 microg/mL; [ADL], &ge;8 microg/mL; [CZP], &ge;27.5 microg/mL.",
"     <br/>",
"     &Delta; [IFX], &gt;7 microg/mL.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ord&aacute;s I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10:1079. Illustration used with the permission of Elsever Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35214=[""].join("\n");
var outline_f34_24_35214=null;
var title_f34_24_35215="Bogalusa threshold boys";
var content_f34_24_35215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51934%7EPEDS%2F59701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51934%7EPEDS%2F59701&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Thresholds for defining cardiovascular risk in boys, Bogalusa Heart Study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 186px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Smoothed body mass index (BMI) and waist circumference thresholds for predicting risk factor clustering among male children and adolescents in the Bogalusa Heart Study (1992-1994). Each curve defines the optimal BMI or waist circumference which predicts having three or more cardiovascular risk factors (high blood pressure; low high-density lipoprotein cholesterol concentration; or high low-density lipoprotein cholesterol, triglyceride, glucose, or insulin concentration, adjusted for age) at a given age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Katzmarzyk PT, Srinivasan SR, Chen W, et al. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics 2004; 114:e198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Thresholds for defining cardiovascular risk in girls, Bogalusa Heart Study",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 183px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Smoothed body mass index (BMI) and waist circumference thresholds for predicting risk factor clustering among female children and adolescents in the Bogalusa Heart Study (1992-1994). Each curve defines the optimal&nbsp;BMI or waist circumference which predicts having three or more cardiovascular risk factors (high blood pressure; low high-density lipoprotein cholesterol concentration; or high low-density lipoprotein cholesterol, triglyceride, glucose, or insulin concentration, adjusted for age) at a given age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Katzmarzyk PT, Srinivasan SR, Chen W, et al. Body mass index, waist circumference, and clustering of cardiovascular disease risk factors in a biracial sample of children and adolescents. Pediatrics 2004; 114:e198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f34_24_35215=[""].join("\n");
var outline_f34_24_35215=null;
